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ABSTRACT 
 
Currently the only effective treatment for end stage liver disease is transplantation together 
with immune-modulating drugs. Human bone marrow derived mesenchymal stem cells 
(MSC) have been shown to suppress inflammation, potentiate regeneration and act as vectors 
for gene therapy. Thus, MSC infusions offer an attractive potential therapy for treating liver 
disease. However a number of obstacles exist in MSC delivery before they can be used 
therapeutically. Although MSC can migrate to sites of injury after in vivo administration, their 
engraftment within the liver is often poor, potentially limiting their therapeutic action. I have 
shown that detaching MSC from culture using non-enzymatic methods is superior in retaining 
surface chemokine receptor expression. Furthermore, I have shown that these receptors are 
functional in migration and attachment assays both in vitro and in vivo in carbon-tetrachloride 
induced liver injury. TGFβ1 stimulated MSC were able to further enhance engraftment via 
up-regulation of surface CXCR3. Additionally the potent immunosuppressive properties of 
MSC, mediated via Prostaglandin E2, were enhanced after TGFβ1 stimulation. Thus my 
studies demonstrate that manipulation of MSC through careful choice of detachment methods 
and exogenous cytokine stimulation can improve their engraftment in injured liver and their 
immunosuppressive properties with implications for improving the efficacy of MSC therapy.  
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CHAPTER 1: INTRODUCTION 
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1.1 The Liver 
1.1.1 Liver function 
 
The liver is the largest gland and solid organ in the body and its size appropriately reflects its 
complexity and functional importance for survival. The primary role of the liver is to process 
material from systemic and portal vein-derived blood and hence the liver has a dual blood 
supply from the hepatic artery and the hepatic portal vein. To process the blood the liver 
performs over 500 metabolic functions. Examples of such functions include metabolism of 
carbohydrates, fats and proteins to glucose, fatty acids/glycerol and amino acids respectively.  
The liver is able to convert glucose to glycogen and vice versa allowing rapid utilization of 
glucose when needed. The liver produces bile which aids fat digestion and absorption, and 
helps excretion of substances such as waste products from metabolism, hormones, drugs and 
bilirubin. The liver is involved in synthesis of plasma proteins and blood clotting factors.  The 
phagocytes in the liver also produce acute phase proteins and immune factors in response to 
microbes in the liver (Wallace et al., 2008). On a cellular level these metabolic reactions are 
carried out by many powerful enzymes which are contained within specialised liver cells 
called hepatocytes (Friedman, 1993). The capillary system of the liver, also known as the 
sinusoids, plays a pivotal role in liver function (Wallace et al., 2008). Sinusoids are lined with 
endothelial cells and phagocytic Kupffer cells, and the fenestrated endothelial layer ensures 
blood constituents can penetrate into the Space of Disse where hepatocytes take up nutrients 
and oxygen as they come into direct contact with the blood components (Figure 1.1).  
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1.1.2 Liver Disease 
 
According to the British Liver Trust, liver disease is the only major cause of death that has 
risen year-on-year since the seventies compared to diabetes, cancer, stroke, heart diseases, 
respiratory diseases, and road accidents, which have remained stable or even decreased. Liver 
disease ranks as the fifth commonest cause of death in England and Wales and kills more 
people than diabetes and road deaths combined. 16087 people in the UK have died from liver 
disease in 2008, a 4.5% increase since 2007 and a 12% increase since 2005 and 100% 
increase since 1991. Since 2005 the total number of deaths is 46244 and deaths are predicted 
to double in 20 years if the current trend continues (www.britishlivertrust.org.uk, 2008). 
 
There are a number of causes of liver disease including alcohol excess, hepatitis virus 
infection, obesity, non-alcoholic fatty liver disease and autoimmune diseases. Liver disease 
can manifest as an acute disease or in a chronic form depending on the cause. Although the 
causes can vary, the disease progression is much the same following sustained injury. Liver 
injury disrupts the normal function of the liver cells, usually by causing mass death of normal 
cells either resulting in, or as a cause of concurrent inflammation. When the inflammatory 
response to liver injury or the injurious cause is sustained without resolution, this leads to a 
buildup of scar tissue without the counterbalanced stimulus for the breakdown of this scar 
tissue, by matrix metalloproteases (MMP). This continued process may eventually lead to 
fibrosis and decreased liver function.  Eventually sustained fibrosis can lead to cirrhosis, 
altering the cellular composition and liver architecture causing liver function to seriously 
deteriorate (Figure 1.1). Cirrhosis is usually followed by complete loss of liver function 
known as liver failure. 
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Figure 1.1: Changes in the hepatic architecture in disease  
Appearance of normal liver (A) and liver in advanced liver fibrosis (B): Inflammatory 
lymphocytes infiltrate the hepatic parenchyma after injury. Hepatocytes can undergo 
apoptosis after being damaged, and Kupffer cells activate, releasing fibrogenic 
mediators. Stellate cells become active and proliferate, secreting large amounts of 
extracellular matrix proteins. Figure reproduced from (Bataller and Brenner, 2005). 
 
 
Resolution of liver inflammation and fibrosis leading to a return to normal histology has been 
observed in humans and in mouse models of inflammation and fibrosis when the sustained 
injury has been stopped (Tsukada et al., 2006). It has also been shown that levels of fibrosis 
can be reached after which resolution cannot occur. At this stage in humans, treatment focuses 
on preventing further progression to cirrhosis and liver failure. Symptoms of cirrhosis include 
ascites (fluid retention in the abdominal cavity), increased risk of infection, hepatic 
5 
 
encephalopathy and a poor quality of life (Wallace et al., 2008). The forms of therapy that 
currently exist have significant drawbacks.  Anti inflammatory medication like corticosteroids 
stop the release of proliferative fibrogenic cytokines but these rarely offer complete 
suppression. The other alternative is liver transplantation, but this too has significant 
drawbacks, the main being a lack of donors and immune rejection. 
 
The British Liver Trust suggests that at the end of March 2009 there were 338 people on the 
remaining on the waiting list for a liver transplant, despite 644 liver transplants from deceased 
donors during the preceding 12 months. This illustrates how there a continuous need for liver 
donors, but there was a distinct shortage in donor organs from 2007 to 2008 where only 58% 
of the 1121 patients waiting received transplants while 25% were still waiting at the end of 
the year. Between 2002 and 2007, the three commonest reasons for a liver transplant included 
alcoholic cirrhosis, hepatitis C related cirrhosis and primary biliary cirrhosis 
(www.britishlivertrust.org.uk, 2008). Considering these statistics, there is clearly a need for 
the development of new, non invasive therapies that work on a cellular level to reduce or 
reverse inflammation and fibrosis. To do this, the mechanisms causing liver fibrosis at a 
cellular level need to be thoroughly understood and factors which increase, reverse or have 
the potential to reduce fibrosis need to be identified manipulated and used as effective 
therapies. 
 
On a cellular level, when liver injury causes sustained inflammation, resident hepatic stellate 
cells in the Space of Disse become activated and take on a myofibroblast-like phenotype and 
rapidly proliferate (Figure 1.1). When activated, these cells are responsible for depositing 
components of extracellular matrix including fibril forming collagens 1 and 3, matrix 
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glycoconjugates including fibronectin, hyaluronic acid, and proteoglycans which make up the 
connective tissue that causes scarring and fibrosis. This matrix fills the subendothelial space 
(which normally contains minimal basement membrane constituents) causing impaired 
hepatocyte function and loss of cell pores, which further activates hepatic stellate cells, 
creating a vicious cycle. The collagen and proteoglycans that are produced by these 
fibroblasts contribute to formation of significant connective scar tissue which may be up to 6 
times more abundant in cirrhotic liver than in normal liver (Tsukada et al., 2006). 
 
1.1.3 Liver Inflammation 
 
Inflammation in liver is characterised by recruitment and retention of circulating immune 
cells during an immune response and can clinically be defined as acute or chronic, when 
inflammation continues for over 6 months. Liver injury or infection causes resident 
macrophages or Kupffer cells to initiate an immune response and mediate inflammation 
which usually precedes stellate cell activation and the development of fibrosis (Figure 1.2). 
During liver injury, there is a mass of apoptotic cells which are phagocytosed by Kupffer 
cells, and in response release cytokines such as TNFα, IL1, IL6 and IL8, which drive 
recruitment of leukocytes. Recruited leukocytes can then exert further damaging effect on the 
liver tissue promoting fibrosis (Liaskou et al., 2012).  
 
The role of Kupffer cells in linking inflammation with fibrosis is shown in studies in mice 
with carbon tetrachloride induced liver injury (Titos et al., 2003), where a reduction of 
Kupffer cells, subsequently reduced fibrosis. Kupffer cells also produce IL8 which is specific 
for the recruitment of neutrophils from circulation (Liaskou et al., 2012). IL10 is an anti-
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inflammatory cytokine which serves to reduce neutrophil recruitment in the liver (Nelson et 
al., 2000). In IL10 knockout mice neutrophil recruitment was increased resulting in increased 
fibrosis, furthermore increased IL10 was shown to have anti-fibrotic effects (Louis et al., 
1998). An obvious way to reduce inflammation would therefore be to selectively deplete 
macrophages to avoid fibrosis. However subsequent studies have found that the presence of 
Kupffer cells is essential during resolution of fibrosis and these cells play an active role in this 
mechanism through the use of MMP which degrade deposited collagen (Duffield et al., 2005, 
Stramer et al., 2007). This highlights the important fact that fibrosis is an essential repair 
mechanism which leads to the resolution of injury providing that the initial insult can be 
stopped. Kupffer cells are an essential part of the recovery mechanism (Figure 1.2). 
 
The problem occurs when the cause of injury cannot be stopped. In this instance Kupffer cells 
still function to promote inflammation and release factors such as TGFβ1, a major cytokine 
involved in fibrosis (Kershenobich Stalnikowitz and Weissbrod, 2003). TGFβ1 is responsible 
for preventing Kupffer cells from degrading deposited collagen via an up-regulation of TIMP 
which inhibits MMP function (Kershenobich Stalnikowitz and Weissbrod, 2003). Such 
cytokines can cause hepatic stellate cells to differentiate to myofibroblasts which further 
express TGFβ1 forming a perpetual loop in activating stellate cells and promoting fibrosis 
(Kershenobich Stalnikowitz and Weissbrod, 2003). Myofibroblasts also have antigen 
presenting capabilities suggesting they can further promote inflammation and are also able to 
induce T cell proliferation (Kershenobich Stalnikowitz and Weissbrod, 2003). Myofibroblasts 
further perpetuate inflammation by enhancing recruitment of lymphocytes and promoting 
cellular damage in the liver (Fernandez-Cruz et al., 1978, Holt et al., 2009). This presents a 
challenge where the inflammation in the liver environment needs to be controlled and 
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suppressed while the fibrotic process is encouraged to resolve the tissue damage. Bone 
marrow derived mesenchymal stem cell therapy provides an option with the means to achieve 
this end.    
 
 
 
 
Figure 1.2: Drivers of hepatic inflammation and fibrosis. 
Damaged hepatocytes and biliary cells release soluble inflammatory factors that 
activate Kupffer cells and recruit activated T cells. Hepatic stellate cells are activated 
by these conditions into fibrogenic myofibroblasts and secrete cytokines that 
perpetuate their activated state. If the cause of injury is not stopped, this leads to an 
accumulation of activated stellate cells and portal myofibroblasts, synthesizing large 
amounts of ECM proteins, leading to tissue fibrosis. ECM degradation is inhibited by 
the actions of TIMP. Apoptosis of damaged hepatocytes stimulates the fibrosis via 
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stellate cells. If the cause of the liver injury is removed, fibrosis can resolve through 
stellate cell apoptosis and hepatocyte regeneration. TIMP expression reduces leading 
to increased MMP activity, which causes collagen degradation. Reproduced from 
(Bataller and Brenner, 2005). 
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1.2 Human Bone Marrow derived Mesenchymal Stem Cells (MSC)  
1.2.1 MSC Markers 
 
This thesis will investigate the process of exogenously applied MSC engraftment into the 
liver, and their potential therapeutic effects. Conflicting reports exist regarding the molecules 
involved in MSC recruitment to organs and the effects they can impart. A potential reason for 
this could be the heterogeneity reported in MSC populations. It is therefore important to 
review current methods of identifying MSC. The first observation of a stromal precursor was 
made from bone marrow from rabbits or rodents, which when seeded at low densities in 
medium containing serum gave rise to discrete colonies of plastic adherent, non phagocytic 
fibroblast-like cells. Each colony was generated from a single cell and these cells were termed 
colony forming units-fibroblasts (CFU-F) (Friedenstein et al., 1974). Subsequent research 
into these cells identified differentiation towards cartilage tendon and muscle and fat 
(Pittenger et al., 1999). Human bone marrow mesenchymal stem cells (MSC) are similarly 
defined as spindle shaped, cell culture plastic adherent and are positive for a profile of 
mesenchymal receptors including SH2, SH3, CD29, CD44, CD71, CD90, CD106, CD120a, 
CD124, CD105, CD73 (Dominici et al., 2006). They can be distinguished from hematopoietic 
stem cells by their lack of hematopoietic receptors including CD11b, CD14, CD34, CD45, 
CD79a, CD19, HLA-DR (Dominici et al., 2006).  For cells to be termed MSC, they must 
have the ability to replicate as undifferentiated cells and display at least tri-lineage plasticity 
to adipocytes, chondrocytes and osteoblasts (Dominici et al., 2006). 
 
Current isolation methods involve culturing whole human bone marrow on tissue culture 
plastic for a number of passages to deplete all non adherent cells or more recently culturing 
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bone marrow in a bioreactor (Boxall and Jones, 2012, Mareschi et al., 2009). The phenotype 
of adherent cells is then confirmed for MSC markers and tri-lineage potential. Of note, an 
accepted and universally used prospective MSC isolation method does not currently exist. 
Although a single specific marker for prospective mesenchymal stem cell isolation from bone 
marrow has not yet been identified, there have been attempts to isolate MSC with a number of 
markers (Table 1.1). CD73, CD90 and CD105 are commonly used as markers of MSC 
however these markers do not vary with MSC age, potency or differentiation potential, 
suggesting these markers only serve a purpose in characterising these cells and these are not a 
specific combination of markers for MSC but may encompass various other populations 
(Boxall and Jones, 2012).  
 
Stro1 is a well known marker of MSC identifying a purer population of cells with tri-lineage 
potential and stem-like qualities. However, Stro1 is not specific for MSC and is expressed by 
other cell populations in the bone marrow (Simmons and Torok-Storb, 1991). On MSC, Stro1 
is a marker that is lost with time on MSC in culture. The function of Stro-1+ is not known but 
it has been implicated in MSC migration and attachment to extracellular matrix, similar to 
CD106 expression (Bensidhoum et al., 2004). Subsequently, CD106 has been coupled with 
Stro-1+ as a marker to isolate a purer MSC population (Gronthos et al., 2003). Like Stro1, 
CD106 expression also reduces with time in culture but also after tri-lineage differentiation, 
suggesting it may be a true marker of potency and tri-lineage potential in expanded MSC 
cultures (Jung et al., 2011a, Liu et al., 2008). PODXL has also been highlighted as a marker 
of highly proliferative MSC and, so could indicate increased potency and stem cell potential 
but this marker is also down regulated in culture over time (Boxall and Jones, 2012). It is 
possible that proliferation potential and age of the cell is closely linked with differentiation 
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potency and CD106, PODXL and Stro1 could be markers of this (Boxall and Jones, 2012). 
However there are reports of certain markers identifying populations which are primed to 
differentiate to a specific cell type, acting as a mesenchymal progenitor rather than a true stem 
cell, such as CD106+ cells, which have shown a propensity to differentiate towards adipogenic 
more than osteogenic cells (Boxall and Jones, 2012). A recently described MSC marker is 
CD271 which when coupled with CD73 expression has yielded consistently potent MSC 
populations (Cuthbert et al., 2012, Veyrat-Masson et al., 2007). However, like Stro1, CD271 
is also found on hematopoietic populations in bone marrow (Cuthbert et al., 2012, Simmons 
and Torok-Storb, 1991). During isolation hematopoietic cells can be gated out isolating only 
the non hematopoietic fraction and in situ CD271 can be couple with CD146, a pericyte 
marker identified on cells with non-hematopoietic MSC-like properties to yield pure MSC 
populations (Boxall and Jones, 2012). Furthermore, W8B2-MSCA 1, a marker for uncultured 
bone marrow MSC and an enzyme known to promote bone mineralisation, has been seen 
consistently expressed on CD271 positive cells and could serve to further purify the MSC 
population (Boxall and Jones, 2012).  
 
In common with a lack of definitive phenotypic marker, a universally used prospective MSC 
isolation method from bone marrow does not exist. As culture expansion to large cell 
numbers is an unavoidable necessity in MSC therapy, potent MSC populations need to be 
selected prospectively and cultured to larger numbers. Furthermore as most markers which 
have been implicated in this role are rapidly lost in culture, it is essential that we can 
prospectively isolate MSC using these markers. A further argument for prospective isolation 
is because contaminating cell types could serve to compete against MSC for oxygen and 
space making conditions less favourable for MSC growth particularly as MSC are now being 
13 
 
produced in bioreactors rather than undergoing multiple passages in culture to decrease 
contaminating cell numbers. Such protocols could increase MSC variability and produce 
inconsistencies between multiple MSC isolations. To avoid such inconsistencies in this 
project we utilised MSC that were acquired commercially from the same source. This 
eliminates variability to some extent and allows us to focus on the therapeutic benefits of 
MSC, which can in future studies be enhanced through purification of the current MSC 
populations we use. 
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Table 1.1: Proposed markers for prospective MSC isolation 
 
Markers Function Expression Specificity Reference 
STRO1 
Unknown 
(potentially 
MSC migration) 
Diminished with age.  
Labels 
hematopoietic cells 
Simmons and Torok-
Storb, 1991 (Simmons 
and Torok-Storb, 1991)  
CD146 
Unknown 
(potentially 
endothelial 
junction protein) 
Diminished with age. 
In-vivo distribution 
when coupled with 
CD271. 
Labels pericytes 
Covas et al, 2008 
(Covas et al., 2008) 
CD106 MSC migration Diminished with age.  
Labels 
hematopoietic cells 
Gronthos et al, 2003 
(Gronthos et al., 2003) 
PODXL Sialomucin Diminished with age.  
Labels 
hematopoietic cells 
Lee et al, 2009 (R. H. 
Lee et al., 2009) 
CD271 
Receptor for 
neurotrophins 
Diminished with age.  
Labels 
hematopoietic cells 
Quirici et al, 2002 
(Quirici et al., 2002) 
W8B2 
Promote bone 
mineralisation 
Strong prospective 
marker when coupled 
with CD271. 
Labels CD271 bone 
marrow cells 
Buhring et al, 2009 
(Buhring et al., 2009) 
 
1.1.1 Function in Niche 
 
Mouse bone marrow derived mesenchymal stem cell colonies seeded under the renal capsule 
of animal models gave rise to bone and bone marrow with hematopoietic cells of host origin, 
suggesting that certain cellular components from this population generated the correct 
microenvironment for hematopoietic stem cell (HSC) homing and growth (Friedenstein et al., 
1970). Stem cells in the bone marrow exist in specialised niches within a highly regulatory 
microenvironment (Spradling et al., 2001). Mesenchymal stem cells provide this environment 
for HSC and maintain them in the bone marrow (Dexter et al., 1977).The most primitive HSC 
are located in the endosteal region, co localised with osteoblasts, suggesting these cells play a 
central role in maintaining stem potential in HSC (Moore, 2004). Progenitor cells derived 
from primitive HSC are found localised in the central vascular region of the marrow space, 
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the cells of which include MSC derived cells (Kopp et al., 2005). This suggests that MSC are 
potentially the source of all cell populations responsible for supporting HSC development.  
 
It is clear that the MSC provide regulation of the HSC niche, however it is less apparent how 
the MSC niche is regulated. MSC can control their own niche using autocrine signals but 
HSC can also provide signals to control the MSC niche. This is best shown in conditions of 
culture expanded MSC where cell cluster size and organisation can regulate the niche 
(Delorme et al., 2006, Simmons and Torok-Storb, 1991). The niche is an immunoprivileged 
environment and acts as a shelter which sequesters stem cells from differentiation stimuli, 
apoptosis and other stimuli which could challenge stem cells acting as a lifelong source for 
differentiated cells (Moore and Lemischka, 2006). It is not unsurprising that MSC have been 
reported to have powerful immunosuppressive and immunomodulatory properties considering 
they are responsible for this role. Furthermore MSC in the niche are responsible for 
safeguarding against excessive stem cell proliferation which could lead to cancer. This effect 
of suppression and protection against challenging stimuli can be observed in some of the 
therapeutic applications of MSC. 
 
1.3 Therapeutic uses of MSC in disease  
1.3.1 MSC as a vector to deliver cellular treatment 
 
Perhaps due to their original function in the stem cell niche MSC have to be poor antigen 
presenters so that they do not initiate any immune response in the niche. For this reason MSC 
have no MHC II molecules (Puglisi et al., 2011). As a result for therapeutic purposes, MSC 
are well tolerated and due to a lack of co stimulatory molecules CD80, CD86, CD40, CD40L, 
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MSC do not suffer from host versus graft response after transplant (Ryan et al., 2005). This 
not only makes them ideal tools for carrying out whatever intrinsic therapeutic properties they 
have as a cell, but also makes them ideal candidates for cellular delivery of treatments for 
various diseases. MSC can be engineered for use as vectors to deliver therapies in cases where 
there are genetic deficiencies as in the case of α-1-anti-trypsin deficiency (Li et al., 2011). 
MSC have also been reported to home to hepatocellular carcinoma (HCC) (Garcia et al., 
2011) so, coupled with their use as vectors, they can be manipulated to carry cancer killing 
signals or agents, like TRAIL (Loebinger et al., 2009) or suicide genes (Niess et al., 2011), to 
tumours after infusion. This type of therapy is central to the focus of this thesis, which is to 
try and understand the mechanism of engraftment to the liver so that this mechanism can be 
manipulated and enhanced to deliver treatment for diseases or to attack tumours. 
 
1.3.2 MSC administration to pre-clinical models of liver disease 
 
This thesis will investigate exogenous delivery of MSC to injured liver, so it is important to 
consider methods that have previously been used and the effects of MSC infusion. The 
common method for MSC infusion in most models of liver injury is intravenous 
administration. However a common problem observed in mice with intravenous injection of 
MSC, potentially due to their large size, is lodging of these cells in the pulmonary vasculature 
(Karp and Leng Teo, 2009). This problem may be overcome using vasodilatory mechanisms, 
but currently experiments suggest only a small reduction in cell lodging (Gao et al., 2001). 
Interestingly Ezquer et al who also used intravenous infusion observed no MSC in lungs, but 
found MSC only in the liver, bone marrow, heart and kidney (Ezquer et al., 2011). This could 
have been due to long term nature of their engraftment experiments where MSC may have 
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ultimately been cleared from the lungs. Infusions through the portal vein as more commonly 
being tested to circumvent problems encountered by using intravenous injections and are 
showing promising results (Li and Li, 2012). Most notably infusions of MSC into pigs with 
Fulminant Hepatic Failure (FHF) were rescued using this method of infusion of MSC (Li and 
Li, 2012). 
 
Transplanted MSC have been shown to home to sites of injury to ensure continued delivery of 
molecules or signals which assist in resolving injury (Yagi et al., 2009). To develop MSC 
transplantation as a viable clinical therapy for liver disease, the administration of these cells 
need to be carried out using the least invasive methods as possible. Infusion methods can be 
intrahepatic, intraportal-vein, intrasplenic or intravenous injection and have all shown efficacy 
in resolving liver diseases (Cao et al., 2012, Kuo et al., 2008, Zhao et al., 2012). Studies have 
also investigated infusion via the jugular vein and showed minimal engraftment compared to 
portal vein infusions in a D-galactosamine induced liver injury model (Parekkadan et al., 
2007b). Intrahepatic infusions are invasive procedures and have been shown to have weaker 
effects than intravenous injections in liver therapy (Zhao et al., 2012).  
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1.3.3 Therapeutic effect of MSC through transdifferentiation into hepatocytes 
 
The focus of this thesis is to further understand and enhance MSC migration to the injured 
liver when administered as a therapy. It is therefore important to review the therapeutic effects 
of MSC that have been documented in the liver and other organs or diseases. As we are 
interested in the therapeutic effects of MSC, I will review some of the therapeutic properties 
of MSC and also some potential safety considerations that may exist with MSC therapy. 
Initial reports focus on MSC transdifferentiation into hepatocytes to restore liver function. In-
vitro differentiation of MSC to hepatocytes in response to liver specific factors has been 
proven (Chivu et al., 2009), specifically Dong et al have shown fibroblast growth factor 4 
(FGF-4), hepatocyte growth factor (HGF) and oncostatin M (OSM) are potent inducers of 
hepatocyte differentiation of mouse bone marrow derived mesenchymal stem cells (Dong et 
al., 2010). Subsequent in-vivo experiments have confirmed differentiation of MSC into 
hepatocytes via expression of markers like human serum albumin, cytokeratin 18, α-1-anti-
trypsin and α-fetoprotein after engraftment into immunocompromised mice (Kuo et al., 2008, 
Tao et al., 2009). Tao et al suggest that hepatocyte differentiation may be mediated by cell 
contact between resident hepatocytes and the transplanted MSC in the injured liver (Tao et 
al., 2009). Later work by Mohamadnejad et al implicated adenosine as responsible for MSC 
retention and differentiation into hepatocytes in the liver (Mohamadnejad et al., 2010). 
Infusion of MSC into pigs with fulminant hepatic failure (FHF) induced by D-galactosamine 
injury showed cells differentiated to hepatocytes in hepatic lobules and increased survival 
rates for over 6 months compared with only 96 hours in pigs without infusion (Li and Li, 
2012). However there is limited evidence to suggest that such a mechanism can significantly 
reduce or resolve liver injury, particularly as the number of differentiated MSC is so small. 
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Pre-differentiation of MSC to hepatocyte-like cells before infusion into CCL4 injured mice 
has sought to resolve this but with little success (Kuo et al., 2008). 
 
Zhao et al pre-differentiated MSC to hepatocyte-like cells and rescued CCl4 induced liver 
injury in Sprague Dawley rats implicating an IL10 mediated reduction of fibrotic factors and 
cytokines (Zhao et al., 2012). Hepatocyte-like cells differentiated from MSC on nanofibers 
before transplantation were also reported to reduce liver fibrosis due to increased 
differentiation (Piryaei et al., 2011). However this study seems inconclusive as control MSC 
derived hepatocyte-like cells which were not grown on nanofibers also showed differentiation 
into hepatocyte-like cells and there was no clear link in fibrosis resolution and hepatocyte 
differentiation. Engraftment of MSC derived hepatocyte like cells has been shown to be long 
lasting but the beneficial effects of this procedure are limited. Alternatively MSC have 
exhibited long term engraftment for 15-20 weeks in pigs with FHF and have shown 
significant beneficial effects in these animals (Li and Li, 2012).  
 
1.3.4 Paracrine anti-fibrotic effects of MSC in liver disease 
 
Experiments with human placenta derived MSC infusions into Chinese miniature pigs with D-
galactosamine induced liver injury resulted in significantly resolved injury through a 
paracrine effect (Cao et al., 2012). It is rather more likely that the reparative anti-fibrotic 
effect is due to MSC and their release of paracrine factors rather than reconstitution of 
hepatocytes. Although Tao et al showed presence of MSC in injured liver, they did not report 
any significant reduction in injury (Tao et al., 2009). Kuo et al reported similar results but 
went further in their findings to suggest that MSC were able to restore liver function and 
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ameliorate injury. They went on to show that this beneficial effect was not dependent on MSC 
differentiation to hepatocytes, although differentiation was observed in some rare cases.  
Alongside MSC, hepatocytes derived from MSC in in-vitro conditions were also infused but 
showed significantly less effect compared with MSC (Kuo et al., 2008).  
 
The resolution of injury and repair of the injured liver was likely to be a result of the MSC 
capacity to resist and reduce the typically high levels of oxidative stress, and the release of 
other paracrine factors which encouraged the repopulation of endogenous hepatocytes (Kuo et 
al., 2008). Certainly MSC seem to have an intrinsic ability to reduce oxidative stress. 
Kanazawa et al observed reduced hepatocyte apoptosis during ischemic injury in rats after 
infusion of MSC, with an associated reduction of collagen deposition, reduced αSMA 
expression and TGFβ1 production, and increased stellate cell apoptosis, compared to injured 
controls (Kanazawa et al., 2011). Increased MMP9 expression, involved in ECM degradation 
and reduction of fibrosis, was also observed in MSC infused rats (Higashiyama et al., 2007).  
 
The role of MSC derived paracrine factors in anti-fibrotic effects of MSC have also been 
highlighted in work by Pan et al who showed that MSC are able to suppress stellate cell 
activation by inhibiting the activation of the Dlk-1 protein in CCl4 injured mice (Pan et al., 
2011). A powerful paracrine effect via bioactive factors of MSC was perhaps a more likely 
explanation to how MSC executed their beneficial effects. This was proven in great detail in 
reports where MSC conditioned media was administered as a bolus or systemically infused 
into rat models of FHF (Parekkadan et al., 2007b). The effects of experiments using 
conditioned media did not last as long as those where MSC were transplanted and could 
deliver local and sustained tropic signalling molecules to the liver environment (Banas et al., 
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2008, Yagi et al., 2009), thus illustrating the importance of persistent signals derived from 
local MSC. Mechanisms by which MSC can act upon the liver microenvironment have not 
been fully defined. However MSC have been shown to directly interact with stellate cells in 
order to reduce fibrosis (Wang et al., 2009a). Parekkadan et al have shown that increased IL6 
from activated stellate cells induces MSC to produce IL10 and increased HGF, which reduce 
stellate cell proliferation and collagen production (Parekkadan et al., 2007a). HGF is able to 
selectively induce apoptosis of activated stellate cells but not normal stellate cells 
(Parekkadan et al., 2007a). Further, Wang et al showed that MSC can produce TGFβ3 which 
behaves in a similar way to HGF and can inhibit collagen 1 and 3 production by activated 
stellate cells by inhibiting ERK1/2 phosphorylation; however the introduction of PDGF into 
the environment can override this inhibition. PDGF is abundant in the liver environment so in 
order for this effect to be observed, PDGF would have to be simultaneously blocked or 
reduced (Wang et al., 2009a). 
 
MSC transplantation into carbon tetrachloride injured mice resulted in recovery from FHF 
again suggesting paracrine mode of action. Although there were rare events where MSC 
differentiated into albumin secreting hepatocyte like cells, liver regeneration seemed to be 
mediated by a reduction of oxidative stress in the liver and by an increase in the proliferation 
and viability of endogenous hepatocytes (Kuo et al., 2008) induced by the MSC. Furthermore 
Mohamadnejad et al showed that infusions of MSC into peripheral veins in cirrhotic patients 
was able to significantly restore liver function and reduce MELD scores in half the patients 
that were treated after 6 months (Mohamadnejad et al., 2007).  
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1.3.5 Immunomodulatory effects of MSC 
 
As part of this thesis we will investigate immunomodulatory effects of MSC and also how 
these may be affected by techniques used enhance engraftment of MSC in the liver. The 
immunomodulatory effects can manifest in a number of ways. Anti-inflammatory effects can 
be carried out through direct cell to cell contact or through paracrine mechanisms. Infiltration 
of inflammatory cells is an essential step leading to liver injury and is an important part in 
causing chronic damage. MSC have a range of effects on immune cells from both the innate 
and adaptive immune systems. MSC may dampen or reduce persistent immune responses that 
can promote fibrosis. MSC are able to suppress the proliferation of cells involved in innate 
immunity including monocytes, dendritic cells (DC), macrophages, natural killer cells (NK) 
(Sotiropoulou et al., 2006) and neutrophils (Puglisi et al., 2011). Jiang et al have reported that 
MSC are able to prevent monocytes from differentiating into DC and can cause mature DC to 
lose stimulatory molecules and cytokines resulting in impaired T cell stimulation (Chiesa et 
al., 2011, Jiang et al., 2005). Early stage DC maturation can be prevented by MSC via IL4, 
GMCSF and PGE2 (Spaggiari et al., 2009). PGE2 has also been implicated in the MSC 
induced suppression of γδ T cells and invariant NK cell proliferation and activation in 
autoimmune disease without affecting the cell antigen presenting capabilities (Prigione et al., 
2009).  
 
Eosinophil infiltration can also be inhibited by MSC during an innate immune response in 
ragweed induced mouse asthma (Nemeth et al., 2010). The mechanism of action appears to 
involve IL4 and IL13 induction of STAT6 which increases TGFβ1 release and therefore 
eosinophil inhibition by MSC (Nemeth et al., 2010). MSC can also have direct effects on 
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adaptive immunity by suppressing NK and T cell responses, blocking B cell differentiation 
and interfering with function of antigen presenting cells. However it is unclear whether this 
occurs via soluble mediators or through cell to cell contact (Puglisi et al., 2011). 
 
1.3.6 Effects of cytokines on immunomodulatory properties of MSC 
 
A key element in this thesis will be to try and identify ways in which cytokines can increase 
the engraftment and therapeutic properties of MSC. There is currently a lot of evidence to 
suggest cytokines can enhance the immunomodulatory properties of MSC. IFNγ and TNFα 
pre-stimulation of MSC has increased immunosuppressive capabilities in numerous reports 
(English et al., 2007, Krampera et al., 2005). In particular, IFNγ stimulated MSC have been 
implicated as being integral to the prevention of graft versus host disease (Polchert et al., 
2008). IFNγ has been identified as the cytokine released by T cells which is responsible for 
the increase in MSC surface B7-H1 which is implicated in T cell suppression through cell to 
cell contact (Sheng et al., 2008). Reports suggest MSC can induce contact-dependent 
suppression on a number of immune cells, but significant non contact dependent suppression 
of immune cell proliferation can only occur after IFNγ stimulation of MSC, with the 
exception of B cells. Perhaps due to the lack of IFNγ expression by B cells, cytokine 
stimulation of MSC is necessary to observe any suppression of B cell proliferation either 
through contact or non contact mechanisms (Krampera et al., 2006). Spaggiari et al report that 
MSC are able to reduce B cell function either by direct contact or through paracrine factors, 
while reducing CD8 T cell proliferation and increasing CD4 T helper cell and regulatory cell 
numbers (Spaggiari et al., 2009). MSC can exert the immunosuppressive effects in a number 
of ways, through TGFβ1 (Soleymaninejadian et al., 2012), IL10 (Yang et al., 2009), PGE2 
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(Soleymaninejadian et al., 2012), IDO (Soleymaninejadian et al., 2012), NO (Ren et al., 
2008), HGF (Soleymaninejadian et al., 2012), HO-1 (Mougiakakos et al., 2011), HLA-G5 
(Selmani et al., 2008) and galectins (Sioud, 2011). Of note, it is now accepted that the NO 
mediated MSC immunosuppressive effects are restricted to mice and not present in humans 
(Ren et al., 2008). 
 
1.3.7 MSC Immunotherapy in liver specific models 
 
Reports of MSC immunotherapeutic effects in models of liver injury are limited. In rat 
models of allogeneic liver transplant, MSC infusions are associated with significantly reduced 
graft rejection (Wang et al., 2009b). Most immunoregulatory effects of MSC as in this case 
seem to work via recruitment and induction of CD4+CD25+FoxP3+ T regulatory cells (Tregs) 
(Di Ianni et al., 2008, Ghannam et al., 2010, Maccario et al., 2005, Prevosto et al., 2007, Ye 
et al., 2008), which are able to assist in suppressing inflammation (Kavanagh and Mahon, 
2011), similar effects were seen in a cardiac allograft model (Zhou et al., 2006). In a 
polyinosinic – polycytidylic acid sodium (polyI:C) induced model of liver injury similar to 
PBC in humans, MSC were able to reduce monocyte infiltration around bile ducts and a 
simultaneous increase in Treg induction was also reported in the circulation and lymph nodes 
(Wang et al., 2011). In a high fat-induced NASH model, obese mice given infusions of 
mesenchymal stem cells from other obese mouse bone marrow showed signs of steatosis only 
without significant hepatitis (Ezquer et al., 2011). Anti-inflammatory effects have also been 
reported in an acute pancreatitis model where there was significantly reduced inflammatory 
cell infiltration after MSC infusion (Jung et al., 2011b). Hong et al showed that infusion of 
IFNγ boosts MSC immune suppression in an in-vivo orthotopic liver transplant model 
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suggesting that cytokine treatment of MSC can enhance their therapeutic effects (Hong et al., 
2009).  
 
1.3.8 The effects of MSC in Cancer 
 
The intrinsic ability of MSC to home to tumours highlights a potentially grey area in MSC 
therapy, the possibility that MSC might support tumour growth (Puglisi et al., 2011). MSC 
may transform into tumours themselves or via their potent immunosuppressive abilities, 
suppress anti-tumour responses, possibly by increasing T regulatory cell numbers (Patel et al., 
2010). MSC effects in cancer are variable and there are contradictory reports in the existing 
literature. MSC associated transplants with colon cancer cells resulted in larger tumours 
developing in nude mice due to the increased angiogenesis and reduced tumour apoptosis 
caused by MSC. MSC can also promote the migration and metastases of tumour cells through 
soluble molecules (Shinagawa et al., 2010). Studies have suggested that MSC can contribute 
to B cell lymphomas but research also shows that MSC can reduce terminal differentiation 
and proliferation of B cells after engraftment into the spleen (Asari et al., 2009, Che et al., 
2012). In contrast to reported tumour promoting effects, MSC have also been described as 
protective against tumour development. Aziz et al have shown MSC were able to suppress 
tumours in a rat HCC model through down regulation of Wnt signalling of target genes 
related to anti-apoptosis, mitogenesis, cell proliferation, and cell cycle regulation (Abdel aziz 
et al., 2011). Other reports also suggest MSC can prevent cancer or reduce it. Recent studies 
involving autologous MSC transplantation in liver failure patients caused by hepatitis B were 
assessed for long term and short term contributions to tumour development but none were 
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observed (Peng et al., 2011). Secchiero et al have also suggested that MSC play an 
insignificant role and have a modest effect on survival of lymphomas (Secchiero et al., 2010) 
 
1.3.9 MSC contribution to fibrosis 
 
This thesis will investigate MSC recruitment to a very hostile and damaged environment 
during liver disease. This means MSC will encounter high levels of factors which may have 
an uncontrolled or unforeseen effect on MSC. Therefore an important question to address in 
this study is whether exogenously administered MSC can contribute to accelerated fibrosis in 
a liver environment. Forbes et al have previously identified that recruitment of other cells 
from the bone marrow occurs during liver fibrosis which take on a myofibroblast phenotype 
and contribute to scarring by depositing excessive levels of extracellular matrix in the injured 
liver (Forbes et al., 2004). Here, cases of gender mismatch transplants in humans with liver 
cirrhosis showed that there were extrahepatic cells and more specifically, cells from the bone 
marrow contributing to the scarring population of myofibroblasts. Morphological studies and 
in-situ hybridisation techniques identified cells that were originally extrahepatic but had 
possibly differentiated to myofibroblasts. Further gender mismatch studies of cirrhotic livers 
suggested that perhaps these cells were from the bone marrow, they infiltrated the liver during 
fibrosis and had subsequently differentiated to a myofibroblast phenotype (di Bonzo et al., 
2008). The presence of bone marrow derived myofibroblast-like cells was clearly identified in 
this study, but data was lacking in respect to how, if at all, these cells contributed to fibrosis.  
 
Subsequently the contribution of these bone marrow derived cells to fibrosis was investigated 
using gender mismatched studies in mouse models of chronic liver disease by Russo et al 
27 
 
(Russo et al., 2006). Female mouse livers were injured in separate experiments by carbon 
tetrachloride and thioacetamide, which cause mass hepatocyte death, and these mice were 
then transplanted with bone marrow from healthy male mice. The study suggested that the 
level of liver fibrosis indicated by αSMA, collagen deposition and transcriptional regulation 
was dependent on recruitment of bone marrow derived cells. Increased cell recruitment 
caused a corresponding increase in myofibroblasts in the liver and contributed to the 
deposition of scar tissue including collagen. To further show that bone marrow cell-dependent 
liver fibrosis played a significant part in scarring of liver tissue, transgenic male Cola1rr bone 
marrow which expressed collagenase-resistant collagen was transplanted into female mice 
(Russo et al., 2006). Upon injury these mice showed significantly more fibrotic tissue in their 
livers than in their control counterparts with wild type bone marrow transplants. The highly 
up-regulated fibrosis in the livers of mice with transgenic bone marrow suggests that the bone 
marrow derived cells make a significant contribution to the scar tissue in fibrotic livers. In the 
same livers the colocalisation of Y chromosome single cells and αSMA corroborates this 
conclusion. 
 
Thus, the bone marrow has been identified as significant contributor to fibrosis in a fibrotic 
organ. However the bone marrow is a mixture of both HSC and MSC. To develop an efficient 
cellular therapy or target it is important to determine what role each of these types of bone 
marrow cells is responsible for within a fibrotic organ. To this end, Russo et al transplanted 
female mice with male bone marrow mesenchymal stromal cells and female HSC and other 
females with female bone marrow stromal cells and male HSC and then induced liver injury 
in these mice with carbon tetrachloride. Through tracking with in-situ hybridisation of the Y 
chromosome Russo identified that female mice with male stromal cells had significantly more 
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Y chromosome-positive myofibroblasts in their fibrotic livers compared to their counterparts, 
suggesting bone marrow stromal cells are the preferentially recruited cells during liver 
fibrosis (Russo et al., 2006). More recently, Sphingosine-1-Phosphate has been identified as a 
multi-functional mediator which may be involved in migration of MSC to liver, and TGFβ1 
has been identified as a mediator of MSC differentiation to myofibroblasts (Li et al., 2009). 
On the contrary, Higayashima showed that such cells rarely took on a myofibroblast 
phenotype and contributed very little to collagen deposition in the liver in models of bile duct 
ligation (Higashiyama et al., 2009).  
 
Research into cells in the bone marrow suggests that hematopoietic stem cells could also 
contribute to the stromal cell compartment in culture (Bucala et al., 1994, Ogawa et al., 
2006). A commonly overlooked contaminating cell which resembles MSC both in terms of 
marker expression and tri-lineage potential, but unlike MSC, promotes fibrosis and 
inflammation, is the fibrocyte. The isolation of MSC is still an unrefined method and as HSC 
derived cells can also be adherent, such cells could dampen down therapeutic effects (Ogawa 
et al., 2006). Little is known of such cells and phenotyping these cells will allow us to identify 
these cells and prospectively exclude them from cultures. The last chapter in this thesis will 
consider mechanisms for isolation and culture of these cells. 
 
1.3.10 Bone marrow derived stromal cells contributing to hepatic fibrosis: HSC derived 
fibrocytes 
 
This thesis will investigate the introduction of MSC to an inflammatory and potentially 
fibrotic environment in the liver. It is therefore essential that we administer a population of 
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cells which will not in any way contribute to the inflammation or fibrosis and will have a 
maximum beneficial effect on the liver. Although MSC have a robust profile of markers for 
their identification from humans and mice, mouse MSC have been shown to express CD34, 
and in some reports isolated populations of human MSC express CD34 but gradually lose 
expression in culture (Delorme et al., 2006). The evidence discussed above suggests that cells 
responsible for laying down scar tissue during liver injury appear to be resident of bone 
marrow derived hepatic myofibroblasts which were shown to be derived from cells enriched 
for mesenchymal stromal cells (Russo et al., 2006). However, in this study there were also 
some myofibroblast like cells that originated from cells enriched for HSC.  
 
Both sets of evidence may reflect a contribution to the myofibroblast population from 
monocyte-derived cells of HSC origin known as fibrocytes. Fibrocytes can be found in tissue 
and in the circulation, they are derived from a hematopoietic lineage and express a 
combination of hematopoietic markers and mesenchymal markers at different stages of their 
maturation (Peng and Herzog, 2012). They are elongated, spindle shaped, cell culture plastic 
adherent cells found in healing wounds and fibrotic lesions (Peng and Herzog, 2012). 
Fibrocytes represent a relatively recently discovered cell, and although literature on fibrocytes 
grew rapidly when they were first identified, research on fibrocytes has equally rapidly 
diminished. Thus further research is needed to characterise these cells and to develop a 
standardised method of isolation.  However it seems clear there is a definite presence of these 
cells in fibrotic tissue (Kisseleva et al., 2006) and it is therefore important to identify how 
these cells may be involved in fibrosis.  
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We have investigated these cells in the current study and our reasons for phenotyping 
fibrocytes further is so that a marker can be determined which allows differentiation between 
fibrocytes and mesenchymal stem cells. Both cell types are plastic adherent, they have a 
similar morphological phenotype, surface antigen profile and tri-lineage differentiation 
potential (Peng and Herzog, 2012). The only reported difference between the two cell types is 
that fibrocytes contribute to inflammation and fibrosis whereas MSC have anti-inflammatory 
and anti-fibrotic properties. There are even similarities in the migratory properties of the two 
cell types. Fibrocytes pose a problem in that without prospective identification isolation and 
depletion of these cells from MSC isolation of bone marrow, these cells may be competing 
with MSC for oxygen and space and not allowing conditions for MSC isolation to be as 
optimal as perhaps they could be. 
 
1.3.11 The mechanism of MSC engraftment 
 
There has been much experimental work investigating direct transplantation of MSC into 
injured liver. However as a valid therapy it is likely that most cells will be delivered to target 
organs using a less invasive method of delivery via the circulation. Thus it is necessary to 
investigate the mechanism of MSC recruitment to the injured liver from circulation. There are 
two potential hypotheses for this mechanism (Figure 1.3). The first is an active mechanism 
similar to the leukocyte recruitment cascade and the second, a passive mechanism where the 
MSC due to their large size get wedged in the small sinusoids within the liver (Karp and Leng 
Teo, 2009). Due to their vast variations in size it is likely that MSC recruitment is a 
combination of these two hypotheses, where the MSC are recruited either actively or by 
getting stuck and then they transmigrate into the liver where they are recruited to specific 
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areas within the liver. At present MSC recruitment to the tissue is loosely based on the model 
of leukocyte migration from peripheral blood circulation to tissue (Ponte et al., 2007). Initial 
contact between the cells and tissue is mediated by adhesion molecules like Selectins and β1 
integrins causing a rolling motion of weakly adherent leukocytes which may be regulated by 
chemokines (Chen et al., 2010). Chemokines (chemotactic cytokines) are a large superfamily 
of small (8-10kda) glycoproteins involved in many biological processes including leukocyte 
trafficking and MSC trafficking. Chemokines on endothelial cells trigger integrin activation 
and cause arrest of the leukocytes which is followed by transendothelial migration of the 
leukocyte into the tissue (Ley et al., 2007). Evidence suggests this transendothelial migration 
is mediated by molecules including PECAM-1, CD99, junction adhesion molecules and 
ICAM-1 (Ley et al., 2007). Once inside the tissue the cells migrate along localised chemokine 
gradients, and finally adhere to target cells or extracellular matrix (Ley et al., 2007).  
 
It seems that leukocytes use molecules such as L-Selectin and α4 integrins amongst others to 
become captured upon endothelial layers before transmigration into tissue (Ley et al., 2007). 
Interestingly MSC do not use L-Selectin, suggesting that although the mechanism for 
migration of the two different cells may be similar, different adhesion molecules and 
chemokines are involved.  It is likely that MSC recruitment into tissue will involve processes 
of arrest in tissue vasculature followed by transmigration across the endothelium. Based on 
these processes, there are potentially two important mechanisms for MSC recruitment. Firstly 
the cell may become lodged in narrow tissue vasculature, alter the blood flow through the 
capillary and as a result of a chemokine gradient in the inflammatory part of the tissue or the 
firm attachment of adhesion molecules, the cell may transmigrate.  The second potential 
pathway is more akin to the leukocyte mechanism where the MSC may tether and roll at a 
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part of a tissue where a chemokine gradient exists due to injury in that area.  The cell without 
changing the blood flow would then quickly flatten and spread onto the endothelium and 
probably transmigrate. It is still unclear what may occur during the lodged MSC 
transmigration but the second method could involve P-Selectin, VLA-4 and VCAM-1 during 
rolling, ICAM-1, VLA-4 and VCAM-1 during firm adhesion and VLA-4, VCAM-1, MMP 
and TIMP during transmigration (Karp and Leng Teo, 2009). Ruster et al have shown with 
knockout mice that P-Selectin is involved in mediating the rolling of human MSC along 
endothelium via a novel carbohydrate ligand expressed by the MSC (Ruster et al., 2006). 
Various other adhesion molecules are expressed by MSC including VCAM-1, ICAM-1, 
ICAM-3, ALCAM and endoglin/ CD105, as well as many integrin molecules including α 1, 2, 
3, 4, 5, v; β1, 3 and 4 (Karp and Leng Teo, 2009). In particular α4β1 integrin has been shown 
to be involved in firm adhesion of MSC to endothelial cells under shear flow conditions via 
VCAM-1 (Karp and Leng Teo, 2009). We have previously described the role of β1 integrin 
and CD44 in MSC engraftment in injured liver but the role of CCR within this mechanism has 
not been elucidated (Aldridge et al., 2012). 
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Figure 1.3: Proposed mechanisms of MSC engraftment into the liver.  
There are two potential hypotheses for the mechanism of engraftment. A passive 
mechanism where the MSC due to their large size get wedged in the small sinusoids 
within the liver (A) or an active mechanism similar to the leukocyte recruitment 
cascade (B). In the active process rolling occurs due to the actions of P Selectin, 
followed by firm adhesion through ICAM-1 and finally by MMPs and TIMPs.   VLA-
4 and VCAM-1 seem to interact throughout this process. Due to their vast variations 
in size, it is likely that initial stages of MSC recruitment are a combination of these 
two hypotheses, where the MSC are recruited either, actively or by getting stuck. 
However later stages of recruitment involving transendothelial recruitment must occur 
through a shared active mechanism (C). CCR may play a role in multiple stages of this 
recruitment which have not yet been elucidated. 
 
To try and understand the role of CCR in the MSC recruitment mechanism to the liver, we 
can look to the well characterised recruitment of the hematopoietic stem cell. A larger body of 
research into HSC adhesion and recruitment has suggested the CXCR4-SDF1α /CXCL12 
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(which is up-regulated in tissue injury and inflammation) CCR-ligand interaction is 
responsible for HSC migration to injured tissue (Fox et al., 2007). As CXCR4 is also a well 
established migratory chemokine in leukocytes, it was hypothesised that MSC may also use 
the CXCR4-SDF1α /CXCL12 axis to migrate and engraft to injured tissue (Wynn et al., 
2004). This was investigated by Ip et al using blocking assays with murine MSC in mice with 
heart injury. However their hypothesis investigated whether CXCR4 was responsible for cell 
engraftment into tissue and unsurprisingly they found the adhesion molecule β1 integrin and 
not CXCR4 was responsible for engraftment. The findings of Ip et al suggest β1 integrin may 
be important for the adhesion mechanism but do not exclude CXCR4 from playing some part 
in the entire mechanism of homing, perhaps as part of the rolling mechanism prior to 
adhesion, or as a localisation signal once the cell has entered the tissue (Ip et al., 2007). 
Interestingly, in culture, MSC show little or no expression of CXCR4 and some groups 
suggest that only a subset of cells demonstrate extracellular expression of CXCR4 (Fox et al., 
2007, Wynn et al., 2004). However this may be due to a downregulation of adhesion 
receptors and CCR when MSC are cultured in-vitro. Receptor profiles are further distorted on 
these cells when cells are trypsinised and detached from their culture surfaces. Cell 
detachment mediums, like TrypLE may be responsible for cleaving some receptors off the 
cells and resting the cells in suspension before using them has been shown to cause the cells 
to regain some of their original receptor expression (Chamberlain et al., 2007, Chamberlain et 
al., 2008).  
 
It seems that due to this changeable extracellular phenotype, reported MSC CCR profiles tend 
to vary between different groups and even between isolations when the procedure is kept the 
same.  Due to the complexity of the MSC there seems to be an ever increasing amount of data 
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emerging about their migration mechanisms. This suggests that small changes in an 
environment and particularly the systemic and local inflammatory state of the environment 
can alter the chemokine profiles of MSC and may influence cell mobilisation and their 
subsequent homing to injured tissues. 
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1.3.11.1 Chemokine Receptors (CCR) 
 
This thesis will investigate the role of CCR in engraftment of MSC and so it is important to 
review the way in which these CCR function. As we are interested in MSC recruitment I will 
review the major CCR likely to be of importance. CCR (Table 2.2) are membrane bound, 7 
transmembrane domain receptors coupled to G-proteins. Generally CCR measure 
approximately 350 amino acids in length and are very similar to each other in their primary 
sequences. They have a short extracellular acidic N terminus and may be sulphated on 
tyrosine residues and contain N linked glycosylation sites. Receptors have an intracellular C 
terminus containing serine and threonine residues that act as phosphorylation sites for 
receptor regulation. On their 7 α helical transmembrane domains, they have 3 extracellular 
and 3 intracellular connecting loops composed of hydrophilic amino acids and these domains 
are positioned perpendicularly to the plasma membrane. A disulphide bond links highly 
conserved cysteines in extracellular groups 1 and 2. G proteins are coupled through the C 
terminus segment and possibly through the third intracellular loop (Murdoch and Finn, 2000). 
There are a number of CCR, but two of the families of CCR we will focus on in this study are 
listed in Table 1.2. 
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Table 1.2: Chemokine receptors (CCR) 
 
Group Receptor Ligand 
CC CCR1 MIP1α/CCL3, Rantes/CCL5 
MCP3/CCL7, MCP2/CCL8, 
MCP4/CCL13, 
HCC1/MIP1δ/CCL15, 
HCC4/CCL16, MPIF/CCL23 
CCR2 MCP1/CCL2, MCP3/CCL7, 
MCP2/CCL8, MCP4/CCL13 
CCR3 Rantes/CCL5, MCP3/CCL7, 
MCP2/CCL8, Eotaxin/CCL11, 
MCP4/CCL13, 
HCC1/MIP1δ/CCL15, 
Eotaxin2/CCL24, 
Eotaxin3/CCL26  
CCR4 Rantes/CCL5, TARC/CCL17, 
MDC/CCL22 
CCR5 MIP1α/CCL3, MIP1β/CCL4, 
Rantes/CCL5, MCP2/CCL8  
CCR6 MIP3α/CCL20 
CCR7 6Ckine/CCL21 
CCR8 I309/CCL1, TARC/CCL17 
CCR9 Teck/CCL25 
CCR10 CTACK/CCL27, CCL28 
CXCR CXCR1 IL8/CXCL8 
CXCR2 GROα/CXCL1, 
GROα/β/CXCL2 
GROγ/CXCL3, 
ENA78/CXCL5, 
GCP2/CXCL6, NAP2/CXCL7, 
IL8/CXCL8 
CXCR3 MIG/CXCL9, IP10/CXCL10, 
ITAC/CXCL11, PF4/CXCL4 
CXCR4 SDF1α/ CXCL12 
CXCR5 BCA1/CXCL13 
CXCR6 CXCL16 
CXCR7 SDF1α/ CXCL12 
 
 
Intracellular signalling via CCR (Figure 1.4) with the exception of CXCR7 depends on 
coupling to heterotrimeric G proteins. CXCR7 is a scavenger receptor so signals differently to 
other receptors in its group. During ligand binding CCR bind G proteins and activate them. G 
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proteins are activated when their subunit which is usually bound to guanosine diphosphate 
(GDP) is exchanged for guanosine triphosphate (GTP), which causes the G protein to 
dissociate into α and β subunits. Gβ subunits are able to activate the membrane associated 
enzyme phospholipase Cβ2 (PLC2) which in turn cleaves phosphatidylinositol 4, 5-
bisphosphate (PIP2) to form the intracellular second messages phosphatidylinositol 1, 4, 5-
triphosphate (IP3) and diacyl-glycerol (DAG). IP3 mobilises calcium from intracellular stores 
but DAG acts in conjunction with calcium to activate various isoforms of protein kinase C 
(PKC). PKC and other calcium sensitive protein kinase activation catalyse protein 
phosphorylation, thus activating a series of co-ordinated signalling events leading to cellular 
responses. G coupling can lead to activation of several downstream effectors including the 
Rock and Rho, phospholipase A2, phosphotidylinositol-3-kinase, tyrosine kinases and the 
MAP kinase pathway (Murdoch and Finn, 2000). After stimulation, CCR become partially or 
totally desensitized to repeat stimulation with same or other agonists. This process involves 
serine and threonine residue phosphorylation in the C tail of the receptor by G protein coupled 
receptor kinases and receptor sequestration by internalisation. This may be a critical process 
for the receptor to sense chemokine gradients (Murdoch and Finn, 2000). 
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Figure 1.4: CCR signalling.  
CCR recognise and bind ligand, to initiate signalling with G protein activation, 
characterised by dissociation of α and βγ unit heterotrimers. Down-stream effectors 
include MAPK, PI-3K and PLC. Desensitisation starts with C terminal CCR tail 
phosphorylation, increasing the affinity of β arrestin proteins for the receptor and 
prevents further interaction between CCR and G proteins. Clathrin mediated 
internalisation of the ligated CCR into vesicles is promoted by G protein coupled 
receptor kinases (GRK) - β arrestin complex and requires GTPase activity of dynamin. 
The internalised receptor is then degraded or recycled. Illustration reproduced from 
(Savarin-Vuaillat and Ransohoff, 2007). 
 
CXCR7 acts as a decoy receptor responsible for clearing chemokines from an inflammatory 
environment preventing or resolving inflammation. It therefore controls the availability of 
chemokines for leukocyte trafficking via CXCR4 and thus regulates innate or adaptive 
immune responses acting as a guidance cue. Unlike other CC or CXC family receptors, 
CXCR7 is classified as a 7TMD-receptor and not as a GPCR because G protein coupling 
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cannot be demonstrated after ligand activation (Thelen and Thelen, 2008). Recent research 
demonstrates that the SDF-1α/CXCL12-CXCR7 signalling pathway regulates genes distinct 
from the SDF-1α/CXCL12-CXCR4 pathway, involved in cell cycle control, amino acid 
metabolism and ligase activity (Yoshida et al., 2009). 
 
1.3.11.2  Integrins 
 
For the purposes of this study which is mainly based on CCR function in MSC engraftment it 
is important to also consider the role of integrins, which have been shown to play a major role 
in MSC engraftment to the injured liver (Aldridge et al., 2012). I, therefore describe the 
various groups of integrins and methods by which integrins are known to function. Integrins 
are one of the major families of cell adhesion and matrix binding receptors. There are 24 α/β 
heterodimers which anchor cells to ECM, plasma proteins or counter-receptors on other cells 
(Humphries et al., 2006). In vertebrates integrins can be separated into four categories listed 
in Table 1.3.  
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Table 1.3: Integrins subfamily 
 
Group Integrins Bind 
RGD binding integrins α5β1, α8β1, α11bβ3, αVβ1, 
αVβ5, αVβ6, αVβ8 
ECM glycoproteins, 
fibronectin, vitronectin, 
fibrinogen 
Non-αA-domain-containing 
laminin-binding integrins 
α3β1, α6β4, α6β1, α7β1 Laminins 
LDV-binding integrins 
SVVYGLR* 
α4β1, α4β7, α9β1, αEβ7 Fibronectin, VCAM-1, 
MAdCAM-1, Osteopontin* 
A-domain β1 integrins 
 (subgroup) 
α1β1, α2β1, α10β1, α11β1 
(αDβ2, αEβ7, αLβ2, αMβ2, 
αXβ2) 
Laminin, collagen 
(Leukocytes, collagen) 
 
The first integrin group recognises the arginine-glycine-aspartic acid motif which binds at an 
interface between α and β subunits. The arginine residue binds to a cleft in a β propeller 
module in the α subunit and the D residue coordinates a cation bound in the von Willibrand 
factor A-domain in the β subunit. β3 integrins bind to a large number of ECM and soluble 
vascular ligands. Ligands are shared by these integrins but the rank order of ligand affinity 
varies reflecting the precision fit of RGD conformation within the specific α-β active site 
pocket (Humphries et al., 2006, Ivaska and Heino, 2011). The second group is widespread in 
the animal kingdom. β4 integrin is structurally unique among all integrins due to a large 
intracellular domain with several phosphorylation sites serving as a docking site for many 
signalling proteins. The LDV connecting ligand in fibronectin lies in its Type III connecting 
segment (Humphries et al., 2006, Ivaska and Heino, 2011). The third group includes the β2 
integrin family subgroup, which has a different mode of ligand binding. The major interaction 
takes place through an inserted A-domain in α subunit. β1/β7 ligands employ an aspartate 
residue for cation coordination whereas β2 integrins use glutamate (Humphries et al., 2006, 
Ivaska and Heino, 2011). The fourth group of integrins, have proteins which are structurally 
different from all other subunits. They contain an extra α inserted domain similar to von 
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Willebrand factor A and these are found only in chordates. A crystal structure of a complex 
between the α2 A-domain and a triple-helical collagenous peptide has revealed the structural 
basis of the interaction, a critical glutamate within a collagenous GFOGER motif providing 
the key cation-coordinating residue (Humphries et al., 2006, Ivaska and Heino, 2011). 
 
The ECM regulates cell proliferation, survival, differentiation and metabolism and integrins 
are the main mediators of ECM generated cellular signals. As integrins do not possess any 
enzyme activity, signalling is dependent on binding of short cytoplasmic integrin domains to 
intracellular proteins. β integrins interact with lots of cytoskeletal and signalling proteins 
whereas α subunits play an important role in heterodimer specific signalling. Transmission of 
signals through the plasma membrane occurs through ligand induced conformational changes 
in β subunits. Receptors activate after separation of α and β subunits (Humphries et al., 2006, 
Ivaska and Heino, 2011). Integrins also mediate mechanical stress related signals. Mechanical 
forces stretch integrin associated intracellular proteins to unveil novel cryptic binding sites 
and in this manner create new protein-protein interactions. High resolution microscopy allows 
visualisation of integrin generated adhesion sites (Figure 1.5) (Ivaska and Heino, 2011). 
  
43 
 
 
Figure 1.5: Schematic diagram of typical Integrin structure  
(A) Schematic diagram of integrin structure. The overall structure is of a head region 
[propeller and thigh domains of α subunit and the βA (also known as β1), hybrid and 
PSI domains of the β subunit] supported on calf1 and calf2 domains in the α subunit, 
EGF repeats and β tail domain in the β subunit. The binding of ligands takes place at 
an interface between the propeller domain and the βA domain. Image reproduced from 
(Askari et al., 2009). 
 
1.4 Hypotheses and Aims 
 
To date, major limitations in MSC therapy which lead to low efficacy are the inefficient 
engraftment of MSC after infusion or the crude isolation methods of MSC due to an apparent 
lack of a marker for prospective isolation. As part of this project I attempt to address both 
these aspects of limited engraftment and impure MSC populations obtained during isolation.  
 
During liver disease there is a major influx of inflammatory immune cells from circulation. 
This is largely mediated by increased cytokine levels in the liver which are able to induce 
recruitment of circulating cells through interaction with corresponding surface ligands such as 
chemokine receptors. Thus I hypothesise that ex vivo stimulation of MSC with these cytokines 
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may increase recruitment of MSC to diseased liver environments through chemokine receptor 
upregulation. 
 
Due to the lack of specific MSC marker allowing for the prospective isolation of MSC it is 
necessary to be able to refine or purify the MSC populations that are isolated in order to get 
maximum and reproducible efficacy. Previously, combinations of markers have been used to 
try and isolate MSC but with limited success. Fibrocytes are a bone marrow derived 
population of cells which could remain undetected in MSC isolations and reduce the 
therapeutic potential of the MSC. There is no known marker which is retained by fibrocytes in 
culture that can allow it to be identified from MSC isolations. Fibrocytes can be isolated from 
the blood as adherent CD45+ cells which express collagen-1 in long term culture and 
eventually lose their CD45 expression. However in the literature, phenotypic data regarding 
fibrocytes is limited and contradictory. Thus I hypothesise that if fibrocytes can be isolated 
from blood and kept in long term culture, they may express markers which could allow them 
to be distinguished and depleted from MSC isolations to yield refined and purer populations 
of therapeutic MSC. 
 
This project focuses on three main areas of MSC biology. The mechanism for MSC 
recruitment to injured liver is likely to closely resemble the leukocyte recruitment cascade 
where CCR play an integral role. However studies investigating CCR expression on MSC 
report an inconsistent repertoire of receptors. A reason for this may be the method by which 
MSC are detached from tissue culture plastic. Our first goal focuses on the effects of MSC 
detachment methods on viability, tri-lineage differentiation potential, and immunomodulatory 
capabilities of the MSC and CCR expression. 
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Studies have shown that cytokine stimulation of MSC can alter their CCR expression and as a 
result, their migratory and adhesive potential. However treatment of MSC with cytokines has 
also been reported to differentiate MSC to a progenitor phenotype and alter their anti-
inflammatory properties. Therefore our second goal investigates the effect of prevalent 
cytokines in liver injury on MSC CCR expression and subsequent engraftment in animal 
models of liver injury.  
 
The ultimate goal for research into MSC therapy is for it to be used as a viable clinical 
intervention. However based on recent research some reports have raised concerns about the 
safety of using MSC clinically. One of the concerns is that MSC could contribute to fibrosis 
and this could be the result of contaminating cells called fibrocytes. In the final chapter we 
have attempted to isolate and phenotype fibrocytes using existing and modified techniques 
with a view to identify and deplete cells which are responsible for pro-fibrotic effects, from 
future studies where we may attempt to isolate MSC from human bone marrow.   
 
The specific aims of this project were to: 
 
(i) Assess the effects of MSC detachment methods on viability, tri-lineage 
differentiation potential, immunomodulation and CCR expression. 
 
(ii) Test the effects of prevalent cytokines in liver injury on MSC CCR expression and 
subsequent engraftment in animal models of liver injury and immunomodulatory 
properties. 
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(iii) Isolate and phenotype fibrocytes using existing and modified techniques with a 
view to identify and deplete cells responsible for pro-fibrotic effects, from future 
studies where we may attempt to isolate MSC from human bone marrow.   
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CHAPTER 2: MATERIALS AND METHODS  
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2.1 Human Tissue 
 
Human liver tissue was obtained from explanted diseased livers including Alcoholic liver 
disease (ALD), Autoimmune hepatitis (AIH), Primary Biliary Cirrhosis (PBC), Primary 
Sclerosing Cholangitis (PSC), Non-alcoholic steatohepatitis (NASH) patients, after 
transplantation. Normal tissue was also taken, which was surplus to transplantation 
requirements, or from tumour margins collected during resection surgery from patients at the 
Queen Elizabeth Hospital, Birmingham, UK. Peripheral blood was obtained from patients 
undergoing routine venesection for haemachromatosis at Queen Elizabeth Hospital, 
Birmingham, UK. Serum was also collected from normal patients and patients admitted to the 
Queen Elizabeth Hospital Liver Unit with Alcohol-induced liver injury. All human tissue and 
blood samples were collected with local research ethics committee approval and written, 
informed patient consent. 
 
2.2 Isolation of human hepatic sinusoidal endothelial cells (HSEC), biliary 
epithelial cells (BEC) and hepatic myofibroblasts (MF) and peripheral blood 
mononuclear cells (PBMC). 
 
Cells were isolated from explanted diseased human livers using standard protocols (Crosby et 
al., 2009). Liver tissue was finely chopped and digested with collagenase type 1A (0.4mg/ml, 
Sigma), filtered through a fine mesh into a beaker, washed several times with PBS and 
separated on a 77% and 33% Percoll (GE Healthcare) gradient to remove parenchymal cells. 
The band of cells at the interface was removed, and washed several times with PBS. Anti-
HEA 125 antibody (5µg/ml Progen Biotec) bound to magnetic goat anti-mouse Dynabeads 
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(Invitrogen) was used to positively select BEC. The remaining unselected cells were exposed 
to anti CD31 antibody (10µg/ml, Invitrogen) bound to magnetic goat anti-mouse Dynabeads 
(Invitrogen) to collect HSEC. HSEC and BEC were cultured in appropriate media (Table 2.1) 
on rat tail collagen (Sigma) coated flasks. 
 
Myofibroblasts (MF) were also isolated from human livers for adhesion assays and as positive 
control cells for alpha smooth muscle actin (αSMA) and collagen-1 expression. Following 
positive selection of BEC and HSEC from tissue digests, CD45+ cells in the remainder were 
selected using anti CD45 antibody (R and D Systems, 10µg/ml) and Dynabeads (Invitrogen) 
as before. Selected cells were plated in fibroblast media or on occasion RPMI-1640 
containing 10% FCS, 1% PSG, 1% NEAA and 1% Sodium Pyruvate (all Invitrogen). 
Fibrocytes were isolated from whole blood or buffy coats layered onto a density separation 
gradient (Lympholyte, Cedarlane Laboratories or Ficoll-Paque, GE healthcare) and 
centrifuged for 30 minutes at 900xg. The mononuclear cell layer was removed, washed with 
buffer (PBS or HBSS, both Sigma) and the pellet was re-suspended in medium (DMEM 
containing 20% Heat Inactivated FBS, and 1% PSG (all Invitrogen)). Cells were then plated 
into ‘Cell-Bind’ (Corning, Appleton Woods Ltd), or conventional 24 well plates or culture 
flasks, with or without a fibronectin (10µg/ml in PBS, Sigma) coating.  
 
To ensure removal of contaminating T cells, B cells and monocytes from fibrocyte cultures, 
isolated PBMC were cultured for 5 days without washing and then media was changed 
regularly for a further 14 days. Cells were then removed from plates using Accutase 
(Innovative Cell Technologies) and negatively selected by removal of CD2+, CD19+ and 
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CD14+ contaminating cells using CD2 (4x108beads/ml), CD19 (4x108beads/ml) and CD14 
(4x108beads/ml) conjugated Dynabeads (all Invitrogen).  
 
On occasion the effects of different cell detachment and isolation methods on fibrocyte 
cultures were assessed. Again total PBMC were isolated from blood and suspended in a 
known volume of media. Cells isolated using Lympholyte or Ficoll-Paque were counted to 
compare cell yields using a haematocytometer as described below (section 3.3).  
 
 
Table 2.1:  Cells used for this study and details of culture media used for propagation 
 
Cells 
Name 
Species: 
Tissue 
Split ration 
Growth media and 
Source 
Cell origin 
MSC 
Human: 
Bone 
marrow 
1:3 
MSC Growth Medium 
(MSCGMTM) (Lonza) 
Primary mesenchymal 
stem cells (MSC) isolated 
from human bone marrow, 
purchased from Lonza. 
HSEC 
Human: 
Liver 
1:2 
Human Endothelial 
Basal Growth Medium 
(Invitrogen), 1% 
Glutamine, Penicillin, 
Streptomycin (PSG, 
Invitrogen), 10% Heat 
Inactivated Human 
Serum, 10ng/ml 
Hepatocyte Growth 
Factor (HGF), 10ng/ml 
Vascular Endothelial 
Growth Factor (VEGF, 
PeproTech). 
Human sinusoidal 
endothelial cells (HSEC), 
isolated as primary 
cultures from human liver 
tissue. 
BEC 
Human: 
Liver 
1:2 
DMEM (Invitrogen), 
10% Heat-Inactivated 
Human Serum, 2mM 
Glutamine, 10ng/ml 
HGF (PeproTech), 
10ng/ml EGF 
(PeproTech), 2mg/ml 
Hydrocortisone, 
Biliary epithelial cells 
(BEC), isolated as primary 
cultures from human liver 
tissue 
51 
 
 
2.3 Cell culture and viability measurement 
 
All primary cells used in this study are detailed in Table 2.1 with details of the media in 
which they were propagated. Cells were maintained in sterile tissue culture flasks or well 
plates as required, and grown at 37oC in 5% CO2. All tissue culture was carried out in a class 
II microflow safety cabinet using aseptic technique and cell growth was monitored using an 
inverted phase contrast microscope. 
10ng/ml Cholera toxin 
(Sigma Aldrich), 2nM 
Tri-iodo-thyronine 
(Sigma Aldrich) 
0.124U/ml Insulin 
100IU/ml Penicillin 
and 100mg/ml 
Streptomycin 
(Invitrogen). 
MF 
Human: 
Liver 
1:2 
Dulbeccos modified 
Eagle Medium 
(DMEM, Invitrogen), 
10% Heat Inactivated 
Foetal Calf Serum 
(FCS, Invitrogen), 1% 
PSG 
Liver myofibroblasts 
(MF), isolated as primary 
cultures from human liver 
tissue 
Fibroblasts 
Human: 
Synovial 
fluid 
1:2 
RPMI-1640 
(Invitrogen), 20% 
FCS, 1% PSG, 1% 
Non Essential Amino 
Acids (NEAA; 
Invitrogen) , 1% 
Pyruvate (NEAA; 
Invitrogen) 
Primary synovial 
fibroblasts were a gift 
from Professor Chris 
Buckley and Dr Andy 
Filer, of The 
Rheumatology group, 
Immunity and infection. 
University of 
Birmingham. 
Lymphocytes 
Human: 
Peripheral 
blood 
----- 
RPMI-1640, 10% 
FCS, 1% PSG  
Lymphocytes, isolated as 
primary cultures from 
human peripheral blood 
PBMC 
Human: 
Peripheral 
blood 
----- 
RPMI-1640, 10% 
FCS, 1% PSG  
Peripheral blood 
mononuclear cells 
(PBMC), isolated as 
primary cultures from 
human peripheral blood 
52 
 
 
To passage cells, media was removed and cells were washed with PBS (Phosphate Buffered 
Saline, Oxoid UK). In general, adherent cells were passaged using TrypLE (Invitrogen), 
followed by incubation at 37oC with gentle agitation. The enzymatic activity of the TrypLE 
was neutralised using spent media and cells were collected by centrifugation at 550xg for 5 
minutes. For cultures of non-adherent cells in suspension which did not require detachment, 
cells were centrifuged at 550xg for 5 minutes. Cell pellets were then re-suspended in new 
media and seeded into new culture flasks.  
 
In contrast, several detachment methods were used for cultures of multiple human MSC 
donors. MSC were purchased from a commercial source called Lonza, designated P1 upon 
arrival from and were grown through multiple passages and used at P4. All experiments were 
repeated with multiple MSC isolates/ donors. MSC were detached from culture flasks using 
enzymatic and non-enzymatic methods. For enzymatic detachment MSC were incubated at 
37oC with either TrypLE (Invitrogen) or Accutase (ebiosciences) for 5 minutes and gently 
agitated until cells detached, at which point enzyme activity was neutralised with MSCGMTM. 
Non-enzymatic methods included incubation of cells with Cell Dissociation Buffer (CDB, 
Sigma) or EDTA (Sigma) at 37oC in a CO2 incubator for 5 minutes with gentle agitation until 
they detached. MSC were also detached by gentle scraping with cell scrapers (BD 
Biosciences).  
 
For long-term storage, cells were cryopreserved in liquid nitrogen. Briefly cells were 
detached, pelleted and re-suspended in freezing media (FCS 5% dimethylsulfoxide (DMSO; 
Sigma)). 1ml aliquots of cells were placed in cryovials at -80oC in a Mr FrostyTM freezing 
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container (Wessington Cryogenics) to permit gradual cooling to minimise cell damage. After 
24 hours, cryovials were transferred to liquid nitrogen for long term storage.  
 
The viability of cells was measured using several methodologies. Firstly, following 
detachment, cells were diluted 1:5 in Trypan blue (Sigma) and 5µl was added to a 
haematocytometer. Viable (unstained) cells were counted and total cell number was 
calculated by multiplying viable cell counts by the dilution factor (5) and by 104 to yield total 
cell count (cells/ml). Alternatively viability of MSC was also determined cytometrically. For 
details of labelling protocols see section 2.6 below. Here, after detachment MSC were 
incubated with an APC labelled live dead cell marker (Invitrogen, 1ul per 1x106cells/ml, 
according to manufacturers instructions) and analysed using a Dako Cyan ADP flow 
cytometer and Summit version 4.3 software. Live and dead MSC were identified by two 
characteristic peaks on an APC histogram. The APC low peak was characteristic of a viable 
cell population and the APC high peak of non viable cells.   
 
Ability of detached MSC to reattach to plastic was also used to assess their functional 
viability. Here MSC were washed with PBS alone or PBS supplemented with PBS 1% FCS 
and centrifuged for 5 minutes at a speed of 900xg or 500xg, before re-suspension in 
MSCGMTM and re-plating on tissue culture plastic. Representative phase contrast microscopic 
images of MSC were captured at 1, 3 and 5 days after re-plating. In addition MTT (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide, Sigma) was used to assess 
function of re-plated cells. MSC were incubated with 0.4mg/ml of MTT for 1 hour at 37oC 
before washing with PBS. Incorporated formazan salts were solubilised with 600µl DMSO 
for 5 minutes with agitation. Supernatants were added to 96 well plates in triplicate and 
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absorbance values were determined at 570nm. Background absorbance signals from DMSO 
alone were subtracted from test values. 
 
2.4 Attachment of cells onto microscope slides using Cytospin  
 
Suspensions of lymphocytes, myofibroblasts or synovial fibroblasts were washed in PBS and 
re-suspended in PBS 0.1% BSA to a concentration 1x106cells/ml. The total cell number was 
adjusted to yield 1.5x105cells per slide in 150µl volume and then aliquots were cytospun 
(Shandon Cytospin) for 5 minutes at 2300xg onto poly-l-lysine (10%, Sigma) coated slides. 
Slides were then air dried, fixed with acetone for 5 minutes, wrapped in foil and stored at -
20oC until used in staining experiments 
 
2.5 Immunohistochemistry 
 
Immunohistochemical analysis was used to quantify receptor expression within human liver 
sections and cytospins or wells of cultured cells. Tissue section slides and cytospin cell slides 
were acetone fixed for 5 minutes, air dried, wrapped in foil and stored at -20oC until needed at 
which time they were thawed for 30 minutes at room temperature. Cells grown in well plates 
were fixed with methanol for 5 minutes, washed with PBS and then stored in PBS at 4oC 
before staining was carried out in wells. A reservoir was created around tissue sections using 
a wax pen (The Binding Site) and subsequent staining was carried out in a humidified 
chamber.  
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Sections were incubated with H202 (Sigma 0.3% in methanol (VWR)) for 30 minutes at room 
temperature on a rocking platform to block non specific endogenous peroxidase activity. 
Following a wash with PBS 0.1% Tween 20, Casein (Vector) 10% in goat serum (Sigma) was 
used to block the specimen for 30 minutes at room temperature on a rocking platform. If a 
biotinylated primary antibody was to be used with streptavidin secondary antibodies, an 
Avidin/Biotin blocking kit (Vectorlabs) was used to reduce any background staining. The 
specimen was incubated in Avidin D solution for 15 minutes at room temperature and with 
Biotin solution for a further 15 minutes, and rinsed briefly before the primary antibody was 
added.  
 
Pre-determined optimal concentrations of primary antibody (Table 2.2) were diluted in PBS 
and incubated on sections at room temperature on a rocker for 1 hour. Sections were washed 
three times with PBS 0.1% Tween 20 and then HRP-conjugated secondary antibody was 
diluted to the working concentration (Table 2.2) in PBS and added to the specimens for 1 
hour. Sections were washed as before and incubated with DAB substrate (DAB reagent and 
substrate, ABD serotec) for 2 to 5 minutes and then washed with tap water. Similar protocols 
were used for cytospins of cultured cells. Finally, sections or cells were counterstained with 
Mayer’s Haematoxylin (VWR) for 15-30 seconds and washed under running tap water to 
“blue”. Sections were dehydrated through graded alcohol (IMS gradient 50%, 70%, and 100% 
for 3 minutes) and incubated twice for 2 minutes in Clearene (Leica Microsystems) before 
mounting with a coverslip (Leica Microsystems Surgipath, Premier Coverglass) using DPX 
mountant (Leica Biosystems). Cells stained in wells were similarly treated with alcohol 
gradient but then washed and covered with PBS and viewed using an inverted microscope. 
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MSC grown to confluence on glass coverslips in 24 well plates and fixed with methanol were 
stained using similar protocols to those described above. However following applications of 
primary (Table 2.2) and secondary antibodies (Table 2.2), cells were treated with Nova red 
substrate (Vectorlabs) for 2 to 5 minutes, washed with tap water, counterstained with Mayer’s 
Haematoxylin for 30 seconds and “blued” under running tap water. MSC were dehydrated 
and stored in PBS before bright field microscopic images were captured at x40 magnification. 
 
PBMC were isolated and seeded in 24 well plates and fixed with methanol. Endogenous 
peroxidase in PBMC was blocked with H202 (0.3% methanol), and casein 10% goat serum. 
PBMC were incubated with pre-determined optimal concentrations of unconjugated primary 
antibodies for collagen 1, CD45, CXCR4, and αSMA for 1 hour alongside controls listed in 
Table 3.2. PBMC were washed with and incubated with Vectastain ABC kit (Vector Labs). 
PBMC were washed and incubated with DAB (Sigmafast Diaminobenzidine tablets, Sigma) 
substrate for 2 to 5 minutes, washed with tap water, counterstained with Mayer’s 
Haematoxylin for 30 seconds and “blued” under running tap water. PBMC were dehydrated 
and stored in PBS before bright field microscopic images were captured at x10, x20 and x40 
magnification. Fibroblasts cytospun on glass slides were used as positive controls for collagen 
1, αSMA and lymphocytes for CXCR4 and CD45. 
 
Paraffin embedded mouse livers were sectioned using a microtome and stained using a 
standard Van Geison protocol. Briefly, after dewaxing and sections were stained with Celestin 
Blue (Leica Biosystems) for 5 minutes, rinsed in dH2O and stained in Mayer’s haematoxylin 
for 5 minutes. Sections were washed well in running tap water for 5 minutes and flooded with 
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Van Gieson stain for 5 minutes. Finally sections were then dehydrated rapidly in alcohols, 
cleared and mounted in DPX. 
 
Hematoxylin and Eosin (Leica Biosystems) staining was carried out on PBMC in 24 well 
plates to identify cell morphology.  Sections were raised in dH2O stained in Haematoxylin for 
4 minutes, in 0.3% acid alcohol for 30 seconds, tap water for 5 minutes and eosin for 2 
minutes with intermittent 5 minute tap water rinses between each step. 
 
Table 2.2: Antibodies for IHC 
 
CCR antibodies 
1oAntibody Type Working 
Conc. 
Source 
Anti-human CCR4 Goat IgG 50ug/ml Pierce antibodies, Thermoscientific 
Anti-human CCR5 Rabbit IgG 20ug/ml Abcam 
Anti-human CCR9 Rabbit IgG 10ug/ml Pierce antibodies, Thermoscientific 
Anti-human 
CXCR3 
Rabbit IgG 20ug/ml Abcam 
Anti-human 
CXCR4 
Rabbit IgG 20ug/ml Abcam 
Anti-human 
CXCR7 
Mouse IgG2A 25ug/ml R and D Systems 
Controls 
Rabbit IgG  ------- 20ug/ml R and D Systems 
Rabbit IgG 
(CCR9) 
------- 10ug/ml R and D Systems 
Rabbit IgG2A 
(CXCR7) 
------- 25ug/ml Dako 
Goat IgG  50ug/ml R and D Systems 
Secondary antibodies 
Goat anti Rabbit 
HRP 
------- 1 in 1000 Abcam 
Rabbit anti Goat 
HRP 
------- 1 in 1000 Abcam 
Rabbit anti mouse 
HRP 
------- 1 in 1000 Abcam 
Fibrocyte phenotyping antibodies 
Antibodies Type IHC 
Conc. 
IF Conc. Flow Cytometry Source 
Anti-human CD45 Mouse IgG1 5ug/ml ------ 5ug/ml R and D 
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Anti-human 
Collagen 1 
Mouse IgG1 5ug/ml 5ug/ml 5ug/ml Sigma 
Anti-human 
Collagen 1 
Rabbit 
biotinylated 
------ 20ug/ml 20ug/ml Rockland 
Anti-human αSMA Mouse IgG2A 10ug/ml ------ ------ Dako 
Anti-human CD45 Mouse IgG2A ------ 10ug/ml ------ Abcam 
Anti-human 
CXCR4 
Mouse IgG2B 2.5ug/ml 2.5ug/ml 2.5ug/ml R and D 
Systems 
Anti-human Procol 
1 
Rat IgG1 ------- ------ 1:50 Abcam 
Controls  
Mouse IgG1 ------ 5ug/ml 5ug/ml 5ug/ml Dako 
Rabbit IgG 
biotinylated 
------ ------ 20ug/ml 20ug/ml Rockland 
Mouse IgG2A ------ 10ug/ml 10ug/ml 10ug/ml Dako 
Mouse IgG2B ------ 2.5ug/ml ------ ------ R and D 
Systems 
Rat IgG1 ------ ------ ------ 1:10 Abcam 
Secondary 
Goat anti mouse 
FITC 
Mouse IgG1 ------ 1:50 1:50 Southern 
Biotech 
Goat anti mouse 
Texas red  
Mouse IgG2A ------ 1:50 1:50 Southern 
Biotech 
Goat anti mouse 
(streptavidin)  
FITC 
Streptavidin ------ 1:50 1:50 Southern 
Biotech 
Goat anti rat FITC Rat IgG1 ------ 1:50 1:50 Abcam 
Goat anti mouse 
Alexaflour 488 
Mouse IgG1 ------ ------ 1:500 Invitrogen 
Goat anti mouse 
Alexaflour 546 
Mouse IgG2A ------ ------ 1:500 Invitrogen 
 
 
2.6 Flow Cytometric analysis of cells 
 
Cell surface or intracellular chemokine and integrin expression, cell viability and autophagy 
were all assessed using cytometric techniques. Specifically, MSC were detached from tissue 
culture plastic by incubating with CDB or TrypLE (other adherent cell types) at 37oC for 3 to 
5 minutes. MSC were washed with PBS and centrifugation for 5 minutes at 900xg with the 
brake at 3 and re-suspended in FACS Buffer at a concentration of 1x106cells/ml. PBMC were 
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grown in culture for 2 weeks and scraped from tissue culture plastic. PBMC were washed and 
incubated with procollagen-1 (Abcam) for 30 minutes at 4oC. Isolated PBMC were washed 
and incubated for 30 minutes with a rabbit anti rat FITC conjugated secondary antibody 
(Abcam). Fibroblasts were tested for procollagen1, collagen1 and αSMA as a positive control, 
and lymphocytes were tested for CXCR4 and CD45 listed in Table 2.3. Cells in suspension 
were washed and re-suspended in FACS buffer (PBS 1% FCS), counted and diluted to 
1x106cells/ml and if necessary labelled with a live/dead marker (Invitrogen) after incubation 
for 30 minutes at 4oC. Labelled cells were washed twice with FACS buffer and re-suspended 
at 1x105cells per tube. The APC labelled fixable live/dead cell marker was added to the cell 
suspension to identify viable MSC upon detachment. Where necessary cells were 
permeablised for intracellular staining using BD Cytofix Fixation/ Permeablisation kit (BD 
Biosciences) according to manufacturers instructions, washed and cells were labelled with 
antibodies in BD Wash Buffer. Once re-suspended in FACS buffer (for cell surface staining) 
or BD Wash buffer (for intracellular staining), cells were labelled with pre-determined 
optimal concentration of antibody (Table 2.3) and incubated for 30 minutes at 4oC in the dark. 
For MSC surface staining, cells were washed twice with FACS buffer. PE-conjugated anti-
human CCR antibodies (CCR1-10, CXCR1-7, all from R and D Systems) or anti-human 
integrin antibodies listed in Table 2.3 were incubated with MSC at pre-determined optimal 
concentrations (typically 1:10) alongside individual controls. PE-conjugated anti-human CCR 
antibodies (CCR1-10, CXCR1-7, all from R and D Systems) or anti-human integrin 
antibodies listed in Table 2.3 were incubated with MSC at pre-determined optimal 
concentrations (typically 1:10) alongside individual controls. Cells were washed and then re-
suspended in 500µl FACS buffer. Labelled cells were analysed using Dako Cyan ADP flow 
cytometer and Summit version 4.3 software (Dako).  
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MSC were stimulated with cytokines detailed in Table 2.4 for 10 minutes and 24 hours in 
MSC Growth Medium (MSCGMTM) and normal or ALD cirrhotic patient serum (1:10) in an 
incubator with 5% CO2 at 37
oC. All serum and cytokines were diluted in complete MSC 
Growth Medium (MSCGMTM). MSC were detached using various methods (section 2.3) from 
flasks, washed with FACS buffer and incubated with live dead cell marker as above. CCR 
expression on treated MSC was then determined as described above. 
 
2.7 Quantification of autophagy and cell stress  
 
After detachment, MSC were incubated with an APC-labelled viability marker for 30 
minutes. Autophagy of MSC was measured by incubating cells with 1µM Pacific orange-
labelled Monodansylcadaverine (MDC, Sigma) for 30 minutes. Intracellular reactive oxygen 
species (IROS), apoptosis, necrosis and autophagy was also measured using a 4 colour 
reporter assay system. IROS accumulation was determined by incubation with 30µM of 
fluorescent probe 2’, 7’-dichlorofluorescin (DCF; Merck) for 30 minutes. DCF binds to 
hydrogen peroxide and fluoresces in the fluoresceinisothiocyanate (FITC) channel. 
Simultaneously, levels of autophagy were determined by incubating cells with 1µM 
Monodansylcadaverine (MDC; Sigma), which fluoresces in the Pacific orange channel, for 30 
minutes. Cells were also incubated for 15 minutes with 0.25µg/ml annexin V (Invitrogen), a 
marker of apoptosis, which is detected in the Pacific blue channel, and with 1µg/ml 7AAD 
(ebiosciences), a marker of cellular necrosis, fluorescent in the Pe-Cy5 channel. Data were 
expressed as mean fluorescence intensity (MFI) of the cells. 
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Table 2.3: CCR and Integrin antibodies used for flow cytometry 
 
Antibody name Dilution of 
manufacturers 
stock 
Type Species Source 
Anti-human CCR1 PE 1/10 IgG2B Mouse R and D 
systems 
Anti-human CCR2 PE 1/10 IgG2B Mouse R and D 
systems 
Anti-human CCR3 PE 1/10 IgG2A Rat R and D 
systems 
Anti-human CCR4 PE 1/10 IgG2B Mouse R and D 
systems  
Anti-human CCR5 PE 1/10 IgG1 Mouse R and D 
systems 
Anti-human CCR6 PE 1/10 IgG2B Mouse R and D 
systems 
Anti-human CCR7 PE 1/10 IgG2A Mouse R and D 
systems 
Anti-human CCR8 PE 1/10 IgG2B Rat R and D 
systems 
Anti-human CCR9 PE 1/10 IgG2A Mouse R and D 
systems  
Anti-human CCR10 PE 1/10 IgG2A Rat R and D 
systems 
Anti-human CXCR1 PE 1/10 IgG2A Mouse R and D 
systems 
Anti-human CXCR2PE 1/10 IgG2A Mouse R and D 
systems 
Anti-human CXCR3 PE 1/10 IgG1 Mouse R and D 
systems 
Anti-human CXCR4 PE 1/10 IgG2A Mouse R and D 
systems  
Anti-human CXCR5 PE 1/10 IgG2B Mouse R and D 
systems 
Anti-human CXCR6 PE 1/10 IgG2B Mouse R and D 
systems 
Anti-human CXCR7 PE 1/10 IgG2A Mouse R and D 
systems 
Anti-human α1 integrin 
PE 
1/10 IgG1 Mouse ABD Serotec 
Anti-human α2 integrin 
PE 
1/10 IgG2A Mouse R and D 
systems 
Anti-human α3 integrin 
PE 
1/10 IgG1 Mouse R and D 
systems 
Anti-human  α4 integrin 
PE 
1/10 IgG1 Mouse R and D 
systems  
Anti-human  α5 integrin 
PE 
1/10 IgG1 Mouse R and D 
systems 
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Anti-human  α6 integrin 
PE 
1/10 IgG1 Mouse ABD Serotec 
Anti-human α8 integrin 
PE 
1/10 IgG2B Mouse R and D 
systems 
Anti-human αV integrin  
PE 
1/10 IgG1 Mouse Abcam  
Anti-human  αVβ3 
integrin PE 
1/10 IgG1 Mouse R and D 
systems 
Anti-human αVβ3 
integrin PE 
1/10 IgG1 Mouse R and D 
systems 
Anti- human β1 integrin 
PE 
1/10 IgG1 Mouse R and D 
systems 
Anti- human β2 integrin 
PE 
1/10 IgG1 Mouse R and D 
systems 
Anti-human β3 integrin 
PE 
1/10 IgG2A Mouse R and D 
systems  
Anti-human CD44 PE 1/10 IgG2B Mouse BD Pharmigen 
Anti-human β7 integrin 
PE 
1/10 IgG2A Rat R and D 
systems 
Anti human β4 integrin 
Unconjugated 
1/10 IgG2b Mouse R and D 
systems 
Controls 
Mouse IgG1 PE 1/10 ------- ------- R and D 
systems 
Mouse IgG2A PE 1/10 -------- -------- R and D 
systems 
Mouse IgG2B PE 1/10 -------- -------- R and D 
systems 
Rat IgG2A PE 1/10 -------- -------- R and D 
systems  
Rat IgG2B PE 1/10 -------- -------- R and D 
systems 
Mouse IgG2B 
Unconjugated 
1/10 -------- -------- R and D 
systems 
Secondary 
Anti-mouse IgG PE 1/10 IgG Goat R and D 
systems 
 
  
63 
 
Table 2.4: Cytokines used for MSC stimulation 
 
Treatment Final Concentration Source 
TNFα 10ng/ml PeproTech 
IFNγ 25ng/ml PeproTech 
TNFα + IFNγ 10ng/ml + 20ng/ml  PeproTech 
TGFβ1 5ng/ml PeproTech 
LPS 200ng/ml Sigma 
IL1β 10ng/ml PeproTech 
IL4 10ng/ml PeproTech 
IL6 10ng/ml PeproTech 
IL8 10ng/ml PeproTech 
IL10 50ng/ml PeproTech 
 
 
2.8 Polymerase Chain Reaction (PCR) 
2.8.1 RNA extraction and cDNA preparation from cytokine stimulated MSC  
 
MSC were stimulated with cytokines detailed in Table 2.4 or media alone, for 24 hours in 
MSC Growth Medium (MSCGMTM) at 37oC in 25cm2 flasks. Media was aspirated, cells were 
washed with PBS and RNA was extracted using the RNeasy mini kit (Qiagen) according to 
the manufacturers instructions. RNA purity was tested using a Nanodrop spectrophotometer 
(Implen Geneflow) and samples were stored at -80oC.  Purity was assessed using the 260/ 280 
absorbance ratio to give an indication of protein contamination, and samples with a value less 
than 1.8 were not used.  
 
CDNA was prepared from RNA using the Biorad iScriptTM cDNA Synthesis Kit (Biorad) 
according to the manufacturers instructions. Briefly, 4µl of 5x iScript reaction mix and 1µl 
iScript reverse transcriptase was added to a mixture to nuclease-free water and RNA 
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(0.25µg/µl) resulting in a reaction volume of 20µl in PCR tubes (Thermoscientific). The 
complete reaction mixture was incubated in a PCR machine (Geneflow TC512) for 5 minutes 
at 25oC, 30 minutes at 42oC and 5 minutes at 85oC. The cDNA was then stored at -20oC. 
Control samples were prepared using water substituted for Reverse Transcriptase.  
 
2.8.1.1 Use of 18S rRNA PCR to test for RNA contamination of cDNA samples  
 
Table 2.5: 18S rRNA Thermal Profile and Primers 
 
Reverse transcription was carried out using 18S rRNA primers (Table 2.5) to assess integrity 
of cDNA and to identify any potential contamination in negative controls. The Hyperladder 
IV DNA ladder (Bioline) was used as amplicon length marker. 1µl of cDNA or RT negative 
sample was added to 1µl of ready mixed primers (Sigma), 3µl nuclease free water and 5µl of 
Mastermix (Bioline) in a PCR tube. 7µl of oil was layered over the samples to avoid any 
evaporation of sample. The thermal profile of the 18S rRNA primers and the reagents that 
were used in the 18S rRNA PCR are shown in Table 2.5 and 2.6 respectively. 
 
  
 Forward Primer Reverse Primer 
18S rRNA primers Gtaacccgttgaaccccatt ccatccaatcggtagtagcg 
Number of Cycles: 30 Temperature (oC) Time (seconds) 
 95 225 
Denaturing 95 45 
Annealing 55 45 
Extension 72 45 
65 
 
Table 2.6: 18S rRNA PCR Reagents 
 
Reagents Final Concentration  Source 
Mastermix (Biomix) x1 Bioline 
MgCl2 1mM Bioline 
dNTPs 0.8mM (total) Promega, Southampton 
Ready Mixed Primers 10µM Sigma 
cDNA 250µg/µl MSC 
 
The PCR product for 18S rRNA was visualised on a 2% agarose gel stained with ethidium 
bromide (10mg/ml, Sigma) using standard protocols. Samples were loaded alongside a lane of 
Hyperladder IV to indicate the size of the bands and run in electrophoresis buffer (Table 2.7). 
The gel was removed and photographed on Genegenius Bioimaging System Imaging 
machine. 
 
Table 2.7:  18S rRNA PCR Electrophoresis Buffer 
 
TBE x10 Electrophoresis Buffer 
Reagents  Molecular Weight (FW) Final Concentration Source 
Trisma Base 121.14 0.89M Sigma 
Boric Acid 61.83 0.89M Sigma 
Na2EDTA.2H20 442.5 0.5M Sigma-Aldrich 
ddH2O 1000ml 
 
 
2.8.2 Use of quantitative PCR (QPCR) to assess expression of CCR by MSC  
 
QPCR experiments were carried out using commercially available QPCR kits (Roche) on the 
Roche Lightcycler 480 instrument.  Cytokine stimulated MSC cDNA was tested for the CCR 
CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7 using primers designed by the Roche 
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primer design library listed in Table 2.8 and reagents in Table 2.10. 1µl of the forward primer 
and 1µl of the reverse primer, 0.4µl of the probe, 5.6µl RNase free H2O and 10µl of probes 
master (Roche QPCR Kit) was added to 2µl cDNA to give a total reaction volume of 20µl in 
a well of a Roche LC 480 multi-well, 96 well plate alongside a positive control sample (from 
PBMC), β Actin as a housekeeping gene and an endogenous control. Each β Actin reaction 
mixture contained 2µl cDNA, 0.4µl primer mixture, 0.4µl probe, 7.2µl nuclease free water 
and 10µl probes master. Similarly, unstimulated MSC and TGFβ1 stimulated MSC cDNA 
was analysed for alpha smooth muscle actin (αSMA) and collagen 1 (col1α1) (Table 2.11), at 
the thermal profile shown in Table 2.9 using reagents in Table 2.12 by QPCR. Human β-actin 
was used as internal control to which the threshold cycle (Ct) values of the target gene were 
normalised. Multi-well plates were covered with Lightcycler 480 sealing film (Roche) before 
they were inserted into the Lightcycler 480 QPCR machine. Differential expression levels 
were calculated according to the 2-ΔΔCt method and the results were analysed using 
Lightcycler 480 SW 1.5 software.   
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Table 2.8: QPCR Primers 
 
Gene 
name 
Gene ID Forward Primer Reverse Primer Roche Probe 
No 
Amplicon 
length (nt) 
CCR4 NM_005508.4 ttgtgctctgccaatactgtg taagatgagctgggggtgtc 25 64 
CCR5 ENST00000479006.1| 
ENSG00000160791.9 
cccttgaaaagacatcaagca Tgcacaatcatatgagacagaaca 63 72 
CCR5 ENST00000426816.1| 
ENSG00000160791.9 
cttgggtggtggctgtgt gaccagccccaagatgacta 14 129 
CCR9 ENST00000422395.1| 
ENSG00000173585.10 
caccatgacacccacagact agcgagggaaggtgatctg 25 63 
CCR9 ENST00000357632.2| 
ENSG00000173585.10 
cagctctttccccagacact catggtgggtcagtcagatg 56 101 
CCR9 ENST00000395963.2| 
ENSG00000173585.10 
tttccccagacactgagagc tcagccatgttaggaataggg 36 87 
CCR9 ENST00000357632.2| 
ENSG00000173585.11 
cacccacagacttcacaagc tcacagtagaagtcagtgaagttgaa 21 111 
CXCR3 ENST00000373691.4| 
ENSG00000186810.6 
ccagccatggtccttgag tccagggccgtacttcct 58 136 
CXCR3 ENST00000373693.3| 
ENSG00000186810.6 
gccatggtccttgaggtg ctccatagtcataggaagagctga 79 94 
CXCR4 ENST00000466288.1| 
ENSG00000121966.4 
ttaagcgcctggtgactgtt gcccatttcctcggtgtag 47 67 
CXCR7 ENST00000272928.3| 
ENSG00000144476.5 
tcacagttgttgcaaagtgct gcagatccatcgttctgagg 36 138 
αSMA NM_001141945.1 ctgttccagccatccttcat tcatgatgctgttgtaggtggt 58 70 
Col1α1 NM_000088.3 aggtccccctggaaagaa aatcctcgagcaccctga 79 96 
Control 
ACTB (Roche) ACTB 05046165001 Primer ACTB 05046165001 Probe  
 
 
Table 2.9: QPCR Thermal Profile 
 
 
 
 
  
QPCR Thermal Profile 
Number of Cycles: 50 Temperature (oC) Time (seconds) Ramp rate (oC/s) 
 95 10 4.4 
Denaturing 95 10 4.4 
Annealing 60 30 2.2 
Extension 72 1 4.4 
Cooling 40 30 2.2 
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Table 2.10: QPCR reagents 
 
CCR 
Reagents Final Volume 
Primers 0.5µM 
Probe 0.4µl 
Roche Mastermix x1 
cDNA 0.5µg/ml 
RNase free water 5.6µl 
Beta Actin 
Reagents Final  Volume 
Primer Mix 0.4µl 
Probe 0.4µl 
Roche Mastermix x1 
cDNA 0.5µg/ml 
RNase free water 7.2µl 
 
 
2.8.3 Measurement of collagen-1 (col1a1) and alpha smooth muscle actin (αSMA) 
mRNA levels in injured mouse livers by QPCR. 
 
Levels of αSMA and col1α1 mRNA were measured in carbon tetrachloride injured and 
uninjured C57 Black 6 mouse livers (section 2.14.2) using a Taqman Gene Expression Assay. 
RNA was extracted from frozen carbon tetrachloride injured and uninjured C57BL/6 mouse 
livers using the Qiagen RNeasy mini kit as described above. RNA purity was tested using a 
Nanodrop spectrophotometer, and cDNA was prepared from RNA using the Biorad iScriptTM 
cDNA Synthesis Kit (Biorad) as before. For analysis of relative expression of col1α1 and 
αSMA Taqman gene expression assays were run on an ABI Prism 7900 sequence detector (at 
University of Birmingham, UK). Col1α1 and αSMA Ct values were normalised to murine 
GAPDH Ct levels which were used as an internal control. Differential expression levels were 
calculated according to the 2-ΔΔCt method as above.   
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Table 2.11: QPCR primers for αSMA and col1α1 
 
 Primer/ Probe Assay ID Source 
α SMA Mm00801666_g1 Applied Biosystems, Invitrogen 
Col1α1 Mm00725412_s1 
GAPDH Mm99999915_g1 
Expendables 
Taqman® Universal PCR Master Mix 
Taqman® 2x Master Mix 
MicroAmp® Optical 96-well reaction plate-0.1ml 
MicroAmp® Optical adhesive film 
 
Table 2.12: Components of QPCR reagents for αSMA and col1α1 
 
Reagents Final Concentration [single reaction (20µl)] (µl) 
20✕ TaqMan® Gene Expression Assay 1 
2✕ TaqMan® Gene Expression Master Mix 10 
cDNA  4 
RNase free water 5 
 
2.9 Measurement of MSC tri-lineage differentiation capacity 
 
The effects of cell dissociation protocol and cytokine (TGFβ1) stimulation on the adipogenic, 
osteogenic and chondrogenic differentiation capacity of MSC was assessed at P4 using 
commercially available differentiation kits. MSC were seeded at equal densities in 24 well 
plates and cultured in osteogenic and adipogenic differentiation media according to 
manufacturer’s instructions (Lonza) alongside controls, which were cultured in maintenance 
medium for approximately 3 weeks.  
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Adipogenic differentiation was indicated by the morphological appearance of lipid droplets 
when stained with oil red O according to standard protocols. Stock oil red O solution (0.5% in 
isopropanol) was diluted to 60% in dH2O prior to experimentation. Cells were fixed with 
formalin and then incubated with 60% isopropanol for 5 minutes. Cells were then incubated 
with oil red O working reagent for 15 minutes, followed by isopropanol for 5 minutes and 
then washed twice with dH2O. Bright field microscopic images were captured at x20 
magnification and percentage area staining red was calculated using Image J Software 
(http://rsbweb.nih.gov/ij/).  
 
Osteogenic differentiation was measured using an osteogenesis assay kit (Millipore) 
according to the manufacturers protocol. Briefly, cells were washed with HBSS, fixed with 
formalin for 5 minutes and washed with dH2O. Cells were incubated with 1ml/well of 
Alizarin red stain solution at room temperature for 20 minutes and washed with dH2O. 400µl 
10% acetic acid was added to each well and incubated for 30 minutes with shaking. The 
contents were scraped from the wells and vortexed vigorously for 30 seconds. Samples were 
heated at 85oC for 10 minutes, put on ice for 5 minutes and centrifuged for 15 minutes at 
550xg. Samples were neutralised with Ammonium Hydroxide and read at an optical density 
405nm against high and low standards from the kit, in order to permit assessment of 
concentration of Alizarin red present (Figure 2.1). 
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Figure 2.1: Standard Curve for Alizarin red Staining 
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To assess chondrogenic differentiation capacity of MSC, cell pellets were formed in 
polypropylene falcon tubes and cultured in chondrogenic differentiation media (supplemented 
with TGFβ3 at a final concentration of 10ng/ml) according to manufacturers instructions 
(Lonza) alongside controls, which were cultured in maintenance medium. Cell pellets were 
stored at 37oC in a cell culture incubator, and caps were loosened to allow gas exchange. 
500µl medium was replenished every 2 to 3 days for 2/ 3 weeks. Cell pellets were snap frozen 
in liquid nitrogen and stored at -80oC until sections were cut using a cryostat. Slides were 
stored at -20oC until sections were analysed for chondrogenic differentiation as indicated by 
the presence of collagen II (Millipore) detected by immunohistochemistry.  
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2.10 Quantification of TGFβ1 in MSC Supernatants by ELISA 
 
Unstimulated and TGFβ1 stimulated MSC supernatant was collected from P4 MSC in culture. 
Supernatants were tested using ELISA for active TGFβ1 using an ELISA kit (R and D 
Systems), according to the manufacturers instructions. Briefly, 96 well plates (Nunc 
Maxisorp) were coated with TGFβ1 capture antibody from the TGFβ1 Duoset ELISA kit (R 
and D Systems). Plates were loaded with kit standards, serum from 3 normal volunteers and 
from 3 with patients ALD cirrhosis and supernatant from 3 unstimulated MSC isolates and 3 
TGFβ1 stimulated MSC isolates. Plates were incubated, washed with PBS 1% Tween 20 and 
then incubated with a biotinylated TGFβ1 detection antibody conjugated to HRP. Wells were 
washed and finally streptavidin-HRP was added to wells. Upon addition of substrate, a blue 
colour developed, at which point a stop solution was added. Plates were read on a microplate 
reader set to 450nm with the wavelength correction set to 540nm. Triplicate readings were 
averaged and the average zero standard optical density was subtracted. The mean absorbance 
for each standard curve was plotted against the concentrations on the x axis and a line of best 
fit was drawn (Figure 2.2). Samples had been diluted, so the concentration read from the 
standard curve was multiplied by the dilution factor to determine actual concentrations.  
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Figure 2.2: Standard curve for TGFβ1 Sandwich ELISA 
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2.11 Adhesion molecule expression of HSEC after stimulation by MSC 
conditioned media 
 
This experiment assessed the effect of cytokine stimulated MSC conditioned media on HSEC 
adhesion molecules expression. HSEC were cultured on collagen coated 96 well ELISA plates 
and pre-stimulated with TNFα (20ng/ml, PeproTech), IFNγ (100ng/ml, PeproTech) or control 
media for 24 hours, and then for a further 24 hours in cytokine stimulated MSC supernatant as 
shown in Table 4. After 24 hours, cells were methanol fixed in 96 well plates, washed with 
PBS and blocked with PBS 1% Bovine Serum Albumin (BSA, Sigma) for 1 hour. ICAM1, 
VCAM1, CD31, P-Selectin, E-Selectin expression on HSEC was then analysed using primary 
antibodies listed in Table 2.13. Cell based ELISA was the method used to do this. Briefly, 
wells were washed with PBS 0.1% Tween 20 and then incubated with a goat anti mouse HRP 
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conjugated secondary antibody (Dako) at 1:1000 dilution for 1 hour. OPD substrate (Dako) 
was used to quantify antibody binding. The ELISA substrate was used according to 
manufacturers instructions and absorbance values of triplicate wells were determined at 
490nm.  
 
 
Table 2.13: Antibodies used for cell based ELISA. 
 
 
 
2.11.1 Quantification of cytokine and pro-angiogenic mediators in MSC supernatants 
 
TGFβ1 stimulated MSC supernatants were tested for changes in secreted angiogenic factors 
and cytokines using the Cytokine/ Angiogenesis kit (R and D systems), according to the 
manufacturers instructions. Briefly array membranes with already bound capture antibodies 
were blocked to prevent non specific binding. Samples were added to the membranes with a 
detection antibody and incubated overnight at 4oC. Membranes were washed, incubated with 
streptavidin-HRP for 1 hour and washed again. Membranes were then exposed to Supersignal 
chemiluminescent reagent (Thermoscientific) as described by the manufacturer, covered with 
plastic wrap and exposed to for 1 minute to enhanced chemiluminescence detection film 
(Amersham Biosciences) and developed using a Kodak X–Omat 1000 processor. Data were 
Primary antibody Working concentration Source 
VCAM1 5 µg/ml R and D Systems 
ICAM1 5 µg/ml R and D Systems 
E Selectin 5 µg/ml R and D Systems 
P Selectin 5 µg/ml Abcam 
CD31 5 µg/ml DAKO 
Control 
Mouse IgG1 5 µg/ml R and D Systems 
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analysed using Image J software. A template was created to analyse pixel density for each 
spot of the array. The average signal (pixel density) of the pair of duplicate spots representing 
each angiogenesis or cytokine related protein was determined and the average background 
signal from blank control spots was subtracted.  
 
2.12 Use of an immunosuppression assay to assess ability of MSC to inhibit T 
effector cell proliferation 
 
CD3+CD4+CD25- T effector cells were isolated from human peripheral blood. Briefly, blood 
was layered onto a Lympholyte®-H (Axis Shield) density separation gradient and centrifuged 
at 900xg for 20 minutes. The cell layer was collected from the density gradient interface, 
washed with PBS and incubated in MACS buffer (1L PBS, 4ml EDTA, 5ml FCS)) with a 
cocktail of selection antibodies (CD3 PB, (4µg/ml, BD Pharmigen), CD4 PE (4µg/ml, BD 
Pharmingen), CD25 APC (4µg/ml, Invitrogen). CD3+CD4+CD25- Cells were then sorted 
using the Mo flow XDP cell sorter (Beckman Coulter). Control or TGFβ1-stimulated MSC, 
treated with or without Indomethacin (Sigma Aldrich), a PGE2 blocker, were cultured with 
the CD3+CD4+CD25- T effector cells and T regulatory suppression inspector beads (Miltenyi). 
Cells were cultured for 5 days in RPMI 1640 (Invitrogen) with 10% human serum 
(Invitrogen) and 5% Glutamine-Streptomycin-Penicillin (PSG) (Invitrogen) at 37OC in round 
bottom 96 well plates (BD Falcon). Finally CD3+CD4+CD25- T effector cells were aspirated, 
washed and re-suspended in 200µl PBS. 20µl Accucheck counting beads (Invitrogen) were 
added to the tubes and samples run on the Dako Cyan ADP flow cytometer. CD3+CD4+CD25- 
T effector cells labelled with CellTrace™ Violet Cell Proliferation Kit (Invitrogen) were 
gated and total number of cells/µl was obtained. 
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2.13 Use of a modified Boyden chamber migration assay to assess MSC 
migration towards chemokines 
 
MSC chemotaxis was determined in a modified 48-well Boyden chamber (Figure 2.3). Pre-
determined concentrations (in the range 0-500ng/ml) of chemokines listed in Table 2.14 in 
serum-free media were placed in the lower wells. A polycarbonate membrane with 8µm pores 
(Neuroprobe) was used, and MSC (control or pre-stimulated with TGFβ1, IL4, IL10 (Table 
2.14)) detached with either TrypLE or CDB were re-suspended in serum free media and 
placed the upper wells. After incubation at 37oC for 24 hours, filters were removed, air-dried 
and stained using Diffquick (Medion Diagnostics). Migrated MSC on the lower face of the 
membrane were counted in 5 fields of view (x40 magnification) per well using a brightfield 
microscope. 
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Figure 2.3: Schematic diagram of the Boyden migration chambers 
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Table 2.14: Chemokine ligands used in Boyden chamber migration assays 
 
Chemokine Source Corresponding receptor Concentration 
range 
Optimal 
concentration 
Human 
TARC/ 
CCL17 
PeproTech CCR4 10-500ng/ml 100ng/ml 
Human MDC/ 
CCL22 
PeproTech CCR4 10-500ng/ml 500ng/ml 
Human MIP-
1β/ CCL4 
PeproTech CCR5 10-500ng/ml 500ng/ml 
Human MCP-
1/ CCL2 
PeproTech CCR4 10-500ng/ml ----- 
Human IP-10/ 
CXCL10 
PeproTech CXCR3 10-500ng/ml 50ng/ml 
Human ITAC/ 
CXCL11 
PeproTech CXCR3 10-500ng/ml 500ng/ml 
Human PF-4/ 
CXCL4 
PeproTech CXCR3 10-500ng/ml ----- 
Human MIG/ 
CXCL9 
PeproTech CXCR3 10-500ng/ml ----- 
Human TECK/ 
CCL25 
PeproTech CCR9 10-500ng/ml 100ng/ml 
Human 
RANTES/ 
CCL5 
PeproTech CCR5 10-500ng/ml 10ng/ml 
Human 
SDF1α/ 
CXCL12 
PeproTech CXCR4, CXCR7 10-500ng/ml 50ng/ml 
Human MIP-
1α/ CCL3 
PeproTech CCR5 10-500ng/ml ----- 
Human MCP-
2/ CCL8 
PeproTech CCR5 10-500ng/ml 100ng/ml 
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2.14 Use of murine liver injury models to assess the hepatic trafficking of infused 
MSC  
 
2.14.1 The CCl4 injury model  
 
Carbon tetrachloride (Sigma Aldrich) diluted 1/4 in mineral oil (Sigma) was administered by 
intraperitoneal (IP) injections of 100ul each into 9 week old (weight: approx 20g) C57BL/6 
wild type mice, twice weekly for 6 to 8 weeks. Immune-compromised Rag2-/-IL-2r γ-/- mice 
were also injured with carbon tetrachloride IP injections at a 1/40 dilution in mineral oil, 
twice weekly, for 9 or 12 weeks. After the course of administration, mice were used for portal 
vein infusion experiments and culled. Livers were snap frozen in liquid nitrogen and stored at 
-80oC to be sectioned by a cryostat. Alternatively livers were fixed in formalin to be cut as 
wax sections and embedded in paraffin.  
 
2.14.2 Measuring injury in carbon tetrachloride injured mice 
2.14.2.1 Picrosirius red staining for quantification of fibrosis 
 
Paraffin sections from injured and uninjured C57BL/6 and Rag2-/-IL-2r γ-/- mouse livers were 
dewaxed using Clearene, and passed through a graded ethanol series. These and frozen 
sections  from 6 week C57BL/6 injured/ uninjured mice or normal/ diseased human liver 
section were washed with dH2O and incubated with 0.5 % phosphomolybdic acid (PMA, 
Sigma) for 5 minutes. 100ml of 0.1% Sirius red stain (Direct red 80 in saturated picric acid; 
Sigma) was added to the sections for 2-3 hours and sections were dipped in 0.01M HCl 
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(Sigma) in dH2O. Finally sections were counterstained with Mayer’s Haematoxylin, 
dehydrated and mounted in DPX. Bright field microscopic images were captured at x20 and 
x40 magnification and analysed by Image J analysis for area fraction that had stained red to 
measure and score fibrosis. 
 
2.14.2.2 Serum albumin levels 
 
Albumin levels were measured in uninjured and carbon tetrachloride injured mouse serum 
using the QuantichromTM BCG Albumin Assay Kit (Bioassay Systems) according to the 
manufacturers instructions. Briefly, standards were diluted in dH2O, samples were diluted two 
fold and 5µl of each was added to the wells of a 96 well plate. 200µl of working reagent was 
added to each well, the plate was tapped lightly to mix, incubated at room temperature for 5 
minutes and the optical density was read at 620nm. Triplicate readings were averaged and the 
average zero standard optical density was subtracted. The log of mean absorbance for each 
standard curve was plotted against the log of concentrations on the x axis and a line of best fit 
was drawn. The concentration read from the standard curve was multiplied by the dilution 
factor to determine actual concentrations. 
 
2.14.2.3 Serum bilirubin quantification 
 
Bilirubin levels were measured in uninjured and carbon tetrachloride injured mouse serum 
using the QuantichromTM Bilirubin Assay Kit (Bioassay Systems) according to the 
manufacturers instructions. Briefly, standards and samples were diluted in working reagent 
and incubated for 10 minutes at room temperature and the optical density was read at 540nm. 
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Triplicate readings were averaged and the average zero standard optical density was 
subtracted. The log of mean absorbance for each standard curve was plotted against the log of 
concentrations on the x axis and a line of best fit was drawn. The concentration read from the 
standard curve was multiplied by the dilution factor to determine actual concentrations. 
 
2.15 Quantification of MSC adhesion and recruitment into injured tissue 
2.15.1 Use of modified Stamper Woodruff assays to assess adhesion of MSC to injured 
human liver sections 
 
10m cryosections cut from explanted human livers (Normal, ALD, AIH, PSC, PBC and 
NASH) were fixed in acetone for 5 minutes, air-dried and wrapped in foil. Sections were 
stored at -80oC until required for adhesion assays. Cultured MSC were detached, washed and 
re-suspended with PBS 0.1% BSA in a conical bottomed 15 ml polypropylene tubes. The 
cells were incubated with 1µM CFSE per ml for 10 minutes at 37oC. CFSE was washed with 
2ml FCS and cells were centrifuged for 5 minutes at 900xg to stop binding of excess CFSE 
and to help remove unbound CFSE from the cell suspension. This wash was repeated twice 
with cold PBS to remove unincorporated CFSE. Finally MSC were re-suspended in cold PBS 
and stored on ice in the dark for 5 minutes to allow leaching of any residual CFSE. MSC were 
washed again and re-suspended in PBS 0.1% BSA (Sigma) at the desired concentration. 
 
Tissue sections were thawed at room temperature for 30 minutes, and transferred to a 
humidified chamber. Alternatively for liver cell monolayers (including HSEC, BEC and MF) 
grown in 24 or 6 well plates, media was aspirated and wells were washed with PBS. 105 
82 
 
CFSE-labelled or unlabelled MSC were added to sections or wells in PBS and incubated for 
60 minutes at room temperature. Slides or wells were washed PBS and fixed for 5 minutes in 
acetone or methanol respectively. Adherent MSC were quantified by microscopic counting of 
CFSE labelled or haematoxylin counterstained MSC. Microscopic images of cell monolayer 
adherent CFSE labelled MSC were taken at x40 magnification using an inverted fluorescence 
microscope. Fluorescence on these images was measured by Image J analysis and measured 
as the area fraction of the pictures which were fluorescent. Alternatively counterstained or 
CFSE labelled adhered MSC on tissue sections were counted in 30 fields of view at x40 
magnification using a brightfield microscope. Where MSC were labelled with CFSE, all 
procedures were carried out in the dark. 
 
2.15.2 Quantification of MSC Engraftment in murine livers following via portal vein 
infusion 
 
Cytokine stimulated MSC labelled with CFSE, were re-suspended in PBS 0.1% BSA at 
appropriate concentration, typically 5x106 to 10x106cells/ml. Where indicated, MSC were 
pre-incubated with blocking antibodies raised against CCR for 15 minutes at 37oC, washed 
and re-suspended in PBS 0.1% BSA. MSC were infused into the portal vein of uninjured or 
injured (carbon tetrachloride for 8 weeks) mice. Post injection, bleeding was encouraged to 
clot using sterile cotton wool buds and Spongostan (Ethicon, acquired through National 
Veterinary Services). Bleeding was stopped and mice were kept under anaesthetic for 15 
minutes to allow engraftment of infused cells. Mice were culled, and livers were immediately 
snap frozen in liquid nitrogen and stored at -80oC. Finally livers were cryosectioned into serial 
sections and CFSE-labelled cells were counted under a fluorescent microscope at varying 
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depths within the liver samples. Cells were counted in 10 fields of view on 4 sections over 4 
depths from each mouse liver.  
 
2.16 Measurement of serum amyloid protein (SAP): an inhibitor of fibrocyte 
differentiation 
2.16.1 Quantification of Serum Amyloid Protein (SAP) in liver samples by Sandwich 
ELISA 
 
Serum Amyloid Protein (SAP) or Pentraxin 2 has been implicated in the differentiation of 
fibrocytes.  Serum Amyloid Protein (SAP) or Pentraxin 2 levels in injured and non injured 
C57 BL/6 mouse liver lysates and serum were tested using a sandwich ELISA kit (R and D 
Systems). All reagents, samples and working standards were prepared as directed in the 
manufacturers instructions and the manufacturers protocol was followed. Briefly, 50µl of 
calibrator diluent was added to each well followed by 50µl of control, standard, or sample and 
incubated for 3 hours at room temperature on a horizontal orbital microplate shaker. The wells 
were washed 5 times with 400µl wash buffer. 100µl of mouse Pentraxin 2 conjugate was then 
added to each well and incubated for 1 hour at room temperature. 100µl of substrate solution 
was added to each well and incubated for 30 minutes at room temperature in the dark. Finally 
100µl of stop solution was added and the optical density of each well was determined within 
30 minutes at 450nm with the wavelength correction set to 540nm. Triplicate readings were 
averaged and the average zero standard optical density was subtracted. The log of mean 
absorbance for each standard curve was plotted against the log of concentrations on the x axis 
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and a line of best fit was drawn (Figure 2.4). The concentration read from the standard curve 
was multiplied by the dilution factor to determine actual concentrations.  
 
Figure 2.4: Standard Curve for mouse SAP Sandwich ELISA 
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Serum Amyloid Protein (SAP) or Pentraxin 2 levels in diseased and normal patient liver 
lysates and serum were tested using a sandwich ELISA kit (Abnova) according to the 
manufacturers protocol, similar to the mouse Pentraxin ELISA kit (R and D systems). The log 
of mean absorbance for each standard curve was plotted against the log of concentrations on 
the x axis and a line of best fit was drawn (Figure 2.5). 
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Figure 2.5: Standard Curve from human SAP Sandwich ELISA 
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2.16.1.1 Quantification of SAP using Western blotting 
 
Protein lysates were made from human livers including ALD, AIH, PBC, NASH, and normal 
livers. Livers were also collected from 6 and 8 week carbon tetrachloride injured and 
uninjured mice. All tissues were frozen and buffers were pre-cooled or stored on ice. Frozen 
tissue was defrosted on ice and 70-90mg of tissue was homogenised in a Miltenyi Gentle 
MACS M-Tube with ice cold lysis buffer [(20l CellLytic MT Buffer; Sigma, 1x Protease 
Inhibitor cocktail; Sigma, 5U/ml DNase; Roche) per mg of tissue] and digested using 
programme Protein-01 on the Gentle MACS (Miltenyi). The tube was centrifuged at 3000xg 
or 3 minutes and lysate collected in a 1.5ml eppendorf tube. Samples were continuously 
agitated for 1 hour at 4oC and then centrifuged at 16000xg for 30 minutes at 4oC. The 
resulting supernatant was aspirated and stored at -80oC. For use, protein concentration was 
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determined using a Bio-Rad DC Protein Assay performed according to manufacturers 
instructions and samples were diluted to 5ug/ml in PBS 0.1% Tween 20. Normal/ uninjured 
and diseased/ injured liver lysates were then tested for levels of serum amyloid protein (SAP) 
using western blot analysis, the reagents for which are listed in Table 2.15 and the buffer 
dilutions in Table 2.16.  
 
Serum was also tested for levels of serum amyloid protein (SAP) using western blot analysis. 
Here, normal human serum was collected from healthy volunteers and compared with serum 
from patients with end stage ALD cirrhosis. Serum was also collected from 6 and 8 week 
carbon tetrachloride injured and uninjured mice. Here blood was collected by cardiac 
puncture, allowed to clot and then spun down at >8000xg for 15 minutes to separate serum. 
Serum was then stored at -80oC in working aliquots. Samples were diluted 1:20000 in PBS 
0.1% Tween 20 before use.  
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Table 2.15: Buffers for SDS PAGE 
 
Buffer Constituents Storage  
10x 
running/electrophoresis 
buffer 
30.3g Trizma Base, 144g Glycine, 
10g SDS, 1000ml dH2O 
Room Temperature 
Transfer buffer 28.8g Glycine, 6.0g Trizma Base, 
400ml Methanol, 1g SDS, 1600ml 
dH2O 
4oC 
Resolving gel buffer 1.5M Trizma Base pH 8.8 Room Temperature 
Stacking gel buffer 0.5M Trizma Base pH 6.8 Room Temperature 
5x SDS-PAGE sample 
buffer 
200mM Trizma Base pH 6.8, 20% 
Glycerol, 10% SDS, 0.05% 
bromophenol blue, 10mM β-ME 
Room Temperature 
Blocking buffer TBS + 0.02% Tween 20, 10% non fat 
milk (25ml per membrane) 
Room Temperature 
Stripping buffer 20.0ml 10% SDS, 12.5ml 0.5M 
Trizma Base-HCL pH 6.8, 67.5ml 
dH2O, 0.8ml β-ME 
Room Temperature 
10% SDS 10g SDS, 100ml dH2O Room Temperature 
TBS-0.1%Tween 20 2000ml TBS pH7.6, 2ml Tween 20 Room Temperature 
 
 
2.16.1.2 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
 
Serum or tissue lysates were loaded in the wells of a 4% polyacrylamide stacking gel (Table 
2.15) which was layered above a 15% resolving gel (Table 2.15) using the BioRad Mini Trans 
Blot Cell System. Samples were diluted in 1x SDS-PAGE sample buffer with β-
mercaptoethanol and boiled at 100oC for 10 minutes on a heat block. Heated protein samples 
were centrifuged and set aside to cool before loading 20ul into wells created in the gel using a 
plastic comb. Pre-stained rainbow molecular weight markers (Amersham, GE Healthcare) 
were used as size markers. Electrophoresis was performed at 200V for 1 hour until the dye 
reached the bottom of the gel.  
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Table 2.16: Gel components for SDS PAGE 
 
 4% Stacking Gel 15% Resolving Gel 
dH2O 6.1ml 2.4ml 
30% Acrylamide mix (Biorad) 1.3ml 5ml 
Stacking Gel Buffer 2.5ml ------- 
Resolving Gel Buffer ------- 2.5ml 
10% SDS 0.1ml 0.1 
10% ammonium persulfate 
(APS) (Sigma Aldrich)* 
40µl 40µl 
N,N,N’,N’- 
tetramethylethylenediamine  
(TEMED) (Sigma Aldrich)* 
20µl 20µl 
 
Components of SDS-PAGE gels. *APS and TEMED were added immediately prior to 
pouring of gels, as the oxygen free radicals released from the reaction between APS 
and the tertiary amine TEMED are responsible for the polymerisation of bis-
acrylamide. 
 
Table 2.17: Reagents for Western Blot 
 
Reagents Molecular Weight (FW) Source 
Trizma Base 121.14 Sigma 
NaCl 58.44 Sigma 
Glycine 75.07 Sigma 
Sodium Dodecyl Sulfate 
(SDS) 
288.38 Sigma 
Methanol ----- Fischer Scientific 
Glycerol ----- Fischer Scientific 
Bromophenol blue ----- Sigma 
Betamercaptoethanol 78.13 Sigma 
Tween 20 ----- Sigma 
Trizma HCl  Sigma 
Non fat milk ----- Marvel 
Antibodies 
Primary Type Working dilution/ 
concentration 
Source 
Mouse Serum Amyloid 
Protein (T-15) 
Goat 
Polyclonal 
1 in 100 Santa-Cruz 
Human Serum Amyloid Mouse IgG1 1 in 1000 Abcam 
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Protein (6E6) 
Secondary 
Rabbit anti goat HRP Goat polyclonal 1 in 5000 Abcam 
Goat anti mouse HRP Mouse IgG1 1 in 1000 Dako 
Control  
Mouse GAPDH Rabbit 
Polyclonal 
0.2µg/ml Sigma 
Human GAPDH Mouse IgG1 0.5µg/ml Sigma 
 
2.16.1.3 Western Blot Transfer  
 
Resolved proteins on the gel were transferred onto a nitrocellulose membrane (Hydrobond 
ECL Amersham Biosciences) at 100V for 1 hour using standard protocols. Efficient transfer 
was confirmed by staining the membrane with Ponceau red solution (0.1% Ponceau S in 5% 
acetic acid, Sigma) for 5 minutes followed by rinsing with water to visualise successful 
protein transfer. Non-specific protein binding sites on transferred membranes were then 
blocked for 1 hour using milk. The membrane was then stained with primary SAP antibodies, 
in non–fat dry milk overnight. After several washes in PBS-Tween 20, blots were stained with 
a HRP conjugated secondary. Membranes were exposed to Supersignal chemiluminescent 
reagent as described by the manufacturer, covered with plastic wrap and exposed to enhanced 
chemiluminescence detection film (Amersham Biosciences) for 5 minutes and developed 
using a Kodak X–Omat 1000 processor . 
 
After SAP levels were quantified, bound antibodies were stripped from membranes by 
incubation in stripping buffer (Table 2.15) for 45 minutes at 50oC and several washes in 
dH2O. The membranes were then blocked with 10% non-fat milk and re-probed with an 
endogenous control and incubated overnight. HRP conjugated secondary was added to the 
membrane followed by exposure to chemiluminescent reagent and film as described 
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previously. Protein density was measured by quantifying signal from the human SAP: 25-
28kDa, mouse SAP: 26kDa and human GAPDH: 37kDa mouse GAPDH: 38kDa bands using 
Image J analysis. Pixel density of SAP protein bands was measured relative to control 
GAPDH bands (Table 2.17). 
 
2.17 Statistical Analyses 
 
Student’s t-test was used to analyse data when comparing numerical variables between two 
groups. In situations where more than two groups were compared against each other, data was 
analysed using a one way ANOVA with Bonferroni post test. All statistical analysis was 
performed using the GraphPad Prism software version 4. Data were considered statistically 
significant when p<0.05. Levels of significance were expressed as follows: *, p<0.05; **, 
p<0.01; ***, p<0.001; ****, p<0.0001. 
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CHAPTER 3: EFFECTS OF MSC DETACHMENT 
METHODS ON VIABILITY, TRI-LINEAGE 
DIFFERENTIATION, IMMUNOMODULATION AND 
CHEMOKINE RECEPTOR EXPRESSION 
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3.1 Introduction 
 
Human bone marrow derived mesenchymal stromal cells (MSC) are multipotent stem cells 
capable of self-renewal and tri-lineage differentiation into adipocytes, chondrocytes and 
osteoblasts (Jiang et al., 2002, Pittenger et al., 1999). MSC have also been shown to 
transdifferentiate into other cell types including hepatocytes (Lee et al., 2004, Pittenger et al., 
1999), neuronal cells (Brazelton et al., 2000, Pittenger et al., 1999), endothelial cells (Oswald 
et al., 2004), cardiac cells (Pittenger et al., 1999) and connective tissue (Pittenger et al., 
1999). In addition, MSC have been shown to have potent immunomodulatory properties 
(Uccelli et al., 2008), with anti-inflammatory actions having been demonstrated in a range of 
murine models of disease including diabetes (Ding et al., 2009), graft versus host disease 
(GVHD) (Ren et al., 2008) and sepsis (Nemeth et al., 2009). Moreover, allogeneic MSC have 
been used in clinical trials of GVHD with evidence of efficacy (Le Blanc et al., 2008), with 
larger trials ongoing in patients with ischaemic heart disease, inflammatory bowel disease and 
diabetes (www.osiris.com). The diverse functions of MSC and proven efficacy in clinical 
trials, combined with their transdifferentiation abilities suggests they are well equipped to 
assist regeneration and recovery of injured organs. In support of this MSC have been shown 
to reduce tissue damage and to exhibit anti cancer properties (Secchiero et al., 2010) by a 
multitude of pathways (Jung et al., 2011b, Lin et al., 2011) indicating their possible 
therapeutic utility. 
 
However, other significant aspects of MSC function, such as an understanding of the 
mechanisms regulating their adhesion and incorporation into tissue, remain less well 
delineated. Although direct transplantation of MSC into injured organs has been shown to 
contribute to recovery (Amado et al., 2005), gaining such direct access is not always practical, 
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and it is more likely that therapeutic cells will be delivered by systemic infusion. Indeed, up-
regulation of adhesion molecules in injured organs increases homing of cells such as 
leukocytes to the site of injury, in a manner critically dependent on the expression of specific 
adhesion molecules and cell surface CCR (Aldridge et al., 2012, Ley et al., 2007, 
Thankamony and Sackstein, 2011). We (Aldridge et al., 2012), and others have demonstrated 
that similar mechanisms operate for MSC recruitment (Chamberlain et al., 2011, Ji et al., 
2004, Karp and Leng Teo, 2009, Sarkar et al., 2010, Wu and Zhao, 2012) although the 
importance of CCR for MSC for tissue homing remains uncertain (Ciuculescu et al., 2011, 
Ponte et al., 2007, Ringe et al., 2007, Sordi et al., 2005). This is particularly relevant as MSC 
are cultured on tissue plastic and are commonly detached with enzymatic methods which may 
cleave surface CCR prior to in vivo delivery (Lubis et al., 2011). Certainly surface receptor 
expression and function on leukocytes alters according to the way they are handled ex vivo 
and this can have an effect on their subsequent adherence to endothelium (Faint et al., 2011). 
However, there has been no comprehensive study of the impact of different methods of MSC 
detachment on the functionality, viability and homing ability of the cells (Frith et al., 2010, 
Girdlestone et al., 2009, Heng et al., 2009, Liu et al., 2011a). 
 
Based on current data I hypothesise that MSC have a reproducible and robust chemokine 
receptor profile but as these receptors are susceptible to proteolytic degradation, enzymatic 
dissociation methods may reduce surface CCR expression leaving them undetectable. 
Although non enzymatic detachment methods may preserve receptor expression, there is a 
significant lack of data reporting the effects of the less commonly used non enzymatic 
detachment methods on MSC properties such as tri-lineage potential and immunotherapy.  I 
predict that non enzymatic methods may, as reported, reduce viability and alter MSC 
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properties through increased levels of stress and damage to the cells. A comparison of non 
enzymatic detachment methods may yield a method which is least detrimental to MSC upon 
dissociation. 
 
Therefore, in this chapter, we specifically considered how culture and detachment of MSC 
may alter their cell surface CCR expression and whether cell processing could influence the 
targeting of intravenously administered cells to injured organs. We also documented how 
preparation techniques may alter receptor expression and also affect viability, multipotency, 
immunomodulatory and migratory properties. These investigations will have important 
implications for the design of methodologies for applications. 
 
The aims of this chapter were: 
 
(i) To identify the most appropriate method to detach viable MSC from tissue culture 
plastic while maintaining functional cell surface CCR expression. 
 
(ii) To assess the effects of the detachment method on MSC tri lineage differentiation. 
 
(iii) To measure the effects of detachment on the immunosuppressive properties of 
MSC. 
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3.2 Results 
 
3.2.1 MSC express high levels of intracellular CCR but negligible levels of cell surface 
CCR when in suspension. 
 
Intracellular and cell surface CCR expression was measured on enzymatically detached MSC 
from tissue culture plastic using flow cytometry. High proportions of MSC expressed 
intracellular CCR4, CXCR3 and CCR5 (Figure 3.1A) but cell surface expression of all CCR 
we investigated (CCR1-10, CXCR1-7) was negligible and often absent (Figure 3.1B). To 
investigate whether CCR expression changed in response to cell passage, intracellular and cell 
surface CCR expression was measured at P2, P4 and P6. Intracellular CCR4, CCR5 and 
CXCR3 were detectable at all passages (Figure 3.2A) but cell surface CCR was negligible 
(Figure 3.2B). Furthermore, stimulation of MSC with inflammatory cytokines, TNFα and 
IFNγ, had no effect on receptor expression and cell surface CCR levels remained absent or 
negligible (Figure 3.2C). Cytokine efficacy was confirmed by treatment of positive control 
cells. TNFα stimulation of HSEC increased cell surface VCAM-1 expression (Figure 3.2E) 
and IFNγ stimulation increased CD40 in a hepatoma cell line (PLC/PRF/5 Alexander, Figure 
3.2D). To assess whether cell detachment altered CCR receptor expression adherent MSC 
were stimulated with cytokines and pre-labelled with CCR antibodies in culture and fixed 
with PFA. If MSC were then detached using TrypLE they still did not express any surface 
CCR (Figure 3.3A and B). Of note, although serum was identified as a potential mediator of 
CCR internalisation in previous data (Figure 3.1A and 3.1B), expression upon cells under 
serum-free culture conditions was similar to MSC tested in serum culture conditions (Figure 
3.3A and B). Similarly when MSC were stimulated with TNFα and IFNγ in culture with and 
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without serum little expression was evident (Figure 3.4A and B). A small shift was noted in 
the absence of serum but back gating the positive population onto the MSC dot plot histogram 
suggested localisation on a dead cell population, or due to debris and not upon the viable 
MSC population (Figure 3.4C). Importantly use of non enzymatic means (CDB) to detach 
cells resulted in much higher surface CCR levels (Figure 3.5A), although use of a viability 
marker to exclude non viable cells reduced the signal somewhat (Figure 3.5B). Nevertheless a 
population of viable cells expressing cell surface CCR was evident (Figure 3.5C).   
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Figure 3.1: Surface and intracellular CCR expression by MSC 
Representative flow cytometry plots of A: Permeablised MSC (gate R1) and B: Non-
permeablised MSC (gate R1). Representative flow cytometry histograms for, A: intracellular 
and, B: cell surface CCR4, CCR5, CXCR3 (green) compared to Isotype-matched negative 
control (red).  Representative of n=3 donors, cells were detached using TrypLE.  
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Figure 3.2: Effect of passage and cytokine stimulation upon MSC surface CCR 
expression.  
Flow cytometry analysis for CCR4, CCR5 and CXCR3, expressed as, A: percentage of MSC 
positive for intracellular CCR expression at passage 2, 4 and 6; and B: percentage of MSC 
positive for surface CCR expression at passage 2, 4 and 6. Bars represent n=1 donor. C: 
Representative flow cytometry histograms of CCR4, CCR5, CXCR3 (green) expression 
compared to immunoglobulin matched negative control (red) after TNFα (10ng/ml) and IFNγ 
(25ng/ml) stimulation. D: Representative flow cytometry histogram of VCAM-1 expression 
on unstimulated (red) and stimulated HSEC (green) compared to an isotype-matched negative 
control (blue). E: Representative flow cytometry histogram of CD40 expression on 
unstimulated and TNFα stimulated hepatoma cell line (PLC/PRF/5 Alexander: green) 
compared to an isotype-matched negative control (red). Representative of n=3 donors. 
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Figure 3.3: Pre-labelling and fixation of cells, and treatment in absence of serum do not 
alter surface chemokine expression.  
Representative flow cytometry histograms of pre-detachment, antibody labelled and PFA 
fixed MSC surface CCR4, CCR5, CXCR3, CXCR4 expression (green) on unstimulated, 
TNFα and IFNγ stimulated MSC compared to isotype matched negative control (red) in the 
A: presence and B: absence of serum.  Representative of n=3 donors. 
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Figure 3.4: The effect of serum on MSC surface receptor expression after cytokine 
stimulation.  
Representative flow cytometry histograms of MSC surface CCR4, CCR5, CXCR3, CXCR4 
(green) on unstimulated, TNFα and IFNγ stimulated MSC compared to isotype matched 
negative control (red) in the A: presence and B: absence of serum. C:   Representative flow 
cytometry plot of MSC (gate R8) of surface CCR positive (blue) and negative (red) MSC 
population with representative flow cytometry histograms of CCR4, CCR5 and CXCR3 
positive cells (blue). Representative of n=3 donors. 
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Figure 3.5: Expression of surface CCR on viable cells after CDB detachment.  
A: Representative flow cytometry plots of MSC detached with CDB (red) and CCR4 
expressing MSC (blue). B: Representative flow plots of MSC detached with CDB (red) and 
labelled with a fixable viability marker to identify non viable MSC (green).  C: Representative 
flow cytometry plots of viable MSC after CDB detachment expressing cell surface CCR4 
(blue). Representative of n=3 donors. 
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3.2.2 Non-enzymatic detachment preserves functionally active cell surface CCR 
expression on MSC 
 
Enzymatically detached MSC had very low CCR expression on their cell surface, with less 
than 2.5% of cells positive for the CCR tested (Figure 3.6A) and those present had very low 
median channel fluorescence values (Figure 3.6B). In contrast, cells detached non-
enzymatically had significantly higher CCR expression and MFI, with the highest levels seen 
in cells detached by scraping. After detachment by scraping MSC were; 55.25+5.878% 
positive for CCR4, 46+7.782% for CCR5, 35.28+9.387% for CXCR3 and 6.25+1.187% 
positive for CXCR7 (Figure 3.6A and B). 35.8+0.494% MSC detached with CDB were 
positive for CCR4, 26.24+0.658% for CCR5, 10.65+0.518% for CXCR3 and 3.31+0.198% 
for CXCR7 (Figure 3.6A and B). Of the non-enzymatic detachment methods CDB offered the 
best compromise of retention of CCR expression and cell viability. Hence this method was 
compared with TrypLE (as the most effective enzymatic detachment method) to assess the 
functional status of CCR on MSC. There was significantly improved migration of cells 
detached using CDB towards CCL22 (4.944+1.098 vs. 1.667+0.3630) (p<0.05), CXCL12 
(3.528+0.4739 vs. 2.133+0.5051) (p<0.05) and CCL4 (2.643+0.4320 vs. 1.161+0.1385) 
(p<0.05), as compared with TrypLE. A trend for improved migration of cells detached using 
CDB was observed, with approximately twice as many cells transmigrating towards CXCL11, 
however this response was not statistically significant (Figure 3.6C-F). 
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Figure 3.6: Expression and function of CCR expression of MSC after non enzymatic 
detachment.  
Flow cytometry analysis for CCR4, CCR5, CXCR3 and CXCR7 expressed as, A: percentage 
of MSC positive for surface CCR expression, B: median fluorescence intensity (MFI) of 
MSC. Bars represent mean + SEM of n=3 donor samples. Migration of MSC to C: RANTES/ 
CCL22 (CCR5 ligand) (500ng/ml), D: MDC/ CCL5 (CCR4 ligand) (500ng/ml), E: SDF1a/ 
CXCL12 (CXCR7 ligand) (50ng/ml) and F: ITAC/ CXCL11 (CXCR3 ligand) (500ng/ml) 
normalised to control/ basal (serum free media only) was assessed by Boyden Chamber 
assays. Optimal concentrations for migration were found by dose response curves. Data is 
expressed as fold over basal migration. Bars represent mean + SEM of n=3 donor samples, *, 
p<0.05; **, p<0.01; ***, p<0.001. 
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3.2.3 MSC viability, re-plating ability and proliferation in culture are altered 
according to detachment methodology. 
 
Cultured Human MSC were detached from cell culture plastic using a range of enzymatic and 
non-enzymatic methods. Viability was best retained following detachment with enzymatic 
methods TrypLE (98.38+0.89%) and Accutase (98.35+0.37%) as depicted in Figure 3.7A. Of 
the non-enzymatic detachment methods EDTA (69.32+3.2%) and cell scraping 
(64.78+6.67%) demonstrated the greatest reduction in viability immediately after detachment 
(p<0.001). Similarly CDB caused a reduction in MSC viability (77.29+6.51%). In view of the 
findings of altered viability following detachment we sought to determine whether this would 
have an impact on the ability of MSC to re-plate and proliferate. Following detachment MSC 
were re-plated and functionally viable numbers remaining bound after 24 hours were 
quantified by measuring their ability to reduce MTT. Enzymatic detachment resulted in higher 
levels of MTT signal suggesting greater numbers of bound MSC (MTT absorbance values; 
TrypLE, 0.397+0.008 and Accutase, 0.483+0.0218 after 24 hours in culture (Figure 3.7B), 
compared to non-enzymatic detachment (CDB 0.225+0.003, EDTA 0.140+0.001, and by 
scraping 0.089+0.001). 
 
Altered viability following detachment and re-plating was accompanied by changes in 
morphological appearance. MSC re-plated after detachment with enzymatic methods retained 
spindle-shaped fibroblast-like morphology, typical of MSC (Figure 3.8A(i) and (ii)), whereas, 
MSC detached by EDTA and scraping exhibited quite different morphology with most cells 
taking on a retracted, circular shape, similar to dying cells with large gaps between cells 
(Figure 3.8A(iii) and (iv)). Notably, MSC detached with CDB mostly retained typical MSC-
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like morphology (Figure 8B(ii)) and proliferated to confluence after re-plating (p<0.001) 
(Figure 3.7C). In contrast, MSC detached using other non enzymatic methods 
(EDTA/scraping) showed no proliferation after 5 days in culture, coupled with a decline in 
viable cells (EDTA (p<0.01)/ scraping (p<0.001), possibly as a result of cell death and 
detachment in culture (Figure 7B and C). However enzymatically recovered cells showed 
higher viability upon re-plating thus quickly reaching confluence and causing cell numbers to 
plateau (Figure 3.7D). 
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Figure 3.7: Measurement of MSC viability and growth of re-plated cells.  
A: MSC viability after detachment from tissue culture plastic measured using flow cytometry 
staining for live/ dead cell marker. Bars represent mean + SEM of n=3 different donor 
samples; **, p<0.01. B: Cell viability by MTT analysis of re-plated cells after 24 hours, 
expressed as an MTT absorbance value. Bars represent mean + SEM of n=3 samples, *, 
p<0.05; ****, p<0.0001. C: Cell proliferation indicated by fold change in cell viability after 3 
and 5 days measured by MTT assay from basal MTT readings at 24 hours culture of re-plated 
cells after non enzymatic detachment and after, D: enzymatic detachment methods. Data 
represent mean + SEM of n=3 samples, **, p<0.01; ***, p<0.001. 
  
113 
 
 
114 
 
Figure 3.8: Morphology of re-plated MSC on tissue culture plastic.  
A: Representative images of re-plated MSC 24 hours after detachment with (i) Accutase, (ii) 
TrypLE, (iii) EDTA and (iv) Scraping; n=3 samples. B: Representative images of re-plated 
MSC detached by CDB after (i) 24 hours, (ii) 120 hours; n=3 samples. Original magnification 
x10, images captured using phase contrast microscopy. 
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3.2.4 Non-enzymatic detachment with CDB results in increased autophagy as a 
response to increased cellular stress.  
 
To determine why of the non-enzymatic methods used to detach MSC, only CDB was 
associated with subsequent viable expansion, the presence of cellular survival strategies such 
as autophagy were examined. We observed that, 13.77+0.81%, (p<0.0001 compared to cells 
only, unlabelled control) of MSC detached with CDB underwent autophagy (Figure 3.9A) 
compared with much lower levels for all other detachment methods (EDTA, 3.00+0.71%, and 
cell scraping, 2.39+0.74%). To better understand the impact of detachment method on cellular 
stress, intracellular reactive oxygen species, and levels of apoptosis & necrosis were also 
measured. Based on our earlier data, this analysis was focussed on the most effective 
detachment methods (TrypLE and CDB). MSC detached with CDB exhibited higher levels of 
autophagy (MFI: 18.06+1.39 vs. 11.59+0.97 (p<0.05), Figure 3.9B) and intracellular reactive 
oxygen species (MFI: 200.7+1.09 vs. 180+19.24, Figure 3.9B) compared with TrypLE 
detached MSC.  In addition, CDB detached MSC displayed a corresponding increase in 
apoptosis (MFI: 10.39+1.16 vs. 8.35+1.6, Figure 3.9B) and necrosis (MFI: 11.74+1.1 vs. 
10.04+1.34, Figure 3.9B) compared with values seen following TrypLE detachment. 
 
Addition of serum during CDB detachment and subsequent washing steps resulted in a 
marked increase in viable MSC numbers re-plating at day 1 (MTT absorbance values; serum+ 
v serum-, 0.753+0.003 vs. 0.210+0.001). By day 5 cells proliferated significantly more when 
serum was used compared to cells re-plated after washing without serum (MTT absorbance 
values; serum+ v serum-, 1.275+0.013 (p<0.0001) vs. 0.243+0.002 (p<0.01)) (Figure 3.10A 
and B). Re-plated MSC washed with PBS alone remained in clumps and seeded sparsely 
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(Figure 3.10C); whereas inclusion of 1% fetal calf serum resulted in fewer, smaller clumps 
and the cells converged into a complete monolayer by day 5. This effect was also observed 
following use of slower centrifugation speeds (1500 vs. 2000 rpm) during washing (Figure 
3.11A and B). 
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Figure 3.9: Measurement of Autophagy in detached MSC.   
A: Representative cytometry histograms for unlabelled MSC (black) and MSC stained with 
autophagy marker, monodansylcadaverine-Pacific Orange (MDC-PO) (red).  Representative 
flow cytometric plots, including unlabelled cells. Dots in gate R3 represent percentage of cells 
undergoing autophagy with representative cytometry histograms. Data represents mean + 
SEM of n=3 different donors, ***, p<0.0001. B: Levels of stress on TrypLE (enzymatic) and 
Cell Dissociation Buffer (non enzymatic) detached cells. Representative cytometry histogram 
for CDB detached MSC (red) and TrypLE detached MSC (black), stained with A: Autophagy 
marker, monodansylcadaverine (MDC), B: IROS marker, 2’, 7’-dichlorofluorescin (DCF), C: 
Apoptosis marker, annexin V, D: Necrosis marker, 7AAD; with corresponding Median 
Fluorescent Intensity (MFI) values. Data represents mean + SEM of n=3 different donors, *, 
p<0.05. 
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Figure 3.10: Impact of serum supplementation on viability and proliferation of MSC 
detached with CDB.  
A: Cell proliferation and survival of re-plated cells indicated by absorbance of MTT after 1, 3 
and 5 days measured by MTT assay after detachment with CDB and wash with PBS with or 
without 1% serum. Data represent mean + SEM of n=3 samples. **, p<0.01; ***, p<0.001. B: 
Representative images of re-plated MSC detached with CDB and washed with PBS with or 
without 1% serum, taken after 1, 3 and 5 days; n=3 samples. Original magnification x10, 
images captured using phase contrast microscopy. 
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Figure 3.11: Impact of centrifugation speed on viability and proliferation of MSC 
detached with CDB.  
A: Cell proliferation and survival of re-plated cells indicated by absorbance of MTT after 1, 3 
and 5 days measured by MTT assay after detachment with CDB, washed with PBS with 1% 
serum at high (2000RPM) and low speed (1500RPM) centrifuge. Data represent mean + SEM 
of n=3 samples. B: Representative images of re-plated MSC detached with CDB, washed with 
PBS 1% serum and centrifuged at high and low speeds, taken after 1, 3 and 5 days; n=3 
samples. Each point represents mean + SEM of n=3 different donors, *, p<0.05; **, p<0.01; 
***, p<0.001. Original magnification x10, images captured using phase contrast microscopy. 
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3.2.5 Impact of detachment method on the differentiation and immunomodulatory 
capabilities of MSC  
 
Adipogenic differentiation was markedly reduced following detachment with non-enzymatic 
methods in particular EDTA and cell scraping (Figure 3.12A), although a degree of 
differentiation did occur following CDB detachment (p<0.001). In contrast, detachment by 
cell scraping resulted in a much higher calcium concentrations (188.3+50.92, p<0.05), 
indicative of greater differentiation into osteoblasts (p<0.05) (Figure 3.12B). Chondrogenic 
differentiation seemed to be maintained in cells detached by both enzymatic (TrypLE) and 
non enzymatic (CDB) methods (Figure 3.12C).  
 
Proliferation of activated CD3+CD4+CD25- T effector cells (Figure 3.13) has been shown to 
be suppressed by co-culture with MSC. Indeed, MSC detached with both TrypLE and CDB 
are able to significantly suppress activated CD3+CD4+CD25- T effector cell proliferation 
when co-cultured at a ratio of 1:5 (Figure 3.14A and B). T effector cells cultured without 
MSC proliferated to 3271+146.1 cells/μl and 3221+101.2 cells/μl but were significantly 
suppressed at a ratio of 1:5 in the TrypLE (1540+338.3 cells/μl, p<0.001) and CDB 
(2188+47.07 cells/μl, p<0.05) assays, respectively.  However it appears that TrypLE detached 
cells are more potent immunosuppressors as they were able to significantly suppress 
proliferation to lower numbers than CDB dissociated cells. TrypLE detached MSC were able 
to significantly suppress T effector cell numbers, 2281+189.3 cells/μl at a ratio of 1:10 
(p<0.05) compared with CDB detached cells (2636+187.9 cells/μl) which did not significantly 
suppress T effector cell proliferation at this ratio. This is particularly evident at a 1:20, MSC: 
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T cell ratio where there was significant suppression by the TrypLE detached MSC population 
(27.37+4.85%, p<0.05) whereas T effector cells cultured with CDB detached MSC seemed to 
proliferate with little suppression (1.2+1.2%) (Figure 3.14C). 
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Figure 3.12: Impact of detachment method on the differentiation capabilities of MSC.  
A: Image J analysis of oil red O staining of MSC differentiated into adipocytes. MSC were re-
plated after various ways of detachment from tissue culture plastic and differentiated into 
adipocytes. Bars represent oil red O stained mean area fraction + SEM of n=3 samples; ***, 
p<0.001. B: Alizarin red staining of MSC differentiated into osteoblasts. MSC were re-plated 
after various ways of detachment from tissue culture plastic and differentiated into 
osteoblasts. Bars represent mean calcium concentration (µM) + SEM of n=3 samples; *, 
p<0.05. C: Representative images of DAB staining of collagen II as a marker of MSC 
differentiated into chondrocytes at x20 magnification. MSC were cultured as pellets after 
detachment from tissue culture plastic using CDB and TrypLE and differentiated into 
chondrocytes.  
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Figure 3.13: Confirmation of efficiency of CD3+CD4+CD25- T cells sorting from 
peripheral blood.  
A: Peripheral blood T cells were gated on forward scatter (FS) side scatter (SS) histogram 
plots. B: CD3+ cells were gated from the peripheral blood T cell population. C: Effector T 
cells were identified by gating on CD4+CD25- cells from the CD3+ T cell population. D: 
Sorted CD3+CD4+CD25- T effector cells were 98% pure.  
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Figure 3.14: Impact of detachment method on the immunomodulatory capabilities of 
MSC.  
Flow cytometry analysis of activated CD3+CD4+CD25- T effector cell proliferation labelled 
with CellTrace™ Violet and analysed with PE labelled Accucheck counting beads. MSC were 
co-cultured with activated  CD3+CD4+CD25-  T effector cell at ratios of 1:5, 1:10, 1:20, 1:40, 
1:80, respectively  and compared to CD3+CD4+CD25-  T effector cell proliferation without 
MSC after, A: TrypLE detachment and B: CDB detachment. C: Comparisons at each ratio 
were made of percentage CD3+CD4+CD25- T effector cell suppression. Bars represent mean + 
SEM of n=3 different donors, *, p<0.05; ***, p<0.001. 
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3.3 Discussion 
 
MSC have been shown to possess powerful therapeutic qualities including 
immunomodulatory (Lin et al., 2011), anti-fibrotic (Zhao et al., 2012) and anti-cancer 
(Secchiero et al., 2010) properties as well as potential for use as vectors for gene therapy (Ley 
et al., 2007, Loebinger et al., 2009, Niess et al., 2011). This repertoire of clinical uses has led 
to an increasingly large number of clinical trials (Houlihan and Newsome, 2008) that assess 
MSC as a cell therapy in a variety of diseases. The typically low yield of cells obtained after 
isolation means that MSC have to be expanded in artificial culture conditions, prior to their 
clinical use (Lubis et al., 2011). Consequently there is a high degree of non-physiological 
manipulation involved in the pre-clinical preparation of MSC. Unfortunately until recently 
there has been no standardised way to do this and a variety of modified methods have been 
employed to isolate, grow and detach MSC for therapeutic use (Wagner et al., 2006). 
Although MSC are commercially available and thus culture conditions are now more 
standardized, one potential preclinical variable that remains to be investigated is the method 
of detachment of MSC from tissue culture plastic (Heng et al., 2009). Thus it is vital to 
investigate how pre-clinical manipulation and treatment of these cells could affect their 
downstream functions including recruitment, engraftment and their anti-inflammatory effect 
at the site of injury.  
 
In the present chapter we have investigated whether different methods of detachment, 
including enzymatic and non enzymatic methods, can affect MSC differentiation, 
immunomodulation and migration via cell surface CCR expression. Previous work has shown 
that enzymatic detachment, specifically using Trypsin can reduce MSC CCR expression 
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whereas EDTA preserves cell surface expression (Chamberlain et al., 2008). Studies using 
embryonic stem cell populations also suggest that detachment strategies such as scraping 
which maintain small groups of cells rather than complete single-cell disaggregation may be 
more successful in terms of maintaining viability (Buzzard et al., 2004, Mitalipova et al., 
2005). I have shown in this chapter that enzymatic, detachment of cells from tissue culture 
plastic preserves cell viability and their adipogenic and osteogenic differentiation but causes 
proteolytic cleavage of cell surface CCR. In contrast, non-enzymatic detachment methods did 
not increase intracellular stress on MSC during detachment, but reduced cell viability and 
adipogenic and osteogenic differentiation capabilities. CDB and EDTA both work to 
dissociate cells by chelating calcium but as there is an apparent difference between the effects 
of both methods (Heng et al., 2009) this cannot solely explain the loss in cell viability. Since 
the loss of viability seems to occur at the point of dissociation from plastic (Heng et al., 2009) 
the physical trauma associated with scraping cells may explain the highest degree of cell 
death following this treatment. This is in agreement with data from adherent cell cultures 
(Batista et al., 2010) which shows damage to plasma membrane domains following cell 
scraping. 
 
Despite reduced viability following non-enzymatic detachment, cells maintained functional 
cell surface CCR expression, resulting in increased migration towards corresponding 
chemokine ligands, compared to TrypLE detached MSC. This suggests that although viability 
is compromised upon cellular detachment, surviving cells may retain functional capabilities if 
allowed to recover.  Thus we investigated how the cells behave once allowed to reattach in 
culture. Here, the morphology, viability and growth dynamics of the differentially detached 
MSC was monitored and recorded after 1, 3 and 5 days.  Viability of equal densities of 
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adherent cells in culture after 24 hours seemed to reflect the initial pattern of viability upon 
detachment. However, in all cases, we observed fewer cells attaching to plastic than would be 
indicated by the numbers of viable cells present. This may reflect the relative insensitivity of 
Trypan blue for identifying cells undergoing early stages of cell death or apoptosis. Over 5 
days in culture  compared to other non-enzymatic methods, CDB-detached MSC appeared to 
exhibit the greatest recovery of growth in culture despite initially lower viability post 
detachment, and their morphology was similar to enzymatic detached cells. EDTA-detached 
and scraped cells showed little or no recovery over 5 days and exhibited a denatured and 
damaged appearance in culture. In contrast, possibly due to higher survival of plated cells and 
rapid development of confluence, resulting in contact inhibition, TrypLE and Accutase 
detached MSC maintained or started to reduce in cell number, respectively, over time. 
 
Centrifugal washing of cells post-detachment is a highly stressful but vital stage of the cell 
preparation protocol. We have shown that post-detachment washing at reduced speed using a 
buffer supplemented with foetal calf serum preserves viability. Low centrifugation speeds 
during washing stages may increase yield of viable cells by minimising the proportion of dead 
cells accumulating in the cell pellets. Similarly the inclusion of serum may increase 
subsequent reattachment by either reducing cell clumping or providing substrates for 
attachment (Horiuti et al., 1982) thus preventing anoikis (Yu et al., 2012). In support of this, 
detachment of rat MSC from temperature responsive platforms suggests the presence of ECM 
proteins around or within the cell membranes can preserve viability (Yang et al., 2012). 
 
We hypothesised that CDB may result in a high percentage of cells entering a cell survival 
mechanism known as autophagy, which has been demonstrated in highly stressed cells 
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(Bhogal et al., 2012). During autophagy cells begin a process of self degradation through a 
lysosomal degradation pathway (Bhogal et al., 2012, Levine and Yuan, 2005) with 
preservation of cytoskeletal elements until later stages (Bhogal et al., 2012, Levine and Yuan, 
2005). Autophagy was first identified as a pre-apoptotic or a pre-necrotic mechanism, which 
would ultimately lead to the death of the cell (Schweichel and Merker, 1973). However recent 
studies have shown that prevention of autophagy does not necessarily prevent cell death 
(Levine and Yuan, 2005) and suggest that autophagy is a cell survival mechanism which may 
precede cell death, or which cells can recover from (Levine and Yuan, 2005). The role of 
autophagy in cell survival is best characterised in nutrient deficiency but has been shown to 
occur in cells under hypoxic stress (Bhogal et al., 2012). During this process, autolysosomes 
generate free fatty acids and amino acids through degradation of membrane lipids and 
proteins to fuel mitochondrial ATP energy production and protein synthesis to promote cell 
survival (Bhogal et al., 2012, Levine and Yuan, 2005). Alternatively, autophagy may activate 
in cells committed to die by apoptosis or necrosis so the cell contents are targeted for 
degradation by its own lysosomes (Levine and Yuan, 2005). This provides a mechanism to 
clear dead cells in the absence of phagocytes (Levine and Yuan, 2005) but in cultured cells 
this may protect surrounding cells from cytotoxic contents of dead or dying cells, thus 
preventing the formation of a necrotic environment. Recent evidence has shown that 
autophagy in hepatocytes can be mediated by increased intracellular reactive oxygen species 
(IROS) due to hypoxic stress (Bhogal et al., 2012). CDB treated cells did not demonstrate 
increased IROS levels compared with cells detached using TrypLE. We therefore suggest that 
CDB seems to preserve long-term viability of MSC compared to the other non enzymatic 
detachments by promoting autophagy. This may operate as a recoverable pre death state, or as 
a self clearance mechanism which protects the viability of surrounding cells. 
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We observed that non-enzymatic detachment methods resulted in reduced adipogenic 
differentiation. Cell scraping is a standard technique which could be employed to passage 
cells before differentiation; our findings suggest that such methods could be detrimental to 
adipogenic differentiation of MSC perhaps as a result of cellular damage during detachment. 
Alternatively methods such as scraping or EDTA cell detachment results in clumps of cells 
rather than single cells. This could mean receptors otherwise used for adipogenic 
differentiation are not exposed to differentiation factors. In contrast, osteogenic differentiation 
was maintained in cells detached by all methods and there was significantly increased 
differentiation when cells were scraped. Evidence suggests that increased cellular stress levels 
induced by shearing cells can push MSC towards an osteogenic phenotype (Yourek et al., 
2010) and thus scraping cells may activate similar processes. This mechanism may be 
designed to drive osteogenesis upon bone fracturing (Carter et al., 1988), and thus shearing 
MSC in culture to drive osteogenic progenitor phenotype may have implications in cell 
therapy for orthopaedics. A recently described alternative method of cell detachment that has 
not been explored in this chapter is the use of temperature responsive platforms. Here cells are 
cultured on poly-N-isopropylacrylamide (PNIPAAm) copolymer films and detached by 
rapidly reduction in temperature (Yang et al., 2012). Rat MSC grown on the copolymer films 
showed significantly higher degrees of differentiation to adipocytes compared with 
trypsinised controls but no significant difference in osteogenic differentiation (Yang et al., 
2012). Such studies also suggest significantly higher levels of viability than enzymatic 
detachment. We have noted reduced adipogenic differentiation and that MSC 
immunomodulatory capacity was diminished following cell scraping and such differences 
with other detachment studies highlight the need to standardise methodology for specific 
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downstream applications. Also we showed that a lower concentration of TrypLE detached 
MSC are able to inhibit T effector cell proliferation compared with CDB detached MSC, 
suggesting CDB detached MSC lose some of their immunosuppressive ability.  
 
The loss of immunosuppression is likely to be due to the detachment method. CDB detached 
MSC have a significantly altered morphology, reduced viability and they appear damaged 
after 24 hours of reattachment to plastic compared with TrypLE detached MSC. This could 
serve to explain why we see a significant decrease in CDB detached MSC 
immunomodulatory capabilities which are tested after 24 hours of reattachment to plastic. 
There could be a number of reasons for this based on our findings. Firstly we see recovery of 
CDB detached cells after 5 days, up to this point MSC may be undergoing autophagy as we 
have shown, thus reducing the production of immunomodulatory cytokines involved in 
immunosuppression. Secondly, the reduced viability of CDB detached cells suggests that 
some cells seeded onto plastic after detachment will be dead or dying, thus reducing 
production of immunosuppressive cytokines. Finally, MSC are an adherent cell type and are 
not physiologically designed to migrate in suspension or through the circulation. Exogenous 
administration of MSC would mean infusing MSC in suspension. To identify receptors that 
MSC may use to migrate through the circulation, MSC need to be analysed for the receptors 
they express whilst non-adherent and in suspension. To identify the receptors on detached 
MSC, CDB is a more appropriate method as TrypLE would cleave off receptors. Alternatively 
to carry out immunosuppressive functions it may be essential for the cell to be adhered. 
TrypLE detached MSC appear to be regain their normal morphology after 24 hours when re-
attached to plastic. TrypLE is perhaps the best method of detachment to enable MSC to retain 
immunosuppressive potential, although receptor expression when in suspension is minimal. 
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An important obstacle in MSC therapy is the application of MSC to the site of injury and the 
method of administration of MSC in the patient. Direct transplantation of MSC to injured 
organs has been shown to contribute to recovery of the organ (Amado et al., 2005) however 
this type of invasive procedure is not always feasible. Therefore a non-invasive method of 
MSC delivery to areas of injury needs investigation, possibly through intravenous 
administration and organ targeting via specific adhesion. According to the well established 
paradigm of leukocyte recruitment to organs, adhesion molecules and cell surface CCR play 
an integral role in cell recruitment (Ley et al., 2007). However, there are inconsistent reports 
on CCR expression on MSC (Ciuculescu et al., 2011, Ponte et al., 2007, Ringe et al., 2007, 
Sordi et al., 2005). In this study we have investigated affects of detachment methods on cell 
surface CCR expression and function. We chose a panel of CCR, namely, CCR4, CCR5, 
CXCR3 and CXCR7 that were retained on the MSC surface when detached by non enzymatic 
methods and demonstrated significantly increased migration towards chemokine ligands, 
suggesting a functional preservation of cell surface CCR expression. We have shown there 
was significant migration towards the respective CCR4 and CCR5 ligands, MDC/ CCL22 
(Imai et al., 1998) and MIP1B/ CCL4 (Raport et al., 1996) when MSC were detached with 
CDB and no difference compared to control when MSC were detached with TrypLE. 
Migration towards the CXCR3 ligand, ITAC/ CXCL11 (Loetscher et al., 2001) showed a 
similar trend but this was not significant. Our data supports previous work by Chamberlain et 
al (Chamberlain et al., 2008) which suggests CCR expression on MSC surface and their 
function is preserved with non-enzymatic detachment methods but significantly reduced after 
detachment with enzymatic methods possibly through proteolytic cleavage. 
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Our studies also suggest that migration towards the CXCR4/ CXCR7 ligand SDF1a/ CXCL12 
(Dambly-Chaudiere et al., 2007) is maintained after detachment. However, there appears to 
be increased migration of CDB detached MSC to SDF1a/ CXCL12. This is of interest as the 
receptor CXCR4 is expressed at negligible levels on MSC and so alternate receptors must be 
responsible. One possible alternative is CXCR7, an unusual CCR implicated mainly in 
scavenging and not in cell migration (Naumann et al., 2010). Although few reports do provide 
evidence for CXCR7 mediated migration, others suggest that CXCR7 forms heterodimers 
with CXCR4 to enhance migration of cells (Decaillot et al., 2011).  Our lack of CXCR4 
expression on MSC suggests CXCR7 may function independently in this case. CXCR7 is a 
cytoplasmic receptor not usually found on the cell surface, with the majority of its function 
dictated by the intracellular tail of the receptor (Ray et al., 2012). Thus enzymatic detachment 
of MSC would have little effect on its function, and cells may retain sustained migration 
towards SDF1a/ CXCL12 via CXCR7 independently or through association with other CCR. 
The reduced migration of TrypLE detached MSC to SDF1a/ CXCL12 supports the hypothesis 
that other enzymatically-sensitive surface receptors may dimerise with CXCR7 in order for 
the cell to migrate towards SDF1a/ CXCL12. Alternately cytoplasmic CXCR7 may also be 
able to mobilise to the cell surface during our migration experiments (Dambly-Chaudiere et 
al., 2007, Naumann et al., 2010).  
 
Clinical studies have shown that although very large numbers of MSC are infused into 
patients during non invasive applications only a very low number of cells engraft in the sites 
of injury (Lin et al., 2011). Furthermore, the immunosuppressive efficacy of these cells has 
been shown to directly correlate with the number of cells engrafted (Lin et al., 2011). 
Therefore an increased number of cells engrafting would lead to greater therapeutic efficacy 
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(Lin et al., 2011). Importantly such trials have all used enzymatic detachment methods. Since 
our results show reduced migration after enzymatic detachment we infer that the low level of 
engraftment in these trials may be due to the loss of important receptors during detachment. 
As MSC migration to sites of injury, binding and retention in organs is highly dependent on 
their cell surface CCR expression (Sordi et al., 2005, Wynn et al., 2004) cleavage of these 
receptors could affect their immediate functional capabilities when detached. Migration is not 
the only function of CCR which also play a role in firm adhesion and cell retention, both of 
which can be abrogated by loss of cell surface CCR (Chamberlain et al., 2008). The loss of 
CCR could also have implications on other TrypLE/ enzyme sensitive receptors on MSC cell 
surfaces.  This report highlights the need for the development of a method of detachment that 
can preserve viability and cell surface receptor profile of MSC.  
 
In conclusion, our data suggest that the optimal choice of MSC detachment method depends 
on the ultimate downstream application of the MSC. For example, if efficient organ delivery 
is likely to require cell surface CCR which are susceptible to proteolytic degradation, TrypLE 
is not a reliable method. However TrypLE preserves viability and the multi-lineage 
differentiation potential to a higher degree than CDB. Thus if cells can be delivered directly to 
the target organ, enzymatic dissociation may be possible. Therefore handling and 
manipulation, of MSC prior to experimental or clinical use has direct implications on the 
downstream outcome. As a result we have to very carefully consider how detachment of cells 
may have downstream effects on cell function otherwise we need to enhance our efforts to 
maintain the natural phenotype of MSC after detachment and before their use as a powerful 
and potent cell therapy. 
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CHAPTER 4: EFFECTS OF CYTOKINES ON MIGRATION 
AND IMMUNOMODULATION BY MSC 
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4.1 Introduction 
 
The therapeutic properties of MSC are well established and research suggests MSC can have 
significant beneficial effects in liver disease (Kuo et al., 2008, Lin et al., 2011, Puglisi et al., 
2011). Previous studies suggest that infused MSC are able to migrate to and enter the site of 
injury and thereby ensure a continued local delivery of mediators order to enact their 
therapeutic properties (Karp and Leng Teo, 2009, Lin et al., 2011). It has been shown that a 
significant reparative or beneficial impact can be carried out by very few MSC and the benefit 
is directly dependent on the number of cells that engraft into the site of injury (Lin et al., 
2011). Thus, for use as a therapeutic intervention in liver disease, MSC need to be infused 
into the patient and then to enter the liver. However the quantity of transplanted MSC needs 
to be far greater than the amount of MSC that are expected to carry out an effect as it is 
unlikely that all transferred cells will end up at the required location (Lin et al., 2011). In 
animal studies, the quantity of transplanted MSC used is usually approximately 106 – 107 cells 
(Lin et al., 2011). Transfer of larger numbers does not seem to increase the therapeutic 
effects, which were seen to plateau (Lin et al., 2011). However such numbers are still very 
large and require a significant degree of cell culture and expansion prior to infusion (Karp and 
Leng Teo, 2009) which may mean that the purity of the cells is difficult to maintain. It is 
therefore important to develop a method to improve MSC transplantation and subsequent 
engraftment in order to improve therapeutic efficacy rather than simply transferring increasing 
numbers of cells. Recent research into MSC recruitment to organs such as the liver is helping 
better understand this process, so that we can try and enhance MSC engraftment. 
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Exogenously administered MSC, like most cells in circulation attempting to enter tissue, will 
potentially arrest in the vasculature of the tissue followed by transmigration across the 
endothelium (Karp and Leng Teo, 2009, Oo and Adams, 2010). It has been hypothesised that 
MSC may be recruited to an organ either through an active process which mimics the existing 
paradigm of leukocyte recruitment or through a physical lodging into small vessels and then 
an active process of extravasation into the organ (Karp and Leng Teo, 2009, Oo and Adams, 
2010). MSC have been shown to actively roll in post capillary venules in mice using intra-
vital microscopy via a P-Selectin mediated process (Ruster et al., 2006). This has led to the 
development of SLex containing protein which couples to the surface of MSC and promoted 
shear resistant low affinity interactions or rolling on vascular endothelium via P-Selectin 
(Sarkar et al., 2008). Subsequent firm adhesion on TNFα activated umbilical vein 
endothelium occurs due to MSC interacting through the β1 ligands, VCAM-1 and VLA-4 
(Ruster et al., 2006, Segers et al., 2006), and blocking β1 integrin on MSC reduces their 
engraftment in ischemic myocardium (Ip et al., 2007). Firm adhesion may follow an initial 
rolling interaction which is the case for leukocytes. Alternatively, large MSC may lodge in the 
narrow vessels of the post-capillary vasculature (Chavakis et al., 2008). To mimic this 
process, researchers have used flow based assay methodology, where they paused the flow to 
allow MSC to adhere to endothelium prior to resumption of flow. Such studies confirm  that 
β1 integrin and CD44 are involved in the firm adhesion of MSC to sinusoidal endothelium 
(Aldridge et al., 2012). Such studies also suggest that MSC rolling on sinusoidal endothelium 
is mediated by β1 integrin and further, engraftment in carbon tetrachloride injured mouse liver 
is mediated by β1 integrin and CD44. This is important as hepatic sinusoidal endothelium 
does not express P-Selectin (Aldridge et al., 2012) and thus requires alternate routes for 
capturing recruited cells.   
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CCR play a large part in leukocyte recruitment, during firm adhesion and transendothelial 
migration stages (Oo and Adams, 2010). Research into the role of CCR in MSC adhesion and 
migration are inconclusive as some suggest that although MSC express CCR, there is no 
contribution of CCR to MSC recruitment (Thankamony and Sackstein, 2011). Alternate 
studies measuring mouse MSC retention to murine aortic endothelium under shear 
(Chamberlain et al., 2011) suggest a functional role for CCR in the firm adhesion, crawling 
and transmigration of MSC. Hence, ITAC/ CXCL9 on TNFα activated endothelium could 
significantly increase the number of MSC that remained firmly adhered under shear stress of 
which a high proportion actively crawled on endothelium in a ITAC/ CXCL9 dependent 
manner. Mouse MSC were also shown to migrate towards CXCL16, ITAC/ CXCL9, MIP3α/ 
CCL20 and TECK/ CCL25, using corresponding CCR, CXCR6, CXCR3, CCR6 and CCR9. 
These investigators have previously reported the expression of these CCR and CXCR2 on 
mouse MSC cell membrane, with other CCR (except CCR3) present on negligible proportions 
of MSC (Chamberlain et al., 2008). Furthermore they showed that human MSC expressed 
similar functional receptors on large proportions of cells but also expressed CCR1, CCR2, 
CCR3, CCR5, CCR7, CCR10, CXCR1, CXCR4, and CXCR5. Negligible proportions of 
human MSC were found to express CCR4 and CCR8 (Chamberlain et al., 2008). 
 
However, there are many inconsistencies in functional CCR profiles of MSC in reports from 
various groups. Isolated human MSC have been reported to express functional CCR1, CCR7, 
CXCR4, CXCR6 and CX3CR1 and could migrate towards corresponding ligands CCL3 
(MIP1α), CCL19 (MIP3β)/ CCL21 (6Ckine), CXCL12 (SDF1α), CXCL16 and CX3CL1 
(Fractalkine) respectively (Sordi et al., 2005). Other groups have detected the expression of 
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CCR1, CCR2, CCR4, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, 
CXCR4, CXCR5, CXCR6, CX3CR1 and XCR at the mRNA level (Honczarenko et al., 2006, 
Ringe et al., 2007). Protein expression of CCR8, CCR9 and CXCR1-6 has also been detected 
on MSC, of which CXCR1 and CXCR2 were proven to have a functional migratory response 
towards CXCL8/ IL8 (Ringe et al., 2007). Growth factors, including PDGF AB, IGF-1, EGF 
and HGF were better chemotactic agents than chemokines, nonetheless, MSC expressed high 
levels of CCR3, CXCR4 and CXCR5, and intermediate levels of CCR2, CCR4 and CCR5 
and showed migration to SDF1a/ CXCL12, Rantes/ CCL5 and MDC/ CCL22, suggesting a 
functional role for CCR4, CXCR4, CCR3 and CCR5 (Ponte et al., 2007). There have been 
particular inconsistencies in reports suggesting presence of CXCR4 on MSC. Many reports 
suggest MSC do not express CXCR4 (Karp and Leng Teo, 2009) but others suggest CXCR4 
is central to MSC migration (Son et al., 2006). Studies have also identified organ specific 
chemokines and receptors on MSC which could be responsible for MSC recruitment. For 
example, the importance of CCR2 has been highlighted in homing of MSC to injured 
myocardium (Belema-Bedada et al., 2008), and MSC have been proven to migrate towards 
pancreatic islets, mediated by the CXCR4/ CXCL12 (SDF1α) and CX3CR1/ CX3CL1 
(Fractalkine) pathway (Sordi et al., 2005). Similarly, transplanted rat MSC have been reported 
to migrate to recombinant human SDF-1α/ CXCL12 in an in vivo chemotaxis assay and could 
use the CXCR4/ CXCL12 (SDF1α) and CX3CR1/ CX3CL1 (Fractalkine) axis during left 
hypoglossal nerve injury to the brain (Ji et al., 2004). 
 
Various chemokines have been shown to be expressed on different cell types at specific sites 
in the liver during injury including CCL3 (MIP1α), CCL4 (MIP1β) and CCL5 (Rantes) 
(Berres et al., 2010, Kirovski et al., 2010) in portal vessels; CXCL9 (ITAC) (Wasmuth et al., 
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2009), CXCL10 (IP-10), CXCL11 (MIG) and CXCL16 in liver sinusoids; CCL28 (MEC), 
CXCL16, CX3CL1 (Fractalkine), CXCL12 (SDF1α) in biliary epithelium; and CCL19 
(MIP3β), CCL21 (6Ckine) in portal associated lymphoid tissue (Oo and Adams, 2010). 
CCL17 (TARC) and CCL22 (MDC) are highly expressed on immune cells and upregulated 
CCL25 expression has been reported on hepatic endothelium (Oo and Adams, 2010). CCL2 is 
upregulated on stellate cells during NASH on ballooning hepatocytes and on Kupffer cells 
(Lalor et al., 2007). In steatotic diseased livers, CCL21 (6Ckine) is also often observed in 
lymphatics and in stromal cells (Lalor et al., 2007). CXCL4 has been is upregulated in 
experimental liver fibrosis as a result of infiltrating platelets (Zaldivar et al., 2010). CXCL1 
(GRO1), CXCL5 (LIX), CXCL8 (IL8) are also observed in inflamed portal tracts usually due 
to infiltrating leukocytes and injured endothelium (Lalor et al., 2007). Thus we were 
interested to determine whether receptors for such chemokines were robustly expressed on 
human MSC populations to determine whether they may play a role in hepatic localisation of 
infused cells. 
 
Whilst documentation of basal chemokine receptor expression by MSC is of value, it is likely 
that pre-infusion expansion strategies may alter expression and furthermore that culture 
conditions could be manipulated to maximise expression of desired hepatic homing cues. 
Before use, MSC have to be expanded to large numbers in culture where cells may encounter 
high levels of confluence and multiple passages, in these cases MSC can lose their migratory 
ability and expression of certain CCR involved in migration, respectively (Karp and Leng 
Teo, 2009). MSC treated with a cocktail of cytokines can increase surface CXCR4 expression 
with corresponding increased migration towards CXCL12/ SDF1α (Shi et al., 2007). 
Stimulation of MSC with TNFα also increases surface expression of CCR3 and increased 
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migration to CXCL12/ SDF1α, CCL5/ Rantes and CCL22/ MDC (Ponte et al., 2007). 
Cytokines like TNFα have been reported to increase expression of CCR5 and CCR10 on 
MSC and thus the migration of MSC toward Rantes/ CCL5 and MEC/ CCL28 (Hemeda et al., 
2010). As well as modifying pre-infusion treatment of MSC it is likely that cells will be 
exposed to soluble mediators upon infusion into a diseased environment. There are vast 
increases in cytokine levels during liver injury (Lalor et al., 2007), and these may act upon 
local and systemic MSC to increase their homing and migratory capabilities. Cytokines such 
as TNFα can induce the invasion by human MSC into extracellular matrix (Bocker et al., 
2008) and can enhance MSC engraftment into infarcted myocardium (Kim et al., 2009). In 
some cases successful engraftment can be limited by cell survival (Burst et al., 2010), 
however manipulation with LPS stimulation of mouse MSC has been shown to enhance 
survival after engraftment (Yao et al., 2009). There has been much research into engineering 
or priming MSC to increase migration and engraftment including IL1β stimulation of MSC 
which has been reported to increase MSC migration (Carrero et al., 2012). Thus we wanted to 
investigate whether cytokines from a selected panel induced during liver injury could enhance 
migration and engraftment when transplanted via increases in CCR expression, specifically, 
TNFα (Lalor et al., 2007), IFNγ (Lalor et al., 2007), TGFβ1 (Achyut and Yang, 2011, Lalor 
et al., 2007, Marek et al., 2005, Weng et al., 2009), LPS (Su, 2002) , IL1β (Gieling et al., 
2009), IL4 (Lalor et al., 2007), IL6 (Danese and Gao, 2010, Lalor et al., 2007), IL8 (Lalor et 
al., 2007, Maltby et al., 1996) and IL10 (Lalor et al., 2007, Thompson et al., 1998, Zhang et 
al., 2011).  MSC have been reported to have receptors for most of these cytokines including 
TNFI and IIR, IFNγR, TGFβRI and RII, (Docheva, 2008) TLR4 (Tomchuck et al., 2008), IL-
1R, IL-4R, IL-6R (Rattigan et al., 2010), IL8R (CXCR1) (Docheva, 2008) and IL10R (Silva 
et al., 2003). 
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Chemicals such as dexamethasone have been reported to significantly increase the migratory 
potential and motility of human MSC (Yun et al., 2011) as have growth factors such as HGF 
(Forte et al., 2006). Hypoxic culture conditions can also be employed to upregulate the 
migration of MSC by upregulating MMP (Karp and Leng Teo, 2009) and also possibly 
through increases in intracellular reactive oxygen species (IROS) as increases in IROS have 
been implicated in inducing cell migration and motility (Novo et al., 2011). Interestingly 
hydrogen peroxide, an inducer of IROS, has been shown to upregulate surface CCR5 on 
monocytes (Lehoux et al., 2003) and may also be how migratory properties of MSC may 
increase.  
 
Retrovirus vectors encoding CXCR4 have been introduced into MSC and subsequently 
enhanced migration (Karp and Leng Teo, 2009). Similarly an adenoviral vector in MSC has 
been used to upregulate the α4 subunit which dimerise with the β1 integrin to form the VLA-4 
integrin and thus increased MSC migration into the bone marrow (Karp and Leng Teo, 2009). 
Cell surface glycans on MSC have been chemically engineered into an E-Selectin binding 
motif in order to encourage engraftment to endothelium that expresses high levels of E-
Selectin (Sackstein et al., 2008). 
 
We wanted to specifically explore the effects of cytokines on MSC engraftment in the injured 
liver via increased CCR expression and function. However a consideration of using such 
cytokine stimulation is that other therapeutic MSC properties such as immunomodulation that 
has been described in the liver after MSC transplantation (Popp et al., 2009) may also be 
modulated. TNFα, IFNγ, IL1α and IL1β have been shown to augment the immunosuppressive 
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capabilities, particularly with regard to T cell suppression, but not all cytokines may act in 
this way (Krampera et al., 2006, Prasanna et al., 2010, Ren et al., 2008). Therefore it must be 
taken into consideration that cytokines which may enhance engraftment could alter the 
immunomodulatory properties of MSC, and so such properties will also be assessed in this 
chapter. A final consideration is the effect of the cytokine on multipotency of the MSC.  As 
the MSC retain stem cell properties they are liable to be pushed towards a particular lineage 
during cytokine stimulation. IL1β and TNFα stimulation have been proven to inhibit 
osteogenic differentiation of MSC and thus influencing certain properties of the cell that may 
diminish the therapeutic potential (Lacey et al., 2009). TGFβ1 may induce chondrogenic 
differentiation of MSC or may push the MSC towards a cardiomyogenic or myofibroblast-like 
phenotype (Li et al., 2009, Mohanty et al., 2011). In this case, a myofibroblast could 
contribute to the fibrosis in the liver. Therefore within this chapter we phenotyped the MSC 
after cytokine stimulation to ensure the cells retained characteristic MSC tri-lineage potential. 
 
The current literature has led to my hypothesis that cytokine stimulation, particularly by 
inflammatory or pro-fibrotic cytokines can increase chemokine receptor expression and 
function and thus the potential of MSC to engraft in the liver. A comprehensive panel of 
cytokines has not yet been tested with most studies focussing primarily on common 
inflammatory cytokines TNFα and IFNγ. Pro-fibrotic cytokines such as TGFβ1 and LPS 
which are responsible for activation of liver resident stromal cells could have similar effects 
on MSC thus increasing their migratory potential. With this, I predict that cytokine 
stimulation could also have beneficial effects on other aspects of the MSC phenotype, but 
limited stimulation protocols (maximum 24 hours) could minimise any detrimental effects on 
the cell phenotype including loss of tri-lineage differentiation potential. 
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The aims of this chapter were: 
 
(i) To measure the intracellular and cell surface CCR profile (CCR1-10, CXCR1-7) 
of MSC. 
 
(ii) To use a panel of cytokines typically upregulated during liver disease to identify 
those that could functionally increase surface CCR expression on MSC. 
 
(iii) To measure effects of selected cytokines on MSC adhesion to diseased human 
livers and isolated cell monolayers. 
 
(iv) To measure effects of selected cytokine stimulation on adhesion of MSC to mouse 
livers in vitro and engraftment into in vivo models of liver injury and to elucidate 
any CCR mediated mechanisms. 
 
(v) To measure effects of selected cytokine stimulation on tri-lineage differentiation 
potential, and on immunomodulatory potential of MSC.  
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4.2 Results 
4.2.1 MSC express a consistent profile of intracellular and cell surface CCR 
expression.  
 
Flow cytometry was used to measure intracellular and MSC surface CCR expression (CCR1-
10 and CXCR1-7) by MSC detached from tissue culture plastic. A large percentage of MSC 
contain large intracellular stores of CCR4 (95.84+0.88%), CCR5 (67.96+5.54%), and CXCR3 
(92.69+1.26%) with correspondingly high MFI (Figure 4.1A and B). A smaller percentage of 
MSC have low levels of CCR6 (18.92+7.56%), CCR9 (13.2+7.16%), CCR10 (13.99+6.39%), 
CXCR1 (22.1+7.12%), and CXCR7 (25.02+8.22%). Very small percentages of MSC 
expressed CCR2 (4.11+1.66%), CCR7 (5.07+2.55%), CCR8 (2.9+1.28%), CXCR2 
(6.51+4.81%), CXCR4 (3.14+1.57%), CXCR5 (3.73+1.93%) and CXCR6 (5.78+2.24%) at 
low levels. Intracellular CCR1 and CCR3 were expressed at negligible levels in a minimal 
percentage of MSC (Figure 4.1A). In all cases we observed that MSC cell surface CCR 
expression was low compared with intracellular stores of CCR. We found CCR4 
(28.51+4.28%), CCR5 (19.34+2.01%), and CXCR3 (17.2+1.87%) to be exhibited on the cell 
surface by the greatest proportion of MSC. CCR6 (4.84+2.60%), CCR9 (5.38+0.81%), 
CCR10 (5.32+1.37%), CXCR1 (6.62+0.84%) and CXCR7 (3.11+0.76%) were also expressed 
but at lower levels on MSC cell surface. The lowest MSC surface expression was of CCR2 
(1.9+0.58%), CCR8 (2.05+0.72%), CXCR5 (1.13+0.33%) and CXCR6 (1.57+0.13%) with 
CCR1, CCR3, CCR7, CXCR2 and CXCR4 absent or negligible on MSC cell surface (Figure 
1A). PBMC isolated from peripheral blood were used as positive control cells and we 
measured positive expression of all CCR on PBMC. Although there was positive expression 
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of CCR3 and CCR8, these were expressed in a very low percentage of PBMC (Figure 4.2A 
and B).  
 
A specific set of MSC surface CCR: CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7, 
were selected for confirmatory analysis by QPCR to measure mRNA levels of receptor 
expression (Figure 4.3). Expression closely followed that seen cytometrically with CCR4 
(21.58+1.36) and CCR5 (20.35+0.43) mRNA expressed at high levels. CXCR3 (6.86+3.43) 
and CCR9 (6.85+3.425) were expressed at lower but more variable levels. We saw consistent 
levels of CXCR7 (7.75+0.45) mRNA expression among multiple donors at a similar level to 
CCR9 and CXCR3 (Figure 4.3). CXCR4 expression was near absent as a protein (Figure 
4.1B) and was also not detectable relative to β-actin levels (Figure 4.3). 
Immunohistochemical techniques were used to image and detect CCR protein expression for 
CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7. In support of findings using flow 
cytometry and QPCR, MSC expressed high levels of CCR4, CCR5 and CXCR3, lower levels 
of CCR9 and CXCR7 and no detectable CXCR4 (Figure 4.4) 
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Figure 4.1: MSC CCR expression.  
A: Flow cytometry analysis of CCR1-10, CXCR1-7 CCR expression shown as percentage of 
CDB detached MSC positive for surface (open bars) and intracellular (closed bars) CCR with 
median fluorescence intensity (MFI) shown for CCR of interest, specifically CCR4, CCR5, 
CCR9, CXCR3, CXCR4 and CXCR7. Bars and MFI represent mean + SEM of n=3 different 
donor samples. B: Representative cytometry histograms for cell surface and intracellular 
CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7 expression of MSC (green) compared 
with immunoglobulin matched control (IMC) (red) of n=3 samples. 
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Figure 4.2: PBMC CCR expression.  
Flow cytometric analysis of cell surface CCR1-10, CXCR1-7 CCR on PBMC as, A: 
percentage positive and B: MFI. Bars and MFI represent n=1 donor sample.  
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Figure 4.3: QPCR analysis of MSC CCR expression.  
Quantitative analysis of total CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7 gene levels 
in MSC, measured by Real Time Polymerase Chain Reaction (QPCR) analysis and expressed 
as relative to endogenous MSC β-actin levels. The results were calculated by the comparative 
threshold cycle (Ct) method, with the Ct for β-actin used to normalise the results. Expression 
of each gene was calculated with the endogenous level of β-actin in MSC defined as 1. Bars 
represent mean + SEM of n=3 different donor samples, performed in triplicate.  
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Figure 4.4: Immunohistochemical analysis of MSC CCR expression.  
Representative images of immunohistochemical staining with Nova red (red/ brown) of CCR4 
(IgG1), CCR5 (IgG1), CCR9 (IgG1), CXCR3 (IgG1), CXCR7 (IgG1), CXCR4 (IgG2a), 
compared to concentration matched controls. MSC are grown on glass cover-slips and 
counterstained with Mayer’s Haematoxylin (n=3 donors at x20 magnification).  
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4.2.2 TGFβ1, IL4 and IL10 stimulation significantly increases surface CCR expression 
by MSC 
 
Flow cytometry was used to measure the percentage of MSC expressing cell surface CCR4, 
CCR5, CCR9, CXCR3, CXCR4 and CXCR7 before and after cytokine stimulation for 24 
hours. TGFβ1 (unstimulated: 23.36+7.2, stimulated: 45.56+5.41; p<0.05), IL4 (unstimulated: 
30.91+3.32, stimulated: 49.15+3.78; p<0.05) and IL10 (unstimulated: 30.19+3.32, stimulated: 
41.62+1.29; p<0.05) stimulation of MSC significantly increased the percentage of MSC with 
CCR4 surface expression. Similarly, TGFβ1 (unstimulated: 18.49+6.94, stimulated: 
38.34+4.73; p<0.05), IL4 (unstimulated: 23.57+1.68, stimulated: 39.26+4.44; p<0.05) and 
IL10 (unstimulated: 23.57+1.68, stimulated: 32.54+1.39; p<0.05) significantly increased the 
percentage of MSC with surface CXCR3 surface expression. However, only TGFβ1 and IL4 
stimulation significantly increased the percentage of MSC with CCR5 surface expression 
(Figure 4.5A and B). TGFβ1 stimulation significantly increased MSC CCR4 (3.21+0.52 fold; 
p<0.05), CCR5 (3.28+0.78 fold; p<0.05) and CXCR3 (3.27+0.92 fold; p<0.05) expression 
compared to unstimulated MSC. TNFαIFNγ stimulation also significantly increased CCR4 
(2.26+0.31 fold; p<0.05) surface expression on MSC. As we further increased the number of 
donors (Figure 4.6A), we found that TGFβ1 stimulation significantly increased the percentage 
of cells which expressed CCR9 (unstimulated: 4.1+0.88%, stimulated: 10.54+2.28%; p<0.05) 
and that IL10 caused a significant increase in CCR5 (unstimulated: 25.26+3.06, stimulated: 
33.24+2.65; p<0.05), CCR9 (unstimulated: 4.11+0.88, stimulated: 8.5+3.21; p<0.01), CXCR4 
(unstimulated: 0.69+0.30, stimulated: 1+0.38; p<0.05) and CXCR7 (unstimulated: 4.07+1.34, 
stimulated: 5.24+0.53; p<0.0001). IL4 stimulation also significantly increased expression of 
CXCR4 (unstimulated: 0.69+0.30, stimulated: 0.86+0.23; p<0.05) on the cell surface 
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although only a very small percentage of MSC were positive (Figure 4.6B).We additionally 
tested whether we could see a significant increase in the percentage of MSC expressing 
CCR4, CCR5 or CXCR3 and a corresponding increase of surface CCR expression in the 
MSC after 10 minutes stimulation with TGFβ1. There was not a significant increase in CCR4, 
CCR5 or CXCR3 expression in MSC or as a percentage of expression after 10 minutes 
TGFβ1 stimulation (Figure 4.7). To measure changes in the selected CCR mRNA before and 
after cytokine stimulation in MSC we used quantitative PCR (QPCR). Here in contrast to 
protein expression changes, we found there was no significant change in CCR mRNA levels 
after cytokine stimulation of MSC (Figure 4.8). However in the case of CCR4, statistical 
analysis using Analysis of Variance (ANOVA) tests and subsequent post-hoc tests showed no 
significant difference in expression after IL8 stimulation, but an individual T test showed a 
significant increase in CCR4 expression. 18S rRNA PCR was used to confirm that no RNA 
contamination of cDNA samples occurred (not shown). 
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Figure 4.5: Expression of MSC CCR after cytokine stimulation.  
Flow cytometry analysis for surface CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7 
after 24 hour cytokine stimulation [TNFα (10ng/ml), IFNγ (25ng/ml), TGFβ1 (5ng/ml), LPS 
(200ng/ml), IL1β (10ng/ml), IL4 (10ng/ml), IL6 (10ng/ml), IL8 (10ng/ml), IL10 (50ng/ml)] 
compared with basal CCR levels expressed as A: percentage positive MSC, and B: MFI. Bars 
represent mean + SEM of n=3 donor samples.  
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Figure 4.6: Confirmation of Flow cytometry results for chemokine expression on 
multiple donors.  
Analysis for surface CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7 after TGFβ1, IL4, 
IL10 stimulation compared with basal CCR levels expressed as A: percentage positive MSC, 
and B: MFI. Bars represent mean + SEM of n=5 donor samples, *, p<0.05, **, p<0.01, ****, 
p<0.0001.  
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Figure 4.7: Effects of short term stimulation with TGFβ1 on receptor expression.  
Flow cytometry analysis for surface CCR4, CCR5, and CXCR3 after TGFβ1 stimulation 
compared with basal CCR levels for 10 minutes and 24 hours. Bars represent mean + SEM of 
n=5 donor samples. MFI of CCR levels in stimulated MSC (closed bars) are expressed as fold 
change over basal MFI levels of CCR in unstimulated MSC (open bars).  
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Figure 4.8: Confirmation of effects of cytokines on CCR expression by QPCR.  
Quantitative analysis of total CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7 gene levels 
in cytokine stimulated MSC, measured by Real Time Polymerase Chain Reaction (QPCR) 
analysis. Stimulated MSC gene levels relative to endogenous β-actin levels (closed bars) in 
stimulated MSC were expressed as fold change over basal levels of CCR in un-stimulated 
MSC (open bars). The results were calculated by the comparative threshold cycle (Ct) 
method, with the Ct for β-actin in cytokine treated and untreated MSC used to normalise the 
results. Expression of each gene was calculated with the difference in basal CCR levels and 
endogenous level of β-actin in untreated MSC defined as 1 (open bars). Bars represent mean + 
SEM of n=3 different donor samples, performed in triplicate.  
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4.2.3 TGFβ1 and IL4 stimulation increases MSC migration to CXCR3 ligand IP10/ 
CXCL10 and CCR4 ligand TARC/ CCL17. 
 
Using Boyden chamber assays the migration of MSC towards chemokine ligands for selected 
CCR was measured across a range of concentrations. Optimal concentrations of ligands where 
maximal MSC migration was observed were identified for further investigation (Figure 4.9). 
There was significant migration of MSC to SDF1α/ CXCL12 (control: 0.4+0.12, ligand: 
1.77+0.34; p<0.01), ITAC/ CXCL11 (control: 1.6+0.24, ligand: 3.23+0.93; p<0.05), MCP2/ 
CCL8 (control: 0.85+0.22, ligand: 2.83+0.91; p<0.05), Teck/ CCL25 (control: 1.65+0.43, 
ligand: 4.57+0.91; p<0.05). We were also interested in further investigation of specific 
ligands where although not significant, there was some suggestion of a small degree of MSC 
migration, namely, MDC/ CCL22 (control: 0.45+0.15, ligand: 2.22+0.70), MIP1β/ CCL4 
(control: 1.4+0.66, ligand: 3.7+1.07), TARC/ CCL17 (control: 2.7+0.27, ligand: 3.57+0.63), 
Rantes/ CCL5 (control: 0.45+0.13, ligand: 1.6+0.51) and IP10/ CXCL10 (control: 0.95+0.26, 
ligand: 1.7+0.33) (Figure 4.10). 
 
When migration of MSC towards chemokine was normalised to controls, the different 
stimulations were compared by how much they influence migration of MSC towards each 
ligand. There did not seem to be any significant difference in migration of MSC after cytokine 
stimulation to most ligands. There was significantly increased MSC migration towards 
TARC/ CCL17 (2.6+0.18 fold; p<0.05) after IL4 stimulation of MSC. TGFβ1 stimulation 
significantly increased MSC migration towards IP10/ CXCL10 (2.3+0.49 fold; p<0.05) 
(Figure 4.11). 
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Figure 4.9: MSC dose response to chemokine ligand.  
Migration of MSC to various chemokines titrated at 5, 10, 50, 100, 500ng/ml, assessed by 
Boyden Chamber assays, n=3. Data is expressed as Migration Index (cells/ field of view). 
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Figure 4.10: MSC migration to chemokine ligands.  
Selection of chemokine ligands (closed bars) compared with media only controls (open bars) 
to which there was significant migration of MSC which include SDF1α/ CXCL12, ITAC/ 
CXCL11, MCP-2/ CCL8, Teck/ CCL25. Other chemokines of interest to be investigated 
further include MDC/CCL22, MIP1β/ CCL4, TARC/ CCL17, Rantes/ CCL5, IP10/ CXCL10. 
Data is expressed as Migration Index (cells/ field of view). Bars represent mean + SEM of 
n=3 donor samples. 
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Figure 4.11: Impact of TGFβ1, IL4 and IL10 stimulation on MSC migration to 
chemokine ligands.  
A: Migration of MSC to selected chemokines (closed bars) compared to media only controls 
(open bars) compared with TGFβ1, IL4 and IL10 stimulated MSC. B: Migration of 
unstimulated, TGFβ1, IL4 and IL10 stimulated MSC towards TARC/ CCL17 and IP-10/ 
CXCL10. Migration to ligand (closed bars) is expressed as fold change relative to migration 
of unstimulated MSC to media only control, defined as 1 (open bar). Bars represent mean + 
SEM of n=3 donor samples. *, p<0.05. 
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4.2.4 TGFβ1 stimulated MSC show increased binding to hepatic sinusoidal 
endothelium in cirrhotic livers and in culture. 
 
Modified Stamper Woodruff experiments were carried out with TGFβ1, IL4 and IL10 
stimulated MSC and liver sections from explanted normal, NASH, PSC, PBC, AIH and ALD 
livers to test whether cytokine stimulations had an effect on MSC adhesion to these livers. 
TGFβ1 stimulated MSC were more adherent to NASH liver sections (unstimulated 1.5+0.26, 
stimulated: 2.28+0.35; p<0.05) and PSC liver sections (unstimulated: 0.88+0.21, stimulated: 
3.23+0.43; p<0.05) (Figure 4.12A). TGFβ1 stimulated MSC were also used in modified 
adhesion assay experiments using HSEC, BEC and MF monolayers. TGFβ1 stimulated MSC 
were significantly more adherent to HSEC monolayers compared to unstimulated MSC 
(unstimulated: 6.82+0.71, stimulated: 9.5+0.65; p<0.05) and compared with TGFβ1 
stimulated BEC (4.65+0.39; p<0.05) and MF (4.87+0.38; p<0.05). HSEC monolayers were 
also stimulated with TNFαIFNγ to mimic an injured environment. Once again TGFβ1 
stimulated MSC (7.69+0.59; p<0.001) exhibited increased adherence to stimulated HSEC 
compared with unstimulated MSC (4.18+0.66; p<0.001) and also compared to adhesion with 
stimulated BEC (2.02+0.26; p<0.001) and MF (1.97+0.2; p<0.001) (Figure 4.12B). 
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Figure 4.12: Impact of cytokine stimulation on adhesion of MSC.  
A: Modified Stamper Woodruff assays showing basal adhesion of MSC (open bars) compared 
with TGFβ1, IL4 and IL10 stimulated MSC adhesion (closed bars) to normal, Non alcoholic 
steatohepatitis (NASH), Primary sclerosing cholangitis (PSC), Primary biliary cirrhosis 
(PBC),  Autoimmune hepatitis (AIH), Alcoholic liver disease (ALD) cirrhotic liver sections. 
B: Modified Stamper Woodruff assays showing basal adhesion of MSC (open bars) compared 
with TGFβ1, IL4 and IL10 stimulated MSC (grey and closed bars) adhesion to unstimulated 
and TNFαIFNγ stimulated human liver cells including, hepatic sinusoidal endothelial cells 
(HSEC), biliary epithelial cells (BEC) and myofibroblast (MF) cell monolayers. Adhesion 
represents area fraction covered by adherent fluorescent MSC using Image J analysis. Bars 
represent mean + SEM cells/ field of view of n=3 liver donors and 3 MSC donors, *, p<0.05; 
***, p<0.001. 
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4.2.5 Upregulation of cell surface CXCR3 modulates increased engraftment of TGFβ1 
stimulated MSC in mice with carbon tetrachloride induced liver injury. 
 
We set up carbon tetrachloride induced liver injury experiments in two strains of mice. Liver 
injury was induced in Rag2-/-IL-2r γ-/- mice after 12 weeks, with twice weekly intraperitoneal 
carbon tetrachloride injections compared with control/ sham injured mice. Figure 4.13A 
shows presence of injury confirmed by high levels of Van Gieson staining and Picrosirius red 
staining of collagen-1 depicting bridging fibrosis. Picrosirius red staining was quantified 
using Image J and we found significantly increased staining in injured mouse livers 
(1.17+0.23) compared to sham injured mouse livers (0.31+0.17) p<0.01 (Figure 4.13B).  
Liver injury was also induced in wild type C57BL/6 mice with 8 week, twice weekly 
intraperitoneal carbon tetrachloride compared with uninjured control mice. H and E staining 
shows tissue damage in injured mouse livers, as does increased Picrosirius red staining for 
collagen-1 (Figure 4.14A). Injured livers had characteristically higher levels of collagen-1 
(6.26+0.49 fold; p<0.0001), αSMA (12.39+0.71; p<0.0001), serum bilirubin (control: 
4.06+0.9 vs. injured: 3.26+0.11; p<0.0001) and reduced serum albumin (control: 0.1+0.004 
vs. injured: 0.17+0.008; p<0.0001) (Figure 4.14B). 
 
Modified Stamper Woodruff experiments were carried out with TGFβ1 stimulated MSC on 
liver sections from Rag2-/-IL-2r γ-/- sham injured and carbon tetrachloride injured mice to test 
whether cytokine stimulations had an effect on MSC adhesion to these livers. TGFβ1 
stimulated MSC were more adherent to sham injured liver sections (1.74+0.23 fold) compared 
to unstimulated MSC, (p<0.01), and there was a similar increase in binding (2.05+0.21 fold) 
of TGFβ1 stimulated MSC to carbon tetrachloride injured mouse Rag2-/-IL-2r γ-/- livers 
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(p<0.001) (Figure 4.15A). Similar experiments were also performed on liver sections from 
wild type C57BL/6 uninjured and carbon tetrachloride injured mice. Here TGFβ1 stimulated 
MSC were 1.56+0.19 fold more adherent to carbon tetrachloride injured sections than 
unstimulated MSC (p<0.05) but there was no significant difference in binding of TGFβ1 
stimulated MSC to uninjured mouse C57BL/6 livers (Figure 4.15B). 
 
To test adhesion and engraftment of MSC in injured liver in vivo we infused CFSE labelled 
MSC into carbon tetrachloride injured and uninjured C57BL/6 mice via the portal vein 
directly into the liver. MSC infused were either unstimulated, or stimulated with TGFβ1, IL4 
and IL10. We observed increased engraftment of TGFβ1 stimulated CFSE labelled MSC in 
injured mouse livers compared to unstimulated MSC (Figure 4.15C). TGFβ1 stimulated MSC 
engrafted 2.29+0.08 fold (p<0.001) more in injured mice, than unstimulated MSC, compared 
with IL4 and IL10 which showed no significant change in engraftment (Figure 4.15D). Figure 
4.15E shows blocking CXCR3 (10μg/ml) on MSC has no significant effect on engraftment of 
MSC in injured C57BL/6 mouse livers, however the 2.32+0.22 fold increase of TGFβ1 
stimulated MSC engraftment (p<0.001) is significantly reduced after blocking CXCR3 on 
TGFβ1 stimulated MSC (p<0.001). CXCR4 (10μg/ml) and CCR5 (10μg/ml) blockade had no 
significant effect on engraftment of MSC or TGFβ1 stimulated MSC in injured mouse livers.   
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Figure 4.13: Carbon tetrachloride induced liver injury in Rag2-/-IL-2r γ-/- mouse models.  
A: Representative 12 week, age matched sham/ mineral oil injured and carbon tetrachloride 
(CCl4) injured Rag2
-/-IL-2r γ-/- mouse liver sections stained with Picrosirius red for collagen-1 
(red) and Van Gieson (purple/pink). Representative images of n=5 mice at x20 magnification. 
B: Image J analysis of Picrosirius red stained 12 week, age matched sham/ mineral oil injured 
and carbon tetrachloride (CCl4) injured Rag2
-/-IL-2r γ-/- mouse liver sections. Data expressed as 
area fraction of Picrosirius red staining in injured mouse livers (closed bars) relative to 
baseline control sham/ mineral oil injured livers. Bars represent mean + SEM of n=5 mice, **, 
p<0.01.  
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Figure 4.14: Carbon tetrachloride induced liver injury in C57BL/6 mouse models.  
A: Representative 8 week, age matched uninjured and carbon tetrachloride (CCl4) injured 
C57BL/6 mouse liver sections stained for collagen with Picrosirius red (red) and to assess 
tissue histology with haematoxylin and eosin (H and E) staining. Representative images of 
n=5 mice at x20 magnification. B: Quantitative PCR analysis of 8 week, age matched 
uninjured and carbon tetrachloride (CCl4) injured C57BL/6
 mouse livers for collagen1α1 and 
αSMA mRNA. Injured liver gene levels relative to endogenous GAPDH levels (closed bars) 
were expressed as fold change over basal levels of genes in uninjured mice (open bars). The 
results were calculated by the comparative threshold cycle (Ct) method, with the Ct for 
GAPDH used to normalise the results. Expression of each gene was calculated with the 
difference in basal gene levels and endogenous level of GAPDH in uninjured mice defined as 
1 (open bars). Bars represent mean + SEM of n=3 mice, performed in triplicate, *, p<0.05. 
Serum albumin levels and serum bilirubin levels in CCl4 injured and uninjured C57BL/6 mice 
measured by ELISA. Bars represent mean + SEM of n=3 different donor samples, performed 
in triplicate, *, p<0.05.  
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Figure 4.15: Impact of TGFβ1 stimulation on MSC adhesion and engraftment.  
A: TGFβ1 stimulated MSC adhesion (closed bars) to sham injured and CCl4 injured Rag2
-/-IL-
2r γ-/- mouse liver sections relative to basal adhesion of MSC (open bars), defined as 1. Bars 
represent mean + SEM of n=3 samples, *, p<0.05; **, p<0.01; ***, p<0.001. B: TGFβ1 
stimulated MSC adhesion (closed bars) to sham injured and CCl4 injured C57BL/6
 mouse 
liver sections relative to basal adhesion of MSC (open bars), defined as 1. Bars represent 
mean + SEM of n=3 donors, *, p<0.05; **, p<0.01; ***, p<0.001. C: Representative images 
of CCl4 injured C57BL/6
 mouse liver sections after infusion of CFSE (green) labelled MSC 
and TGFβ1 stimulated MSC into liver via portal vein infusions and 15 minute incubation. 
Representative of n=3 mice at x20 magnification. D: TGFβ1 stimulated MSC engraftment in 
CCl4 injured and uninjured C57BL/6
 mice relative to baseline unstimulated MSC 
engraftment, defined as 1. MSC treated with IL4 and IL10 and infused into CCl4 injured 
C57BL/6 mice as control cytokine stimulations. Data represents CFSE labelled MSC counted 
in 10 fields of view in four sections at four depths into the liver at x40 magnification. Bars 
represent mean + SEM of n=3 donors, *, p<0.05; **, p<0.01; ***, p<0.001. E: The number of 
CFSE labelled MSC and TGFβ1 stimulated MSC that engraft in murine liver following portal 
vein injection was determined after treatment with function blocking antibodies to CXCR3 
(10μg/ml), CXCR4 (10μg/ml), CCR5 (10μg/ml), and the relevant IgG control. Data is 
represented relative to IgG control labelled unstimulated MSC. Bars represent mean + SEM 
of n=3 different donor samples, ***, p<0.001. 
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4.2.6 TGFβ1 stimulation of MSC increases binding and engraftment of enzyme 
detached MSC to injured mouse livers  
 
We repeated some of the studies above using enzymatically detached TGFβ1 stimulated MSC 
to compare effects with earlier experiments. There was no significant difference between 
binding of unstimulated or stimulated MSC to normal liver sections. However TGFβ1 
stimulated MSC were significantly more adherent to NASH liver sections (unstimulated: 
2.09+0.21, stimulated: 3.76+0.54; p<0.05), PBC liver sections (unstimulated: 1.03+0.13, 
stimulated: 1.7+0.17; p<0.05), AIH liver sections (unstimulated: 2.58+0.26, stimulated: 
4.61+0.34; p<0.05), PSC liver sections (unstimulated: 1.22+0.17, stimulated: 1.83+0.19; 
p<0.05) and ALD liver sections (unstimulated: 2.61+0.17, stimulated: 3.26+0.2; p<0.05) 
(Figure 4.16A). Enzymatically detached TGFβ1 stimulated MSC were 1.49+0.13 fold 
significantly more adherent to TNFαIFNγ stimulated HSEC monolayers (p<0.05) but there 
was no significant change in TGFβ1 stimulated MSC binding to HSEC compared with 
unstimulated MSC (Figure 4.16B). 
 
We observed 2+0.19 fold  and 1.89+0.17 fold increases in binding of enzymatically detached 
TGFβ1 stimulated MSC to sham injured and carbon tetrachloride injured Rag2-/-IL-2r γ-/- mouse 
liver sections respectively (p<0.001) (Figure 4.16C).  On uninjured and carbon tetrachloride 
injured C57BL/6 mouse liver sections there was 1.56+0.14 fold (p<0.01) and 1.88+0.16 fold 
(p<0.001), significantly increased binding, respectively, of TGFβ1 stimulated MSC (Figure 
16D). Upon portal vein infusions of MSC into C57BL/6 mouse livers we observed 
significantly increased engraftment of TGFβ1 stimulated MSC in uninjured (2.12+0.17 fold) 
(p<0.001) and carbon tetrachloride injured mouse livers (2.74+0.2 fold) (p<0.001) compared 
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to unstimulated MSC or TNFα stimulated MSC which showed no significant change in 
engraftment of MSC (Figure 4.16E). 
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Figure 4.16: Impact of TGFβ1 stimulation on MSC after enzymatic detachment.  
A: Modified Stamper Woodruff assays showing basal adhesion of enzyme detached MSC 
(open bars) compared with TGFβ1 stimulated enzyme detached MSC adhesion (closed bars) 
to normal, Non alcoholic steatohepatitis (NASH), Primary sclerosing cholangitis (PSC), 
Primary biliary cirrhosis (PBC),  Autoimmune hepatitis (AIH), Alcoholic liver disease (ALD) 
cirrhotic liver sections. Bars represent mean + SEM cells/ field of view of n=3 samples, *, 
p<0.05; ***, p<0.001. B: Modified Stamper Woodruff assays showing enzyme detached 
TGFβ1 stimulated MSC (closed bars) adhesion relative to basal adhesion of MSC (open bars), 
defined as 1, to unstimulated and TNFαIFNγ stimulated human hepatic sinusoidal endothelial 
cells (HSEC). Bars represent n=3 samples, *, p<0.05; ***, p<0.001. Enzyme detached TGFβ1 
stimulated MSC adhesion (closed bars) to C: uninjured and injured C57BL/6, or D: sham 
injured and CCl4 injured D: Rag2
-/-IL-2r γ-/- mouse liver sections relative to basal adhesion of 
MSC (open bars), defined as 1. Bars represent mean + SEM of n=3 samples, *, p<0.05; **, 
p<0.01; ***, p<0.001. E: Enzyme detached TGFβ1 stimulated MSC engraftment in CCl4 
injured and uninjured C57BL/6 mice relative to baseline unstimulated MSC engraftment, 
defined as 1. MSC treated with TNFα and infused into CCl4 injured C57BL/6 mice as control 
cytokine stimulations. Data represents CFSE labelled MSC counted in 10 fields of view in 
four sections at four depths into the liver at x40 magnification. Bars represent mean + SEM of 
n=3 donors, *, p<0.05; **, p<0.01; ***, p<0.001. 
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4.2.7 TGFβ1 stimulation of MSC does not significantly alter tri-lineage differentiation 
of MSC and does not increase intracellular stress or the production of pro-
fibrotic factors. 
 
Using QPCR we measured mRNA levels of collagen-1 and αSMA in MSC after TGFβ1 
stimulation of CDB detached MSC for 24 hours. There was no significant change in mRNA 
levels of collagen-1 or αSMA in TGFβ1 stimulated MSC (Figure 4.17A). Tri-lineage 
differentiation of MSC was maintained and there was no significant change in differentiation 
of enzymatically or non-enzymatically detached MSC into osteoblasts, adipocytes and 
chondrocytes after 24 hour TGFβ1 stimulation (Figure 4.17B and C). We also observed no 
indication of a difference in the presence of IROS, autophagy or MSC undergoing apoptosis 
or necrosis after TGFβ1 stimulation, regardless of the detachment method (Figure 4.17D). 
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Figure 4.17: Effect of TGFβ1 stimulation on production of pro-fibrotic factors, tri-
lineage differentiation and intracellular stress in MSC.  
A: Quantitative analysis of total collagen-1 and αSMA gene levels in cytokine stimulated 
MSC, measured by Real Time Polymerase Chain Reaction (QPCR) analysis. Stimulated MSC 
gene levels relative to endogenous β-actin levels (closed bars) in stimulated MSC were 
expressed as fold change over basal levels of CCR in un-stimulated MSC (open bars). The 
results were calculated by the comparative threshold cycle (Ct) method, with the Ct for β-
actin in cytokine treated and untreated MSC used to normalise the results. Expression of each 
gene was calculated with the difference in basal CCR levels and endogenous level of β-actin 
in untreated MSC defined as 1 (open bars). Bars represent mean + SEM of n=3 different 
donor samples, performed in triplicate. B: Image J analysis of oil red O staining of enzyme 
and non enzyme detached TGFβ1 stimulated MSC differentiated into adipocytes. Bars 
represent oil red O stained mean area fraction + SEM of n=3 samples. Alizarin red staining of 
enzyme and non enzyme detached TGFβ1 stimulated MSC differentiated into osteoblasts. 
Bars represent mean calcium concentration (µM) + SEM of n=3 samples. C: Representative 
images, DAB staining of collagen II as a marker of chondrocyte differentiation. TGFβ1 
stimulated MSC differentiated into chondrocytes at x20 magnification. MSC were cultured as 
pellets after detachment from tissue culture plastic and differentiated into chondrocytes. D: 
Levels of stress on TrypLE (enzymatic) and Cell Dissociation Buffer (CDB) (non enzymatic) 
detached, TGFβ1 stimulated cells. Table of CDB and TrypLE detached unstimulated MSC 
(red) and TGFβ1 stimulated MSC (black), labelled with IROS marker, 2’,7’-
dichlorofluorescin (DCF), autophagy marker, monodansylcadaverine (MDC), apoptosis 
marker, annexin V, D: Necrosis marker, 7AAD; with corresponding Median Fluorescent 
Intensity (MFI) values. Data represents mean + SEM of n=3 different donors. 
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4.2.8 TGFβ1 stimulation of MSC increases cell surface CD44 expression and secretion 
of CCL2 and IL-6 
 
MSC were tested for differences in cell surface integrin expression after enzymatic and non 
enzymatic detachment. Based on preliminary experiments, integrin expression appeared to be 
preserved even after enzymatic detachment of MSC from tissue culture plastic so further 
experiments measuring surface integrin expression were carried out with enzyme detached 
MSC (Figure 4.18A). MSC expressed integrins α1-6, α8, αv, αvβ3, αvβ5, β1-4, β7 and CD44 
(Figure 4.18B) but there was no indication of a change in expression after stimulation. 
However this is based only on one experiment so could change based on further repeats. 
However there was an indication of a change in MFI for CD44 (Figure 4.18B and C). TGFβ1 
stimulated MSC expressed higher levels of CD44 (MFI: 723.84) compared to unstimulated 
MSC (MFI: 496.37) but this could also change after repeat experiments (Figure 4.18B and C). 
 
TGFβ1 stimulated MSC supernatants were tested using arrays for cytokine and angiogenic 
factor secretion. Supernatants from 24 hour TGFβ1 stimulated MSC contained significantly 
higher levels of MCP-1/ CCL2 (pixel density: 2.05+0.21 units) than unstimulated MSC 
supernatant (pixel density: 0.2+0.1 units) (p<0.05) (Figure 4.19A). There was also a trend 
towards an increase of IL6 in TGFβ1 stimulated MSC supernatant (pixel density: 8.91+1.99 
units vs. 4.72+0.05 units in controls, Figure 4.19B). Unstimulated and TGFβ1 stimulated 
MSC supernatants showed no significant changes in levels of other cytokines that were 
present, including TGFβ1 (Figure 4.19A, B and C).  Cell based ELISA was then used to 
measure the effects of supernatant from cytokine stimulated MSC on HSEC adhesion 
molecule expression. In general exposure of HSEC treated with TNFαIFNγ to MSC 
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supernatant had no additional effects on expression However IL6 stimulated MSC 
conditioned median modestly increased ICAM-1 levels (9.97+0.63 fold; p=0.09) (Figure 
4.20).   
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Figure 4.18: TGFβ1 stimulated MSC surface integrin and adhesion molecule expression.  
A: Flow cytometry analysis for surface integrins and adhesion molecules as percentage 
positive MSC after enzymatic (open bars) and non-enzymatic detachment (closed bars) with, 
B: median fluorescence intensity (MFI). D: Flow cytometry analysis for surface integrins and 
adhesion molecules as enzyme detached percentage positive MSC (open bars) after TGF 
stimulation (closed bars) with, E: median fluorescence intensity (MFI). Bars represent n=1 
sample. C: Representative cytometry histograms for enzymatic detached MSC (blue) and 
TGFβ1 stimulated MSC (blue) expression of CD44 compared with immunoglobulin matched 
control (IMC) (black) of n=1 sample. 
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Figure 4.19: Cytokines and angiogenic factors in TGFβ1 stimulated MSC supernatant.  
A: Supernatant collected from MSC stimulated with TGFβ1 for 24 hours was tested for 
various cytokines and angiogenic factors using an array for angiogenic factors, and for, B: 
cytokines. Bars represent mean + SEM of n=2 different donors, *, p<0.05. C: MSC were 
stimulated with TGFβ1 for 24 hours and cultured for a further 24 hours before supernatants 
were removed and TGFβ1 levels were measured using Sandwich ELISA. Bars represent mean 
+ SEM of n=3 different donors, *, p<0.05. 
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Figure 4.20: Adhesion molecules on HSEC after culture with cytokine stimulated MSC 
supernatant.  
24 hour treatment of TNFαIFNγ stimulated hepatic sinusoidal endothelial cells (HSEC) with 
supernatant from 24 hour cytokine stimulated MSC. Levels of adhesion molecules expressed 
on HSEC were tested with cell based ELISA relative to media only control on unstimulated 
HSEC, defined as 1. Bars represent mean + SEM of n=3 different donors. 
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4.2.9 TGFβ1 stimulated MSC exhibit increased suppression of CD4 T cell proliferation 
mediated by increased PGE2. 
 
MSC are able to suppress CD4 T cell proliferation from 3176+117.2 CD4 T cells/µl to 
2244+178.2 cells/µl at a ratio of 1 MSC: 10 CD4 T cells/µl (p<0.05) and further to 
2131+11.39 cells/µl at a ratio 1:5 (p<0.01) (Figure 4.21A). TGFβ1 stimulated MSC showed 
more potent suppression of total CD4 T cell proliferation (3207+108.5 cells/µl) to 1685+163 
cells/µl at a ratio of 1:10 (p<0.0001) and also to 1184+185.5 cells/µl at a ratio of 1: 5 
(p<0.0001) (Figure 4.21A). There was a significant increase in suppression of CD4 T cell 
proliferation at a 1:5 ratio in TGFβ1 stimulated MSC compared to unstimulated MSC 
(p<0.05) (Figure 4.21A). Control and TGFβ1 stimulated MSC were treated with 
Indomethacin to block PGE2, a known suppressive agent produced by MSC. When treated 
with Indomethacin, control MSC lost all suppressive ability, with a significant increase in 
CD4 T cell proliferation (4004+571.9 cells/µl) compared to untreated MSC (2394+164.7cells/ 
µl) (p<0.5) (Figure 4.21B). Similarly TGFβ1 stimulated MSC treated with Indomethacin 
demonstrated a similar loss in immunosuppressive efficacy (Figure 4.21C). 
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Figure 4.21: TGFβ1 stimulated MSC mediated suppression of CD4 T cell proliferation.  
Flow cytometry analysis of activated CD3+CD4+CD25- T effector cell proliferation labelled 
with CellTrace™ Violet and analysed with PE labelled Accucheck counting beads. A: MSC 
or B: TGFB1 stimulated MSC were co-cultured with activated CD3+CD4+CD25- T effector 
cell, respectively and compared to CD3+CD4+CD25-  T effector cell proliferation without 
MSC. C: Comparison of MSC and TGFβ1 stimulated MSC suppression of CD3+CD4+CD25- 
T effector cell proliferation at ratios of 1:5, 1:10, 1:20, 1:40, and 1:80. The number of 
CellTrace™ Violet labelled CD3+CD4+CD25- T effector cells after co-culture with, B: MSC, 
and C: TGFβ1 stimulated MSC, was determined after treatment with Indomethacin, a 
chemical blocker of Prostaglandin E2 (PGE2) at each ratio.  Bars represent mean + SEM of 
n=3 different donors, *, p<0.05; **, p<0.01; ***, p<0.001. 
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4.2.10 Treatment of MSC with serum from cirrhotic ALD patients reduces cell surface 
CCR expression and increases levels of β1 integrin. 
 
MSC integrin expression was preserved after enzymatic detachment (not shown) and so 
enzymatically detached MSC were exposed to patient serum. There was no change in the 
percentage of MSC expressing integrins α1-6, α8, αv, αvβ3, αvβ5, β1-4, β7 and CD44 after 
treatment (Figure 4.22A). However there was trend for increased integrin β1 expression 
(Figure 4.22B). ALD serum stimulated MSC express higher levels of β1 (MFI: 110.92) 
compared to unstimulated MSC (MFI: 55.92) (Figure 4.22C).There was also a suggestion of a 
decrease in percentage of MSC expressing cell surface CCR levels, CCR4 (ALD: 13.39%, 
Normal: 47.15%), CCR5 (ALD: 12.06%, Normal: 45.37%), CCR9 (ALD: 0%, Normal: 
7.04%), CXCR3 (ALD: 3.76%, Normal: 40.31%), CXCR7 (ALD: 0 %, Normal: 3.63%) after 
ALD serum stimulation compared to control, respectively (Figure 22D). After ALD serum 
stimulation there was a decrease in the levels of MSC surface CCR4 (ALD: 2.04, Normal: 
5.09), CCR5 (ALD: 1.83, Normal: 4.03), CCR9 (ALD: 0, Normal: 0.66), CXCR3 (ALD: 
0.99, Normal: 2.71), CXCR7 (ALD: 0, Normal: 0.43). However, there was no detectable cell 
surface CXCR4 (Figure 4.12C and D). TGFβ1 levels were tested in normal and end stage 
cirrhosis ALD patient serum using sandwich ELISA. ALD patient serum (4.84+0.87pg/ml) 
had significantly lower levels of TGFβ1 levels than normal serum (7.57+0.33pg/ml) (p<0.05) 
(Figure 4.22E). 
 
To determine whether this alteration in surface receptors had any functional relevance we 
carried out modified Stamper-Woodruff assays using normal and ALD serum stimulated 
MSC on normal and ALD liver tissue. Binding of ALD serum stimulated MSC (2.24+0.33 
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cells/ field of view) was significantly reduced compared to normal serum stimulated MSC 
(5.36+0.73 cells/ field of view) (p<0.001) on normal liver sections. Similarly on ALD liver 
sections, ALD serum stimulated MSC (2.18+0.27 cells/ field of view) were significantly less 
adherent compared with normal serum stimulated MSC (6.11+0.74 cells/ field of view) 
(p<0.001) (Figure 4.23A)). Modified static adhesions were also performed on HSEC and 
TNFαIFNγ stimulated HSEC monolayers using normal serum and ALD serum stimulated 
MSC. ALD serum stimulated MSC were significantly less adherent to unstimulated HSEC 
(1.48+0.28 cells/ field of view) and TNFαIFNγ (1.98+0.25 cells/ field of view) stimulated 
HSEC compared with normal serum stimulated MSC (3.45+0.51, 4.16+0.4 cells/ field of 
view) on unstimulated and TNFαIFNγ stimulated HSEC, respectively (p<0.001) (Figure 
4.23B).  
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Figure 4.22: Impact of ALD serum on MSC surface receptor expression.  
A: Flow cytometry analysis for surface integrins and adhesion molecules as enzyme detached 
percentage positive normal serum stimulated MSC (open bars) and after ALD serum 
stimulation (closed bars) with, B: median fluorescence intensity (MFI). Bars represent n=1 
samples. C: Flow cytometry analysis for surface CCR as percentage positive normal serum 
stimulated MSC (open bars) and after ALD serum stimulation (closed bars) with, D: median 
fluorescence intensity (MFI). Bars represent n=1 samples. E: TGFβ1 levels in normal and 
ALD serum were measured using Sandwich ELISA. Bars represent mean + SEM of n=3 
different donors, *, p<0.05.  
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Figure 4.23: Effect of ALD serum on MSC adhesion.  
A: Modified Stamper Woodruff assays showing adhesion of normal serum stimulated MSC 
(open bars) compared with ALD serum stimulated MSC (closed bars) adhesion to B: normal 
and ALD livers; and I: to unstimulated and TNFαIFNγ stimulated human HSEC. Bars 
represent mean + SEM cells/ field of view of n=3 samples, *, p<0.05; ***, p<0.001.  
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4.2.11 Treatment of MSC with normal or end stage cirrhotic ALD patient serum can 
alter tri-lineage differentiation of the MSC without inducing intracellular stress 
 
There was no indication of a difference in the presence of IROS, autophagy or percentage of 
cells undergoing apoptosis or necrosis after normal or ALD serum stimulation, regardless of 
the detachment method (Figure 4.24). However cells treated with normal serum for 24 hours 
expressed increased levels of collagen II compared to ALD serum stimulated MSC (Figure 
4.25A). It seems that stimulation with human serum induces some degree of chondrogenic 
differentiation. Culture of MSC in chondrogenic differentiation media (test) after serum 
stimulation induces expression of collagen II. Interestingly even culture of MSC in 
maintenance media (control) after stimulation with serum induces collagen II expression at 
low levels. There was no significant difference in adipogenic differentiation capability 
between Normal and ALD serum stimulated MSC (Figure 4.25B). However there was 
significantly increased osteogenic differentiation after MSC stimulation with ALD serum 
(46.86+1.19µM) compared to normal serum (36.03+1.79µM) as reported by higher levels of 
Alizarin red calcium staining (p<0.05) (Figure 4.25C).   
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Figure 4.24: Effect of ALD serum on cellular stress.  
Levels of intracellular stress in normal and ALD serum stimulated MSC. Representative 
cytometry histogram for ALD serum stimulated MSC (red) and normal serum stimulated 
MSC (black), labelled with IROS marker, 2’,7’-dichlorofluorescin (DCF), Autophagy marker, 
monodansylcadaverine (MDC), apoptosis marker, annexin V, D: Necrosis marker, 7AAD; 
with corresponding median fluorescent intensity (MFI) values. Data represents mean + SEM 
of n=1 donors. 
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Figure 4.25: Impact of ALD serum on tri-lineage differentiation.  
A: Representative images, DAB staining of collagen II as a marker of chondrocyte 
differentiation. ALD serum and normal stimulated MSC differentiated into chondrocytes at 
x20 magnification in maintenance media (control) and chondrogenic differentiation media 
(test). MSC were cultured as pellets after detachment from tissue culture plastic and 
differentiated into chondrocytes. B: Image J analysis of oil red O staining of normal and ALD 
stimulated MSC differentiated into adipocytes. Bars represent oil red O stained mean area 
fraction + SEM of n=3 samples. C: Alizarin red staining of normal and ALD serum stimulated 
MSC differentiated into osteoblasts. Bars represent mean calcium concentration (µM) + SEM 
of n=3 samples.  
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4.3 Discussion 
 
The therapeutic effects of MSC when engrafted in the liver (Lin et al., 2011, Popp et al., 
2009) are well established and MSC have even been used in clinical trials (Houlihan and 
Newsome, 2008). There are still limitations that exist in MSC therapy and these may lie with 
the transplant efficiency of MSC (Lin et al., 2011). In order to overcome the impracticalities 
of expanding MSC to high numbers and to get maximal engraftment of infused cells the 
mechanism of MSC recruitment and engraftment needs to be elucidated and better understood 
so it can then be manipulated. In this chapter we have tried to utilise an important part of the 
cellular recruitment process by focussing our attention on MSC cell surface CCR.  We have 
used cytokines commonly upregulated during liver injury to try and upregulate functional 
CCR which will likely play a major part in MSC migration to the site of injury. In this way 
we have tried to prime MSC for engraftment in the injured liver before exogenous 
administration.  
 
The MSC CCR profile is still not established and has been inconsistent between reports from 
different groups (Honczarenko et al., 2006, Ponte et al., 2007, Ringe et al., 2007, Sordi et al., 
2005). This may be due to a number of reasons, all of which we have tried to address in this 
chapter to ensure that we have found an accurate, reproducible and reliable profile of CCR on 
MSC. Firstly, there is no specific marker for MSC that can be used for prospective isolation; 
as a result, MSC populations are a variable heterogeneous mix of cells (Karp and Leng Teo, 
2009). Any slight variations in isolation technique could drastically alter the MSC population 
that is obtained, so MSC populations could vary between groups. MSC are now commercially 
available and to avoid such issues we have purchased MSC. As a result, the repertoire of CCR 
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that we have identified is preserved and similar between every donor that we have analysed. 
Although there are some similarities with what other groups have found, the entire receptor 
profile we have observed has not been reported previously. To ensure the results we saw were 
not due to a defect with the antibodies we were using, we used them on PBMC as a control 
cell population. This population served as an adequate control for most of the CCR except for 
CCR3 and CCR8. This is of concern as CCR3 and CCR8 have previously been reported as 
present on MSC (Ponte et al., 2007, Ringe et al., 2007), but there are also reports of an 
absence of both CCR3 and CCR8 (Sordi et al., 2005). Levels of CCR3 and CCR8 are variable 
between cell surface and intracellular expression suggesting that it is likely these antibodies 
are working as there is not a complete absence of expression. 
 
Although all CCR warrant closer investigation we selected CCR4, CCR5, CCR9, CXCR3, 
CXCR4 and CXCR7 for further investigation based on a combination high levels of 
expression, upregulation of corresponding chemokine ligands in injured liver, and previous 
reports. CCR4 was expressed at the highest levels compared to other CCR. There is an 
upregulation during liver injury of CCR4 chemokine ligands, specifically, CCL2 (MCP-1), 
CCL4 (MIP-1β), CCL5 (Rantes), CCL17 (TARC) and CCL22 (MDC) (Oo and Adams, 
2010). Also there have been previous reports of CCR4 expression on MSC (Ponte et al., 
2007, Ringe et al., 2007). CCR5 is also highly expressed on MSC, with an upregulation of 
corresponding ligands, CCL3 (MIP3β), CCL4 (MIP1β) and CCL5 (Rantes), in injured liver 
(Oo and Adams, 2010) and its presence on MSC has been observed in previous reports (Ponte 
et al., 2007). Although CCR9 is expressed at intermediate levels, its presence on MSC has 
been reported in the past (Honczarenko et al., 2006, Ringe et al., 2007) and there are 
increased levels of its ligand CCL25 (Teck) on injured endothelium (Oo and Adams, 2010). 
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CXCR3 is highly expressed and appears in previous reports (Ringe et al., 2007), with high 
levels of all its ligands in injured endothelium (Oo and Adams, 2010).  
 
CXCR4 and CXCR7 are not expressed at very high levels but there are various reports 
suggesting the presence of CXCR4 on MSC (Ponte et al., 2007, Ringe et al., 2007, Son et al., 
2006, Sordi et al., 2005). Equally there are also reports suggesting CXCR4 levels are absent 
or neglible (Phinney and Prockop, 2007, Ruster et al., 2006, Sackstein et al., 2008, Wynn et 
al., 2004). Although most evidence for the significance of CXCR4 is based on migration 
towards CXCL12/ SDF1α (Son et al., 2006), there has been very little investigation into 
CXCR7. Although we see no cell surface CXCR4, there are smaller populations of MSC with 
intracellular CXCR4 expression. However we do not know if CXCR4 and CXCR7 are on the 
same cell population but this may be likely as CXCR4 and CXCR7 have been shown to work 
together to migrate towards SDF1α/ CXCL12 (Decaillot et al., 2011, Levoye et al., 2009). 
CXCR7 by itself is a scavenger receptor and there is little evidence to suggest it can solely 
mediate migration to SDF1α/ CXCL12. SDF1α/ CXCL12 levels are significantly increased 
during injury and could be a potent recruiter of MSC (Oo and Adams, 2010). 
 
The selected panel of CCR was validated using immunohistochemistry and QPCR. Both 
methods supported our findings using flow cytometry, with receptors expressed at similar 
levels. However CXCR4 was not detectable either by QPCR or by immunohistochemistry, 
this may well be because of its presence in such a small population of cells. The techniques 
may not have been sensitive enough and to pick up such small levels in such small MSC 
populations.  
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Surface CCR levels were measured after stimulation using a panel of cytokines which are 
upregulated during most forms of liver injury. TGFβ1, IL4, and IL10 were able to 
significantly upregulate CCR on the cell surface. TGFβ1 was the most interesting as not only 
did it increase the proportion of MSC which expressed CXCR3, CCR4 and CCR5, but unlike 
IL10 and IL4, it was able to increase levels of CCR on the cell surface. As donor numbers 
were increased, increases in CCR expression became more apparent suggesting this was an 
accurate consistent and reproducible result. MSC were stimulated for 10 minutes with TGFβ1 
to investigate whether upregulation in receptor expression was happening at an earlier time 
point and then being sustained for the 24 hours. However this was not the case, MSC did not 
upregulate CCR at such early time points. This does not mean that upregulation occurs only 
after 24 hours. A more detailed time-course experiment needs to be carried out to identify 
exactly when this upregulation occurs. 
 
Of note, the largest increases in proportions of cells expressing surface CCR occurred with 
receptors which had high intracellular stores. It has been shown that CCR can be re-expressed 
on the cell surface from intracellular stores, once they have internalised, and this may explain 
our observations (Borroni et al., 2010). To prove this we analysed changes in mRNA levels of 
CCR after stimulation and found there was no significant changes after stimulation with these 
cytokines. This means the cell surface expression may be due to recycling CCR from 
intracellular stores back to the cell membrane. To ensure there were no false positive results 
we test for contaminants in the reagents by creating some cDNA samples with water rather 
than reverse transcriptase and running cDNA samples on gels after 18S rRNA PCR to ensure 
these samples were negative. 
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The migratory potential of the MSC to chemokine ligands was tested to determine which 
CCR were functional. Due to the multiple ligands for each CCR, there were many chemokine 
ligands for the selected CCR. Unstimulated MSC were titrated on over a range of 
concentrations from which certain ligands were selected based on whether there was 
significant migration towards that chemokine or if this was potentially a chemokine which 
could be highly expressed in injured liver. According to the chemokines that MSC migrated 
towards, it seemed that CCR5, CCR9, CXCR3 and CXCR4/ CXCR7 were all functional. 
However in experiments testing migration towards TARC/ CCL17 we saw very high levels of 
migration towards basal medium. This suggests there may have been some non-specific 
migration, or that CCR4 function was induced in some way. It is interesting that there was 
significant migration to SDF1α/ CXCL12 considering there were such low levels of its 
receptor. However, research suggests that migration towards SDF1α/ CXCL12 ligands may 
be regulated without CCR (Aldridge et al., 2012, Sarkar et al., 2008). 
 
Comparisons of the migratory potential of stimulated MSC were analysed. TGFβ1 
significantly increased migration to IP-10/ CXCL10 and IL4 to TARC/ CCL17. Both TGFβ1 
and IL4 had also upregulated CXCR3 and CCR4 which may then have increased migration 
towards IP-10/ CXCL10 and TARC/ CCL17 respectively. This suggests that migration of a 
receptor towards a ligand may be dependent on the type of cytokine stimulus the receptor 
receives. 
 
TGFβ1 stimulation not only increased migration to IP-10/ CXCL10, but also made MSC more 
adherent to NASH cirrhotic and PSC explanted liver sections, compared to normal livers 
sections; and to unstimulated, IL4 and IL10 stimulated MSC. This effect of TGFβ1 stimulated 
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MSC binding may be specific to the disease types such as NASH and PSC which have a high 
inflammatory component at the time of transplantation. However PBC and AIH patients may 
receive high doses of anti-inflammatory drugs, thus reducing the inflammatory component 
which may be responsible for increased binding of TGFβ1 stimulated MSC. Inflammatory 
agents may reduce in ALD livers due to abstinence from alcohol before transplant. The MSC 
may be binding to inflammatory or fibrotic factors in NASH and PSC livers where anti 
inflammatory drugs are not used before the liver is explanted. Alternatively this may be due to 
high baseline binding of cells in the control, as this assay has a high degree of variability 
when physically washing off unbound cells from adherent cells. PBC livers show a slight 
increase in binding of TGFβ1 stimulated MSC but this is not statistically significant. Modified 
Stamper Woodruff assays were also performed with cytokine stimulated MSC on 
unstimulated and TNFαIFNγ stimulated (to mimic injured conditions) HSEC, BEC and MF. 
TGFβ1 stimulated MSC bound significantly more to HSEC in uninjured and injured 
conditions.  
 
IFNγ stimulated HSEC have been shown to increase ligand expression for CXCR3 receptors 
to recruit more leukocytes during inflammation and inflammatory diseases such as PBC have 
been shown to express higher levels of CXCR3 ligands (Curbishley et al., 2005). As MSC 
bind indiscriminately to injured and uninjured HSEC, it is likely that increased binding could 
be due to increased receptors on the MSC surface rather than increased ligand in the cell 
monolayer, which would usually be the case when leukocyte recruitment occurs.  
 
To investigate how TGFβ1 stimulated MSC would behave in circulation in an in vivo model 
of liver injury, carbon tetrachloride liver injury was induced in C57BL/6 wild type mice. 
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Studies in these mice were to determine the initial binding and engraftment mechanisms 
employed by MSC and to determine whether TGFβ1 stimulation of MSC could enhance 
engraftment in injured liver. Potentially for further long term studies, as a comparison to wild 
type mice, we set up a similar model in Rag2-/-IL-2r γ-/- knockout immunocompromised mice. 
We found that TGFβ1 stimulated MSC bound significantly more to frozen sections of livers 
from both strains of mice than unstimulated MSC. An obvious issue with these experiments 
was that we were using human MSC in mouse models. However such experiments have been 
carried out with human MSC in mice and even pigs, not only to investigate engraftment, but 
also to research the therapeutic effects of MSC in mouse and pig models of disease (Jung et 
al., 2011b, Li et al., 2012).  
 
To infuse the MSC into circulation a number of methods can be employed. MSC can be 
infused through the tail vein or during intravital microscopy or other such procedures to 
investigate the early stages of adhesion and engraftment. However a problem specific to MSC 
is that administration through these routes means a significant number of cells become lodged 
in the lungs due to their large size (Gao et al., 2001, Karp and Leng Teo, 2009). One of the 
ways around this has been by using a vasodilator sodium nitroprusside before intra arterial 
and intravenous MSC infusion which allowed more MSC to migrate to the liver and be 
cleared from the lungs, where they were previously becoming stuck (Gao et al., 2001). 
Another way to overcome this is to infuse MSC through the portal vein. A major criticism is 
that this method is a highly invasive procedure that could lead to portal hypertension (Lin et 
al., 2011). Eventually we will have to overcome this issue, one way may be to FACS sort 
MSC based on size before infusion, and then potentially infuse MSC via the tail vein. This 
may work as some cells do get to the liver albeit a small proportion. However experiments in 
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this chapter are investigating the interaction between MSC and mouse liver endothelium so 
are sufficient for this purpose. 
 
Ideally we would have liked to carry out intravital microscopy experiments but because we 
employed portal vein infusions instead of infusion through the carotid, to administer cells, this 
did not leave enough time to view circulating and engrafting cells in the mouse liver. This 
meant that we had to cull mice after the procedure, freeze and section livers and count the 
number of CFSE pre-labelled MSC which had engrafted. Although this was not an ideal way 
of counting engrafted cells, sufficient measures were taken to ensure accurate and 
representative counting of engrafted cells. For future experiments we would need to develop a 
method to cannulate the portal vein, or collect the whole liver, homogenise to a single cell 
suspension and count the number of engrafted fluorescently labelled MSC using flow 
cytometry to give a more accurate result. 
 
TGFβ1 stimulated MSC engrafted into injured and uninjured mice at significantly higher 
levels than unstimulated MSC, IL4 and IL0 stimulated MSC which further proved this effect 
was TGFβ1 specific. We then functionally blocked CXCR3 and CCR5 and CXCR4 with and 
without TGFβ1 stimulation. Without stimulation of MSC there was no reduction in 
engraftment of MSC with any of the blocking antibodies. TGFβ1 stimulation increased 
engraftment as we had previously observed but only blocking with CXCR3 blocking antibody 
was able to reduce the engraftment back to baseline levels. This suggests that the TGFβ1 
stimulation induces binding through CCR expression and without stimulation MSC CCR do 
not play a significant part in engraftment. This suggests that by preserving receptor 
expression, it may help in the study of MSC receptor profiles and we may even see increases 
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in their migratory function (as shown in the previous chapter) but there is limited functional 
effect on engraftment into livers without TGFβ1 stimulation. Clearly not all CCR have been 
tested and further work needs to investigate the entire process of engraftment which may 
involve more chemokines and receptors than just CXCR3.  
 
We hypothesised that even if MSC were detached from tissue culture plastic using enzymatic 
methods which we have shown can cleave CCR from the cell surface, TGFβ1 stimulation 
should mobilise or prime internal MSC stores to a point where they can promptly come to the 
surface and significantly promote engraftment of MSC. The presence of surface receptors 
after CDB detachment could have been responsible for higher baseline line levels of MSC 
binding to tissue. Enzymatic detachment would cleave receptors and so lower baseline 
binding was observed. This may have been why TGFβ1 stimulated increases in binding would 
have appeared significant after enzymatic detachment. Similarly we saw significantly 
increased binding to mouse liver sections and HSEC monolayers.  Infused TGFβ1 stimulated 
MSC in vivo after enzymatic detachment also exhibited significantly increased engraftment, 
in both injured and uninjured mice compared with unstimulated and TNFα stimulated MSC 
which shows that the effect is specific to TGFβ1. TGFβ1 has been reported to upregulate 
CXCR3 on NK cells but the reasons behind why this happens were not pursued in the study 
(Inngjerdingen et al., 2001). 
 
Some studies suggest that TGFβ1 stimulation can differentiate MSC towards a myofibroblast 
lineage and therefore a pro-fibrotic phenotype (Li et al., 2009). We tested the MSC after 
TGFβ1 stimulation for mRNA expression of collagen (col1α1) and alpha smooth muscle actin 
(αSMA) but observed no significant difference in expression from unstimulated MSC. Tri-
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lineage differentiation of MSC was tested using both enzymatic and non enzymatic 
detachment methods. The reason for this was to investigate whether TGFβ1 could alter its 
effects on the MSC depending on the way it had been detached. However we saw no 
difference in MSC tri-lineage differentiation after TGFβ1 stimulation. Increased IROS has 
been implicated in stimulating MSC migration (Novo et al., 2011). We hypothesised that 
TGFβ1 may increase MSC migration or cause an upregulation in CCR expression through 
increased IROS. We tested MSC for IROS and for other stress related responses but saw no 
difference between unstimulated or TGFβ1 stimulated MSC. 
 
Recruitment of MSC to organs rarely occurs without the interaction of integrins (Karp and 
Leng Teo, 2009). To identify any obvious changes in integrin expression we began by testing 
enzymatic and non-enzymatic methods of detachment but saw no difference. This suggests 
that integrins are less susceptible to enzymatic cleavage than CCR. Interestingly we saw a 
marked increase in CD44 expression on TGFβ1 stimulated MSC. Based on previous reports it 
is highly likely that this molecule increases MSC adhesion after being upregulated and 
therefore must be working in conjunction with CCR to increase engraftment (Aldridge et al., 
2012, Sarkar et al., 2008). However this experiment has only been carried out once and 
further investigation will need to be done to elucidate the role of CD44 in this mechanism.  
 
MSC have numerous and well characterised immunomodulatory properties including 
suppression of CD4 T cell proliferation (Newman et al., 2009, Uccelli and Prockop, 2010). 
The suppressive effect exerted by MSC can be enhanced by cytokines including TNFα and 
IFNγ (Prasanna et al., 2010). We found that TGFβ1 can also increase suppressive properties 
of MSC which they seem to exert through PGE2. PGE2 has been reported to be used by MSC 
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to suppress T cell proliferation (Newman et al., 2009). TGFβ1 may increase PGE2 expression 
by MSC and this in turn increases the potency of the MSC suppressive effect. We also found 
that TGFβ1 stimulated MSC supernatants contain higher levels of IL6 although this is not 
statistically significant; which may be explained by low donor numbers that were tested. IL6 
production by MSC has been implicated in inducing an increase in PGE2 levels secreted by 
MSC in an autocrine manner (Bouffi et al., 2010). IL6 is an interesting cytokine as it has pro-
fibrotic and pro-inflammatory properties as it has been implicated in increasing an increase in 
liver fibrosis and stimulating T cell proliferation, but it is also capable of inhibiting dendritic 
cell maturation and protects neutrophils from apoptosis (Newman et al., 2009). This means 
that the point at which MSC are used as a therapy needs to be thoroughly evaluated when 
considered, for example, such cells would be more beneficial as a treatment of higher 
inflammatory periods than during high levels of fibrosis.  
 
An important consideration in using TGFβ1 stimulated MSC is the increased expression of 
MCP-1/ CCL2. Unfortunately this could add to the pro-fibrotic environment of the liver when 
there are already high levels of MCP-1/ CCL2 particularly during NASH and alcoholic liver 
disease where recruitment of neutrophils and macrophages could be promoted (Lalor et al., 
2007). MCP-1/ CCL2 expression by MSC has been previously reported (Honczarenko et al., 
2006) and mesenchymal stromal cells can use MCP-1/ CCL2 to recruit monocytes to sustain 
malignant B cell growth and set up a niche for the development of lymphomas (Guilloton et 
al., 2012). There is equally compelling data which suggests that MCP-1/ CCL2 from 
mesenchymal stromal cells can suppress plasma cell immunoglobulin production and could 
potentially be used as a therapy for pathologic humoral responses (Rafei et al., 2008). CCL2 
stimulation of MSC has also been shown to induce MSC motility (Anton et al., 2012) but at 
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the same time MSC have been shown not to migrate to MCP-1/ CCL2 (Ringe et al., 2007). 
Higher MCP-1/ CCL2 levels could contribute to the increased migration we observe in 
TGFβ1 stimulated MSC. MSC secreted MCP-1/ CCL2 has been shown to function in a 
paracrine way by promoting angiogenesis, increasing cell migration and preventing apoptosis, 
thus adding to the beneficial effects of stem cell therapy (Boomsma and Geenen, 2012). 
 
We have seen MSC are able to bind to the endothelium, and to further investigate the effect of 
MSC in the surrounding environment we treated sinusoidal endothelium with cytokine 
stimulated MSC conditioned media and then measured levels of adhesion molecules on 
HSEC. There was no significant effect by this media. However there was a trend for ICAM-1 
upregulation by IL6 stimulated MSC conditioned media, a significantly downregulation by 
TNFα stimulated MSC conditioned media and a slight downregulation by IL1β. This suggests 
using MSC in a highly inflammatory environment containing TNFα and IL1β (Greco and 
Rameshwar, 2008) could reduce inflammation by down regulating ICAM-1 and thus reducing 
recruitment of inflammatory cells. However in an environment with high levels of IL6, typical 
of most types of liver fibrosis, ICAM-1 expression on endothelium can be upregulated, 
suggesting this would promote inflammation. It is therefore important to delineate when MSC 
need to be used during liver disease to exhibit their most potent therapeutic effects. 
 
To test the effects of TGFβ1 in serum we used normal human serum and serum from end 
stage ALD patients to stimulate MSC for 24 hours. ALD disease patient serum has been 
reported to contain high levels of TGFβ1 compared to normal serum (Grigorescu, 2006, 
Marek et al., 2005). However we found the ALD serum to have lower levels of TGFβ1 
possibly as it was collected from patients after a period of alcohol abstinence and after a 
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lengthy course of anti-inflammatory drugs which would considerably reduce platelet levels in 
blood, which are a major source of TGFβ1. As a result we observed significantly increased 
levels of surface CCR on MSC and there was increased binding of MSC to both frozen 
normal and ALD liver sections in modified Stamper Woodruff assays. A higher level of β1 
integrin was seen on the surface of MSC after ALD serum however this did not increase 
binding to tissue sections as we would expect. A reason for this could be that CCR have been 
implicated in integrin phosphorylation, so a lack of CCR may prevent phosphorylation of the 
integrins (Ley et al., 2007) or that other receptors such as CD44 are more important in this 
context (Aldridge et al., 2012). 
 
Addition of serum did not seem to alter levels of stress in the cells as was measured by 
markers of IROS, autophagy, necrosis and apoptosis. Normal serum appeared to increase 
chondrogenic differentiation, which has been reported as a result of high levels of TGFβ1, 
compared to ALD serum. There was no significant difference in adipogenic differentiation 
after stimulation of MSC with normal or diseased patient serum. There was a significant 
increase in osteogenic differentiation after stimulation by ALD patient serum and this could 
be due to lower levels of TNFα or IL1β which has been reported (Lacey et al., 2009). The 
findings from experiments with ALD patient serum supported the results of TGFβ1 and its 
effects on CCR expression. The results suggest that TGFβ1 stimulation could play a 
significant part on binding of cells to liver tissue through the control of CCR.   
 
The intracellular and cell surface CCR expression profile, of receptors (CCR1-10 and 
CXCR1-7) of MSC has been clearly described in this chapter. The effect of stimulation of a 
range of cytokines, typically upregulated during liver injury, on a select panel of receptors, 
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CCR4, CCR5, CCR9, CXCR3, CXCR4 and CXCR7 was investigated further. Distinct 
increases in CCR were observed, and of these, TGFβ1 stimulation was able to induce an 
increase of CXCR3 surface expression and also an associated increase in CXCR3 function, 
both in terms of migration to IP-10/ CXCL10 and in binding to diseased human and mouse 
tissue. TGFβ1 stimulation increased CXCR3 mediated engraftment of MSC into the liver of 
an in vivo model of CCl4 induced liver injury. TGFβ1 stimulation of MSC was not able to 
induce a pro-inflammatory phenotype on MSC or alter tri-lineage potential but increased 
immunosuppressive properties of MSC mediated via PGE2. In all this suggests that 
engraftment and immunomodulatory properties of MSC can be increased using TGFβ1 
stimulation without promoting any known negative effects, therefore our results warrant 
further research into the long term effects of TGFβ1 stimulated MSC after engraftment in in-
vivo models of liver injury. 
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CHAPTER 5: FIBROCYTE ISOLATION AND 
PHENOTYPING 
  
224 
 
5.1 Introduction 
5.1.1 HSC derived fibrocytes   
 
As demonstrated in the preceding chapters, MSC hold great promise as a cellular therapy in 
many clinical therapies for a range of diseases. Pro-inflammatory or pro-fibrotic 
haematopoietic populations (Ebihara et al., 2006, LaRue et al., 2006, Wilkins and Jones, 
1996), namely fibrocytes within MSC populations may be responsible for much of the 
contradictory data reported regarding the effects of MSC (Auffray et al., 2009, Baertschiger et 
al., 2009, Carvalho et al., 2008, Strieter et al., 2009a). Hematopoietic stem cells (HSC) are 
multi-potent stem cells which give rise to all cell subsets from the myeloid and lymphoid 
lineages in the blood. HSC are a heterogeneous population of cells, which reside in the bone 
marrow of adults but can mobilise into the circulation.  These cells are able to self renew and 
replenish blood cell types including monoblasts which further differentiate into monocytes 
(Auffray et al., 2009). 
 
Monocytes, dendritic cells and macrophages are involved in three major roles as part of the 
immune system including antigen presentation, phagocytosis of invading pathogens and the 
release of pro-inflammatory or anti-inflammatory cytokines to recruit more inflammatory 
cells (Geissmann et al., 2010). Under normal conditions monocytes differentiate into different 
types of macrophages and dendritic cells in tissue as a means of immune surveillance but 
during injury and as part of an inflammatory response monocyte levels in circulation increase, 
with a subsequent increase in tissue recruitment and dendritic cells and macrophage 
differentiation to combat pathogens (Geissmann et al., 2010). Monocytes exist as 3 major 
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subsets identified by their CD14 and CD16 surface receptor/ marker expression to generate 
CD14+CD16-, CD14+CD16+ and CD14-CD16+ subsets (Wong et al., 2012). 
 
Fibrocytes are a recently identified stromal cell type derived from monocytes (Shirai et al., 
2009) which possess monocyte-like immune cell attributes such as antigen presentation and 
cytokine production but are unable to phagocytose pathogens (Kisseleva et al., 2011).  Instead 
fibrocytes respond to bacteria by releasing extracellular traps formed by DNA fibres and 
containing the antimicrobial peptide cathelicidin (Kisseleva et al., 2011). Fibrocytes are 
elongated, spindle shaped, cell culture plastic adherent cells found in healing wounds and 
fibrotic lesions (Wu et al., 2007). All CD14+ monocytes can contribute to the fibrocyte pool, 
although CD14+CD16- monocytes preferentially differentiate to fibrocytes (Abe et al., 2001).  
Fibrocytes circulate in the blood as monocytes and differentiate to fibrocytes when they enter 
tissue (Bucala et al., 1994), although some literature suggests that ‘mature’ fibrocytes can also 
exist in the circulation (Quan et al., 2004) this has never been definitively proved (Bournazos 
et al., 2009). When a monocyte differentiates into a fibrocyte it loses CD14 and CD16 
expression, but retains CD45 and CXCR4 expression (Bellini and Mattoli, 2007). The 
fibrocyte also expresses low levels of collagen-1 and high levels of αSMA once it has 
differentiated from a monocyte (Kisseleva et al., 2006). Eventually in culture and in tissue 
due to chronic inflammatory and fibrotic stimuli, a fibrocyte can differentiate into a 
myofibroblast (Bellini and Mattoli, 2007). These myofibroblasts can completely lose CD45 
expression and increase levels of collagen-1 and αSMA expression, appearing phenotypically 
identical to tissue-resident myofibroblasts (Bellini and Mattoli, 2007, Iredale, 2008).  
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In the liver, resident myofibroblasts differentiate from hepatic stellate cells during liver injury. 
Myofibroblasts are responsible for laying down extracellular matrix and thus contribute to 
scar forming tissue in injured liver (Iredale, 2008). The ongoing inflammation concurrent with 
most forms of chronic fibrosis led to the hypothesis that monocyte derived fibrocytes of HSC 
origin could contribute to the hepatic myofibroblast population and thus to liver fibrosis 
(Kisseleva et al., 2006). Subsequently, specific inflammatory and fibrotic stimuli responsible 
for monocyte differentiation to fibrocytes and then to myofibroblasts have been identified 
(Bellini and Mattoli, 2007). 
 
5.1.2 Fibrocytes in diseased organs  
 
Fibrocytes have been identified in cardiac fibrosis, pancreatitis, pancreatic insulinomas, 
rheumatoid arthritis, Graves’ disease, skin fibrosis, renal fibrosis, lung disease and the spleen 
(Direkze et al., 2004, Douglas et al., 2010, Galligan and Fish, 2012, Keeley et al., 2009, 
Kisseleva et al., 2011, Krenning et al., 2010, Wada et al., 2007, Wang et al., 2008). In 
common with MSC, fibrocytes are very potent immunogenic cells. They play a role in antigen 
presentation and T cell priming (Chesney et al., 1997), and are able to present antigen to 
CD4+ and CD8+ cytotoxic T cells (Balmelli et al., 2005). Also, fibrocytes express both MHC 
class I and class II antigens and co-factors CD80 and CD86. The immunogenic potential of 
these cells suggests that should these enter the liver environment, possibly during 
inflammation, they could then contribute to the development of fibrosis (Scholten et al., 
2011). 
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The point at which fibrocytes appear in a diseased organ is still unclear, as is their specific 
role during this phase of injury.  Due to their production of collagen and potential pro-fibrotic 
role it has been assumed they appear during active fibrogenesis. Furthermore in most forms of 
lung disease it has been shown that resident activated myofibroblasts, are responsible for 
driving fibrocyte recruitment (Gomperts and Strieter, 2007). Once recruited, fibrocytes can 
themselves differentiate into myofibroblasts and produce ECM molecules (Gomperts and 
Strieter, 2007), further stimulating new fibrocyte recruitment and fibrogenesis (Andersson-
Sjoland et al., 2011, Vannella et al., 2007). It has also been suggested that autocrine and 
paracrine fibrocyte activation pathways encourage monocyte differentiation into fibrocytes 
(Vannella et al., 2007). Recent data also suggests that fibrocytes retain some inflammatory 
cell features suggesting a bridging role between ongoing inflammation and concurrent fibrosis 
(Iwaisako et al., 2012, Stramer et al., 2007).   
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Figure 5.1: Sources of fibrocytes, fibroblasts and myofibroblasts in inflammation 
and fibrosis.  
Blood borne fibrocytes and monocytes derived from the bone marrow enter the tissue 
where they may play roles in inflammation or elaborating matrix. Monocytes recruited 
during inflammation can also differentiate into fibrocytes in the tissue. Fibrocytes 
secrete paracrine factors to recruit more fibrocytes from the circulation. Fibrocytes 
retain inflammatory properties and take on low level fibrotic properties including low 
level ECM deposition during early stages of fibrosis. Finally resident fibroblasts are 
also capable of transdifferentiation into myofibroblasts, which exhibit both a 
contractile and matrix-producing phenotype. ECM = extracellular matrix. 
 
It is also possible that specific monocytes may enter during long term inflammation and be 
retained in the tissue as a pro-fibrotic cell, thus switching from their original function and 
adapting to the fibrotic environment in the organ (Figure 5.1). This is supported by data 
showing that blockade of monocyte differentiation to fibrocytes reduced injury in models of 
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pulmonary and renal fibrosis (Nikam et al., 2010, Nikam et al., 2011, Sakai et al., 2006, Song 
et al., 2010, Tourkina et al., 2011). In particular it has been suggested that increased serum 
amyloid protein (SAP) (Pilling et al., 2003) and blocking Adenosine A2A receptor (Katebi et 
al., 2008) on monocytes may reduce monocyte differentiation to fibrocytes in injured tissue 
and consequently reduce fibrosis in injured organs. Th1 cytokines have also been suggested to 
promote fibrocyte differentiation and Th2 cytokines inhibit fibrocyte differentiation 
suggesting a significant role of T cells in monocyte differentiation (Shao et al., 2008), which 
is physiologically appropriate during chronic inflammation, leading to fibrosis. Cytokines 
such as TGFβ1 and IL4 have been shown to differentiate monocytes to collagen producing 
macrophages with antigen presenting abilities and reduced phagocytosis similar to fibrocytes 
(Gordon, 2003, Porcheray et al., 2005), and there has been some discussion about fibrocytes 
being alternatively activated macrophages (Pilling et al., 2009a, Reilkoff et al., 2011). 
However, their pro-fibrotic phenotype and evidence from microarray analysis of these cells 
suggests that they constitute a discrete cell type from macrophages and dendritic cells 
(Curnow et al., 2010). 
  
5.1.3 The contribution of fibrocytes to liver disease 
 
Much of the research on fibrocytes in fibrotic organs has focussed on lung disease and models 
of lung injury. The presence of fibrocytes is well documented in various types of lung disease, 
including asthma (Schmidt et al., 2003), idiopathic pulmonary fibrosis (Moeller et al., 2009) 
and obliterative bronchiolitis (Andersson-Sjoland et al., 2009), which have their own specific 
local niche that influences the fibrocyte phenotype (Andersson-Sjoland et al., 2011). 
Migration of fibrocytes into the lung has been shown as dependent on CCR5 (Ishida et al., 
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2007, van Deventer et al., 2008), CXCR4 (Mehrad et al., 2009, Phillips et al., 2004), CCR2 
(Ekert et al., 2011, Ishida et al., 2007, Moore et al., 2005, Moore et al., 2006, Sun et al., 
2011) and CCR7 (Keeley et al., 2009) and the use of inhibitors or knockouts of CCR in 
mouse models has proved their involvement in fibrocyte recruitment to the lung (Ekert et al., 
2011, Keeley et al., 2009, Song et al., 2010, van Deventer et al., 2008). Research into 
fibrocytes in lung disorders has identified fibrocyte differentiation from blood as a potential 
diagnostic tool as a clinical biomarker of lung disease.  
 
In contrast there is significantly less research on the presence of fibrocytes in the liver and 
less still in human liver. The existence of fibrocytes in injured mouse liver has been 
demonstrated by Kisseleva et al (Kisseleva et al., 2006) who transplanted bone marrow from 
transgenic mice with GFP-tagged collagen promoters into irradiated wild type mice, and then 
induced liver injury by bile duct ligation. Liver infiltrating cells were analysed and found to 
be positive for GFP, collagen producing cells, and expressed CD45.  These cells were 
isolated, and after prolonged culture were found to take on a myofibroblast phenotype, with 
increasing collagen expression and loss of CD45 expression. It was found that the speed of 
differentiation to a myofibroblast was enhanced by the addition of TGFβ1, a cytokine that is 
increased in fibrotic livers (Kisseleva et al., 2006). Similarly in a model of CCL4 injury in 
mice, fibrocytes were identified in the liver, (Kisseleva et al., 2011). However Kisseleva et al 
went further to suggest fibrocyte migration was induced by TGFβ1 and LPS, mediated by 
CCR1 and CCR2 which changed with age and therefore impaired fibrocyte recruitment. 
Fibrocytes were also described in the Abcb4-/- mouse model of Sclerosing Cholangitis and 
identified in fibrotic parenchyma where they infiltrated hepatic lobules from portal fields 
where stellate cell-derived myofibroblasts were absent (Roderfeld et al., 2010).  
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However, the contribution of bone marrow derived fibrocytes to human liver disease is likely 
to be complex and may involve mechanisms similar to those described in other organs or 
organs in mice. The fate and impact of these cells in human liver is not clear and may be 
dependent on injury or even specific to mouse models. Although blocking fibrocyte 
recruitment could lead to reduced fibrosis, this seems only applicable in situations where the 
contribution of fibrocytes (as opposed to other cell populations) to fibrosis is significant. Also 
evidence confirming that fibrocytes can exist in normal or uninjured organs suggests that 
these cells may have key roles in normal organ homeostasis which could be impaired in the 
event of therapeutic intervention.   
 
5.1.4 Are fibrocytes likely to contaminate cultures of MSC?  
 
The current protocols used to isolate MSC from bone marrow involve plating bone marrow 
onto tissue culture plastic (Pittenger, 2008). A major flaw with this strategy is that it assumes 
MSC will out outgrow and outlast all CD45+ haematopoietic cells on tissue culture plastic, the 
majority of which will not adhere to the plastic. However, fibrocytes are CD45+ and can 
acquire a MSC-like phenotype and over the period of time used for MSC isolation 
procedures, could lose their haematopoietic markers (Abe et al., 2001). Interestingly over 
large periods of time, fibrocytes have been shown to acquire markers similar to MSC and 
share the tri-lineage differentiation potential thought to be unique to MSC (Choi et al., 2010, 
Hong et al., 2005). Thus conflicting experimental evidence describing pro- vs. anti 
inflammatory effects of MSC may be linked to fibrocyte contamination (Wilkins and Jones, 
1996). Thus, where MSC have been shown to possess anti-fibrotic and anti-inflammatory 
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properties, pro-fibrotic and potent inflammatory effects have been described for fibrocytes. 
Removal of fibrocytes from MSC populations may ensure a more potent population of MSC 
and would permit clearer understanding of the exact roles of MSC within tissue.  
 
5.1.5 Current methodologies used to isolate and culture fibrocytes 
 
There has been much controversy over the optimal isolation and culture conditions for 
fibrocytes. Currently there are two different protocols used to isolate fibrocytes from blood. 
One method includes isolating fibrocytes from blood using negative selection and culture in 
serum media for 14 days (Phillips et al., 2004), where Leukophoresis packs containing 
concentrated leukocytes are used, to yield a higher number of fibrocytes. An alternative 
protocol exists suggesting culture in media without serum for only 3 to 5 days (Pilling et al., 
2009b).  Pilling et al suggest they isolate the same cell as Phillips et al and although some 
markers and receptors are similar between the two cells (Pilling et al., 2003), an extensive 
comparison by Curnow et al suggests otherwise (Curnow et al., 2010).  
 
Phillips et al define fibrocytes as a circulating cell type but Pilling et al suggests that 
fibrocytes only appear in culture or in tissue, under low serum conditions, from a circulating 
monocyte precursor. Fibrocytes occurring in physiological conditions will most likely arise in 
an environment with serum, and for this reason we have focused on isolating cells obtained 
via the more established method of isolation by Bucala and then modified by Phillips et al. 
One component of serum thought responsible for inhibiting monocyte differentiation to 
fibrocytes was identified as serum amyloid protein (SAP) (Pilling et al., 2003). 
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Importantly, recent work by Curnow et al suggests that different methods of isolation can 
result in inherently different populations of fibrocyte-like cells (Curnow et al., 2010). This has 
been validated by work on isolated splenic fibrocytes which highlights unique features 
compared to other fibrocytes (Crawford et al., 2010, Kisseleva et al., 2011), and validates the 
hypothesis that fibrocytes differentiate according to their microenvironment.  
 
It is important to phenotype and better understand the nature and functions of HSC-derived 
fibrocytes so measures can be taken to identify and exclude these cells from isolated MSC 
populations used therapeutically. Furthermore, although much of the existing research has 
utilised fibrocytes isolated from blood or from fibrotic organs, there is a distinct lack of 
convincing data showing the existence of fibrocytes in bone marrow or human diseased livers. 
In addition to this there is controversy in the literature regarding optimal culture and isolation 
procedures for fibrocytes. 
 
Based on the current literature we hypothesise that fibrocytes can be isolated from blood 
using negative selection and plastic adherence. However the groups that have been able to do 
this reproducibly are limited and use only specific methods of phenotyping. It is also well 
documented that isolation is difficult and inconsistent among donors. Phenotyping of 
fibrocytes is also unresolved and for this reason we assume that isolation of fibrocytes will 
have its difficulties, including low cell number, donor variation and reproducibility among 
antibodies. Secondly there has been a lack of literature regarding presence of fibrocytes in 
human livers and I predict that fibrocyte presence may be mediated by a lack of serum 
amyloid protein (SAP) as has been shown in the lungs.  
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The aims of this chapter are: 
 
(i) To determine whether SAP may have a role in their occurrence in patients with 
liver disease, and to measure circulating SAP levels in patient serum  
 
(ii) To optimise protocols for isolation of fibrocytes from whole blood  
 
(iii) To address whether fibrocytes exist in circulation or are an artefact of culture 
conditions which can be manipulated to enhance their isolation.  
 
(iv) To identify whether fibrocytes are present in explanted cirrhotic livers  
 
 
 
 
 
 
 
 
 
 
 
 
 
235 
 
5.2 Results 
5.2.1 Murine liver injury results in increased levels of Serum Amyloid Protein (SAP) 
levels in liver and serum. 
 
SAP has been identified as a factor present in serum which may be responsible for inhibition 
of fibrocyte differentiation from monocytes in tissue. We measured levels of SAP in normal 
and patient serum by ELISA and showed no significant differences in serum from ALD 
patients (0.36+0.06ng/ml) compared with normal patients (0.2+0.01ng/ml) (Figure 5.2A). 
However there were significantly higher levels of SAP in serum from mice injured with 
carbon tetrachloride for 8 weeks (0.13+0.004ng/ml) compared with baseline uninjured SAP 
levels (0.03+0.005ng/ml) using ELISA (Figure 5.2B) (p<0.0001).  In support of this, Western 
blot assays, confirmed mouse SAP levels in serum significantly increased 2.02+0.35 fold 
upon injury (Figure 5.2C) (p<0.05). Again, there was no significant difference in SAP level 
between human normal and ALD serum, (Figure 5.2D). 
 
If whole liver lysates were analysed, no significant difference in SAP levels was observed in 
livers of humans and mice with or without liver injury using ELISA (Figure 5.2A, 5.2B and 
5.2E). Human liver lysates were also measured for SAP levels using Western blot and showed 
significantly higher (149.2+49.9 fold) levels in human diseased livers compared to normal 
human livers (Figure 5.2F) (p<0.05).  
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Figure 5.2: SAP levels in serum and liver during liver injury.  
A: Sandwich ELISA to measure levels of SAP in normal human serum and serum from 
patients with end stage ALD liver cirrhosis. SAP levels in liver lysates of normal and other 
disease livers. B: Sandwich ELISA to measure levels of SAP in uninjured C57BL/6 mice 
serum and liver lysates, compared with 8 week carbon-tetrachloride injured C57BL/6 mice. 
Data represent SAP levels as mean + SEM in n=3 donors, ****, p<0.0001. C: Representative 
images of Western blot from 3 different donors to measure SAP levels in serum of uninjured 
and 8 week injured carbon tetrachloride injured mice, alongside a GAPDH endogenous 
control with quantification by densitometric analysis of replicate blots of mouse serum. D: 
Representative images of Western blot from 3 different donors to measure SAP levels in 
serum of normal and ALD patients alongside a GAPDH endogenous control with 
corresponding densitometric analysis of replicate blots of human serum. E: Representative 
images of Western blot and densitometric analysis from 3 different donors to measure SAP 
levels in liver lysates of uninjured and 8 week injured carbon tetrachloride injured mice, 
alongside a GAPDH endogenous control. F: Representative images of Western blot with 
corresponding densitometry from 3 different donors to measure SAP levels in liver lysates 
from normal and disease livers, alongside a GAPDH endogenous control. In all experiments 
data represent mean ± SEM of relative intensity of at least n=3 donors compared to 
expression in normal/uninjured donors, *, p<0.05.  
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5.2.2 PBMC isolated from peripheral blood separated on Lympholyte-H gradient and 
grown on tissue culture plastic do not express a fibrocyte phenotype. 
 
PBMC were isolated using a standard leukocyte isolation method (Figure 5.3A) with 
separation on a Lympholyte-H gradient and cultured on tissue culture plastic in medium 
containing serum and therefore, SAP. Adherent cells were grown in culture for 10-14 days 
with regular media changes. Resulting cells were uniformly circular in appearance. Cells were 
tested for presence of the fibrocyte markers, CXCR4, CD45, collagen-1 and αSMA using 
immunohistochemistry. Cells expressed high levels of CD45 and CXCR4, but no collagen-1 
(Figure 5.3B) in contrast to positive control fibroblasts. These results were validated by flow 
cytometry, as shown in representative histograms, indicating an absence of collagen-1 but a 
distinct presence of CD45 and CXCR4 on these cells (Figure 5.3C). 
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Figure 5.3:PBMC isolated from peripheral blood on Lympholyte-H.  
A: Protocol for isolation of human fibrocytes via a standard human PBMC isolation 
procedure using Lympholyte-H. B: Representative images at x20 magnification of Nova red 
immunohistochemical staining of isolated PBMC for fibrocyte markers. Images are 
representative from staining of cells from 3 different blood donors. C: Representative 
cytometry histograms showing isotype matched controls (red peak) and antibody labelled 
cells (blue peak) for cultured PBMC from 3 different donors for fibrocyte markers. 
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5.2.3 PBMC isolated from peripheral blood separated on Ficoll-Paque gradient and 
grown on fibronectin coated Cell Bind tissue culture plastic vary between donors 
and on occasion small numbers of cells with a fibrocyte phenotype can be 
detected. 
 
PBMC were isolated according to a different, more reproducible, method  which involved 
separation on a Ficoll-Paque gradient, and culture on fibronectin coated ‘Cell Bind’ tissue 
culture plastic in media containing serum (Figure 5.4A). The original published protocol 
suggested use of a high concentration of PBMC in the form of Leukophoresis packs, but a 
lack of a regular supply of this cell source meant we had to use large volumes of blood 
instead. Preparations using this method were inconsistent both in terms of cell number and 
morphology, from different donors (Figure 5.4B). Cells were detached using long incubations 
with Accutase and contaminating cells were removed using beads conjugated to anti-CD2, 
anti-CD14 and anti-CD19 antibodies. The resulting cell suspension was cytospun onto slides 
and stained for fibrocyte markers CD45 and collagen-1. Cells were strongly positive for 
CD45 expression, but contained only small numbers which expressed low levels of collagen-1 
(Figure 5.4C). Of note this cell population was greatly reduced in cell number after negative 
selection with even fewer cells which expressed collagen-1 in the predominantly CD45+ cell 
population. 
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Figure 5.4: PBMC isolated from peripheral blood on Ficoll-Paque.  
A: Protocol for isolation of human fibrocytes using Ficoll-Paque. B: 3 representative images 
of isolated PBMC at x10 magnification using phase contrast microscopy, from 4 different 
blood donors. C: Representative images of APAAP immunohistochemical staining of isolated 
fibrocytes for fibrocyte markers. Images are representative from staining of cells from 3 
different blood donors. 
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5.2.4 PBMC isolated directly from blood or pre-prepared buffy coat using Ficoll-
Paque or Lympholyte-H show no significant differences in cell number upon 
isolation. 
 
Different cell gradient preparations may be more efficient at cell isolation and thus yield a 
different number of fibrocytes. So we counted the number of cells isolated using Ficoll-Paque  
(1.77x107+ 5.3x106 cells/ml) and Lympholyte-H (2.66x107+4.26x106 cells/ml) from 500ml 
peripheral blood. Statistically there was no significant difference in cell number isolated using 
Ficoll-Paque or Lympholyte-H (Figure 5.5). To try and mimic the high concentration of cells 
achieved using Leukophoresis packs in some published protocols, we prepared buffy coat 
suspensions of peripheral blood prior to gradient centrifugation. The buffy coat preparation 
did show a trend towards an increase in cells recovered from both Lympholyte-H 
(3.38x107+4.43x106 cells/ml) and Ficoll-Paque (4.22x107+8.93x106cells/ml) preparations 
compared to whole blood but the effect was not significant.  
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Figure 5.5: Number of PBMC isolated from blood or pre-prepared buffy coat using 
Ficoll-Paque or Lympholyte-H.  
Human PBMC were prepared from whole blood or buffy coats placed onto indicated gradient 
preparation. Data is expressed as total cell number. Bars represent mean + SEM of n=4 donor 
samples. 
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5.2.5 The effect of culture substrate and cell seeding density on morphological 
appearance.  
 
As there was no significant difference in the number of cells obtained from either whole blood 
or buffy coats, we wanted to investigate the effect of using different separation gradients on 
the types of cells generated after culture based on morphology. Cells isolated using buffy 
coats and Ficoll-Paque gradients were cultured on fibronectin coated Cell Bind tissue culture 
plastic according to the protocol in Figure 5.4. Cell source (blood vs. buffy coat) and 
separation gradient used had no effect on morphology of cells from individual donors. 
However there was a clear difference between different donors. In the indicated images for 
example, Donor 2 seemed to yield a higher number of spindle shaped cells (Figure 5.6). 
However we noted there was a low total number of cells present from all donors after culture 
on fibronectin coated plastic. For this reason we next used buffy coats separated on Ficoll-
Paque and investigated whether total numbers of cells binding and a change in morphology of 
cells was dependent upon a specific type of culture surface (Figure 5.7). Although again there 
was a clear difference in the behaviour of cells isolated from different donors, there was no 
significant difference in the morphology or binding of cells between different substrates. 
Next, PBMC isolated using buffy coats and Ficoll-Paque gradients were seeded and cultured 
at higher densities, 8x105cells/ml/cm2 compared to 6.67x105cells/ml/cm2. The higher culture 
density seemed to reproducibly enhance binding of cells to tissue culture plastic and increase 
the number of spindle shaped cells in the final culture (Figure 5.8).  
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Figure 5.6: PBMC isolated from blood or pre-prepared buffy coat using Ficoll-Paque or 
Lympholyte-H cultured on fibronectin coated Cell Bind tissue culture plastic.  
Representative images of human PBMC. Images were taken at x10 magnification using phase 
contrast microscopy, from 4 different blood donors.  
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Figure 5.7: PBMC isolated from buffy coat using Ficoll-Paque cultured on fibronectin, 
Cell Bind tissue culture plastic, or tissue culture plastic.  
Representative images of human PBMC isolated from buffy coat with Ficoll-Paque and 
cultured on Fibronectin coated Cell Bind, Cell Bind alone, fibronectin alone or untreated 
tissue culture plastic as indicated. Images were taken at x10 magnification using phase 
contrast microscopy, from 4 different blood donors. 
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Figure 5.8: PBMC isolated from buffy coat using Ficoll-Paque cultured on tissue culture 
plastic at low and high cell densities.  
Representative images of isolated human PBMC cultured at low density (6.67x107 
cells/ml/cm2) and high density (8x105 cells/ml/cm2) at x10 magnification using phase contrast 
microscopy, from 4 different blood donors. 
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5.2.6 Significantly higher numbers of fibrocyte-like spindle shaped cells are observed 
when PBMC are cultured on tissue culture plastic. 
 
Next we specifically determined the effects of cell processing and culture on the numbers of 
cells which exhibited fibrocyte-like morphology (as opposed to total cell yields). Spindle 
shaped cells (Figure 5.9A) resembling a fibrocyte morphology were counted in PBMC 
cultures after isolation from blood or buffy coat and separation on a Lympholyte-H or Ficoll-
Paque gradient as before.  
 
Figure 5.9B shows that there was no significant difference between number of spindle shaped 
cells due to the cell source or the gradient used to isolate PBMC. However, on normal tissue 
culture plastic, PBMC isolated from blood using Ficoll-Paque and Lympholyte-H yielded 
19.4+4.08 cells/ field of view and 20.07+1.85 cells/ field of view respectively. This was the 
highest yield of any of the culture substrates, in contrast, PBMC isolated from buffy coat 
using Ficoll-Paque yielded 12+1.69 cells/field of view and Lympholyte-H, 13.27+1.67 cells/ 
field of view. On fibronectin coated normal tissue culture plastic, Cell Bind tissue culture 
plastic and fibronectin coated Cell Bind tissue culture plastic, PBMC isolated from blood or 
buffy coat using Ficoll-Paque and Lympholyte-H yielded a similar low number of cells.  
 
If the same data is compared based on the culture surface used (Figure 5.9C), rather than 
separation gradient (Figure 5.9C), it seems that PBMC isolated from blood separated on 
Ficoll-Paque, and seeded on normal tissue culture plastic yielded significantly higher numbers 
of spindle shaped cells, 19.4+4.08 cells/ field of view than on a fibronectin coated surface, 
7.07+1.9 cells/ field of view. PBMC isolated from buffy coat separated on Ficoll-Paque, and 
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seeded on normal or fibronectin coated tissue culture plastic yielded 20.07+1.85 cells/ field of 
view and 4.67+1.01 cells/ field of view respectively. PBMC seeded on normal or fibronectin 
coated Cell Bind tissue culture plastic yielded 2.93+0.78 cells/field of view and 5.87+1.83 
cells/ field of view respectively. PBMC isolated from blood separated on Lympholyte-H, and 
seeded on normal tissue culture plastic yielded 12+1.69 cells/ field of view, significantly 
higher, than any other surface. A similar effect is repeated in other isolations suggesting that a 
significantly higher number of spindle shaped PBMC are observed when cultured on normal 
tissue culture plastic compared to culture on any other type of surface (Figure 5.9C).  
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Figure 5.9: Number of spindle shaped cells arising from PBMC isolated from blood or 
buffy coat using Ficoll-Paque or Lympholyte-H cultured on fibronectin, Cell Bind tissue 
culture plastic, or tissue culture plastic.  
A: Representative images of spindle shaped cells amongst human PBMC in culture. Images 
were taken at x10 magnification using phase contrast microscopy, from 4 different blood 
donors. B: Comparison of effect of cell source (blood or buffy coat) and separation gradient 
(Lympholyte-H and Ficoll-Paque) on occurrence of spindle shaped, fibrocyte-like cell 
numbers of among PBMC after culture on (i) tissue culture plastic, (ii) fibronectin coated 
tissue culture plastic, (iii) Cell Bind tissue culture plastic, and (iv) fibronectin coated tissue 
culture plastic. Bars represent mean + SEM of n=4 donor samples. C: Comparison of effect of 
tissue culture plastic (normal or Cell Bind) and surface matrix (none and fibronectin) on 
occurrence of spindle shaped, fibrocyte-like cell numbers of among PBMC after isolation 
from (i) blood on Ficoll-Paque (ii) blood on Lympholyte-H, (iii) buffy coat on Ficoll-Paque, 
and (iv) buffy coat on Lympholyte-H. Bars represent mean + SEM of n=4 donor samples, *, p 
<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.  
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5.2.7 Improvement in yield of fibrocytes using collagen-coated plastic and pre-selection 
of cells 
 
Since diverse extracellular matrix molecules including collagen are upregulated during 
fibrosis, we used collagen and fibronectin-coated plastic ware in culture experiments. 
Fibronectin has inconsistent effects on numbers of spindle shaped cells evident in culture (see 
images from donor 2 vs. others (Figure 5.10)). However use of collagen-coated tissue culture 
plastic seemed to consistently result in more fibrocyte shaped cells arising in culture (Figure 
5.10). Again the different donors seem to have varying capabilities in forming fibrocyte like 
spindle shaped cells. Next we used unselected monocytes isolated from PBMC by allowing 
them to adhere to tissue culture plastic for 2 hours and washing off any remaining unbound 
cells, including lymphocytes. Over 2 weeks these cells acquired varying phenotypes on tissue 
culture plastic with a small proportion acquiring a fibrocyte like morphology. With these cells 
again, use of collagen coated plastic, increased the number of spindle shaped cells evident in 
culture (Figure 5.11). Finally we used positively selected CD14+ cells as our source of 
fibrocytes. Here, spindle shaped fibrocyte-like cells seem to occur at high numbers among 
isolated CD14+ cells but in contrast to unselected cells, use of matrix components during cell 
culture appeared to inhibit this process (Figure 5.12). If the non-adherent cells including 
lymphocytes were collected from adherent PBMC after 2 hours and plated on normal, 
fibronectin coated and collagen coated tissue culture plastic, these PBMC acquired a spindle 
shaped fibrocyte like appearance, significantly surpassing any number of spindle shaped cells 
seen before with any other isolation (Figure 5.13).  This effect occurred in all conditions 
consistently among all 3 donors. 
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Figure 5.10: PBMC cultured on normal, fibronectin coated and collagen coated tissue 
culture plastic.  
Representative images of human PBMC isolated from buffy coat with Ficoll-Paque and 
cultured on A: normal tissue culture plastic; B: fibronectin; or C: collagen coated tissue 
culture plastic. Images were taken at x10 magnification using phase contrast microscopy, 
from 3 different blood donors. 
 
 
  
259 
 
Figure 5.11: Adherent PBMC cultured on normal, fibronectin coated and collagen 
coated tissue culture plastic.  
Representative images of adherent PBMC isolated from buffy coat with Ficoll-Paque and 
cultured on A: tissue culture plastic; B: fibronectin; or C: collagen coated tissue culture 
plastic. Images were taken at x10 magnification using phase contrast microscopy, from 3 
different blood donors. 
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Figure 5.12: CD14+ and CD14- PBMC cultured on normal, fibronectin coated and 
collagen coated tissue culture plastic.  
A: Representative images of human CD14- PBMC isolated from buffy coat with Ficoll-Paque 
and cultured on tissue culture plastic. Representative images of CD14+ bead selected PBMC 
isolated from buffy coat with Ficoll-Paque and cultured on B: normal tissue culture plastic; C: 
fibronectin; or D: collagen coated tissue culture plastic. Images were taken at x10 
magnification using phase contrast microscopy, from 3 different blood donors. 
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Figure 5.13: Non adherent PBMC cultured on normal, fibronectin coated and collagen 
coated tissue culture plastic.  
Representative images of non adherent human PBMC isolated from buffy coat with Ficoll-
Paque and cultured on A: tissue culture plastic; B: fibronectin; or C: collagen coated tissue 
culture plastic. Images were taken at x10 magnification using phase contrast microscopy, 
from 3 different blood donors. 
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5.2.8 Spindle shaped-cells isolated from peripheral blood do not consistently express 
fibrocyte markers. 
 
We suspected that removal of contaminating blood cells after culture of fibrocytes resulted in 
a loss of remaining fibrocytes after treatment. Therefore we stained cells for fibrocyte markers 
without the negative selection step hoping to quantify cells positive for fibrocyte markers 
amongst the PBMC population in culture. PBMC isolated from buffy coat and cultured on 
normal tissue culture plastic consistently expressed CD45 and CXCR4. However expression 
of αSMA was less uniform with samples from donors 1 and 2 only containing cells positive 
for αSMA. Interestingly, the one donor (donor 4) positive for collagen-1 expression was 
negative for αSMA expression (Figure 5.14A). Binding of the anti-collagen-1 and anti-αSMA 
antibodies was confirmed on cytospun fibroblast positive controls (Figure 5.14A) and anti-
CXCR4 and anti-CD45 on cytospun lymphocytes (Figure 5.14B).  
 
We confirmed that anti-procollagen-1 antibody stained CD90+ synovial fibroblasts (Figure 
5.15A) and was not expressed by lymphocytes using flow cytometry (Figure 5.15) and titrated 
optimal antibody concentration using fibroblasts. Procollagen-1 levels were then measured 
with optimised antibody dilutions (1:50) on monocytes before culture and on PBMC cultured 
on plastic with the optimised PBMC culture method. Figure 5.15E and F shows that both 
populations of cells had no detectable procollagen-1 expression before or after culture. 
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Figure 5.14: Expression of fibrocyte markers on PBMC isolated from buffy coat and 
cultured on tissue culture plastic.  
A: Representative images at x10 and x20 magnification, of DAB immunohistochemical 
staining, of isolated human PBMC, for fibrocyte markers. B: (i) Positive controls for 
collagen-1, αSMA, CD45 and CXCR4 as a positive control alongside an isotype matched 
negative control on cytospun cells. Images are representative from staining of cells from 4 
different blood donors.  
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5.2.9 Expression of αSMA and collagen-1 by fibroblast populations 
 
CD90+ synovial fibroblasts (Figure 5.16A) were used to optimise anti-collagen-1 and anti-
αSMA antibodies for dual staining with CD90 in flow cytometry and immunofluorescence. 
Cytometric analysis confirmed that CD90+ cells were positive for collagen-1 and αSMA 
(Figure 5.16B). Similarly although cytospins of synovial fibroblasts dual labelled positively 
using immunofluorescent anti-αSMA Texas red and anti-collagen-1 FITC antibodies (Figure 
5.16B), staining for αSMA was weak.  
 
An alternative anti-αSMA antibody was then optimised on CD90+ synovial fibroblasts using 
flow cytometry using lymphocytes as a negative control. We saw large differences between 
the intensity of staining using both antibodies (Figure 5.17) and observed that whilst both 
synovial fibroblasts and liver-derived myofibroblasts are positive for αSMA, the intensity of 
expression varied (17.42+1.16 vs. 112.2+0.81 MFI for synovial and liver fibroblasts 
respectively using R and D reagent). A similar pattern occurred with anti-collagen-1 
antibodies from two suppliers (Figure 5.17), and again there were fewer collagen-1 expressing 
synovial fibroblasts compared to PBC liver-derived myofibroblasts (Figure 5.17). 
 
We then performed dual staining of human normal and diseased liver sections for CD45 (red) 
and collagen-1 (green) co-expression using immunofluorescence techniques (Figure 5.18A). 
Total collagen-1 was increased in diseased liver compared to normal livers accompanied by 
an increase in CD45+ cells. Of note cells co-expressing fibrocyte markers (yellow) were only 
detectable in some diseased livers (PSC, AIH and ALD) although this effect was dependent 
on the antibody used (Figure 5.19B). 
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Figure 5.15: Expression of procollagen-1 on PBMC isolated from buffy coat obtained 
from peripheral blood.  
A: Representative flow cytometric plots, including i-dots in quadrant R4 representing CD90+ 
human synovial fibroblasts positive for procollagen-1. Flow cytometry plots represent results 
from n=3 different donors. Anti-procollagen-1 antibody titration for flow cytometry on 
synovial fibroblasts (positive control) and peripheral blood lymphocytes (negative control). 
Data represents mean + SEM of percentage positive and MFI of cells expressing procollagen-
1 from n=3 samples. B: Representative flow cytometric plots, of human hymphocytes in gate 
R1 with representative histogram of isotype labelled control cells (black) and procollagen-1 
labelled cells (red). Plots represent results from n=3 different donors. C: Representative flow 
cytometric plots, of monocytes in gate R1 with representative histogram of isotype labelled 
control cells (black) and procollagen-1 labelled cells (red). D: Representative flow cytometry 
plot of PBMC cultured for human fibrocyte isolation and labelled for fibrocyte marker 
procollagen-1, where, gate R1 includes only monocytes but no lymphocytes, from n=9 
different donors, with representative histogram of isotype labelled control cells (black) and 
procollagen labelled cells (red). E: Representative flow cytometry plot of PBMC labelled for 
fibrocyte marker procollagen-1, where, gate R1 includes only lymphocytes but not 
monocytes, from n=9 different donors, with representative histogram of isotype labelled 
control cells (black) and procollagen labelled cells (red). 
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Figure 5.16: Collagen-1 and αSMA expression on CD90+ synovial fibroblasts.  
A: A representative flow cytometry histogram stained with CD90 (red) against isotype 
matched control labelled cells (black). CD90 and αSMA, CD90 and collagen-1 dual labelled 
human fibroblasts. B: Representative images at x10 magnification of cytospun lymphocytes 
for collagen-1 (green) and αSMA (red). Images are representative from staining of cells from 
3 different blood donors  
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Figure 5.17: Collagen-1 and αSMA expression on CD90+ synovial fibroblasts and PBC 
liver derived myofibroblasts.  
Flow cytometry analysis using anti-αSMA antibody (R and D systems), anti-αSMA antibody 
(Dako), anti-collagen-1 antibody (Sigma) and anti-collagen-1 antibody (Rockland) on human 
synovial and PBC liver derived fibroblasts expressed as percentage cells positive for surface 
CCR expression, median fluorescence intensity (MFI) of cells. Bars represent mean + SEM of 
n=3 donor samples, ****, p<0.0001.  
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Figure 5.18: CD45 and collagen-1 co-expression in human liver injury.  
Representative images of human liver sections labelled for co-expression (yellow) of CD45 
(red), DAPI (blue) and collagen-1 (Sigma) (green), or collagen-1 (Rockland) (green). A: 
Representative images of, (i) isotype matched negative controls vs (ii) normal livers. B: 
Representative images of (i) ALD livers, (ii) AIH livers, (iii) NASH livers, (iv) PBC livers, 
(v) PSC livers. Images are representative of n=3 donors at x10 magnification.  
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5.2.10 CD45+ cells isolated from HSEC isolation waste from ALD livers have a spindle 
shaped fibrocyte-like phenotype compared to normal livers. 
 
We routinely use human liver slices to isolate hepatic cell populations (see earlier chapters). 
As our staining data indicated that a population of CD45+/αSMA+ cells is present in injured 
human livers we decided to try and isolated these cells. Thus waste taken from HSEC and 
BEC isolations from liver was immunomagnetically selected with anti-CD45 antibodies. In 
culture, cells from normal livers took on a circular shape similar to macrophages (Figure 
5.19A) compared to CD45+ cells from ALD livers which took on a more spindle shaped 
fibrocyte-like morphology (Figure 5.19C). CD45- cells from both livers adopted a spindle 
shaped myofibroblast like morphology as expected (Figure 5.19B and D).  
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Figure 5.19: CD45+ selected cells from HSEC and BEC depleted, digested liver slices.  
Representative images of cells selected from HSEC and BEC depleted liver slice waste. A: 
CD45+ cells, B: CD45- cells from normal liver slices. A: CD45+ cells, B: CD45- cells from 
ALD liver slices. Images were taken at x10 magnification using phase contrast microscopy, 
from 2 different liver donors. 
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5.3 Discussion 
 
It is difficult to remove fibrocytes from MSC isolations because fibrocytes express both 
stromal and hematopoietic markers (Wilkins and Jones, 1996). Fibrocytes lose the latter in 
culture (Abe et al., 2001), retention of stromal markers means that the two cell types are 
indistinguishable in culture. The method of MSC isolation commonly used is plastic 
adherence, due to the lack of a specific marker for MSC positive selection (Pittenger, 2008). 
Most hematopoietic stem cells are non-adherent and lost during culture, fibrocytes are tissue 
culture plastic adherent and express most of the markers used to identify MSC as well as 
possessing a MSC-like tri-lineage potential (Choi et al., 2010, Hong et al., 2005, Sera et al., 
2009, Strieter et al., 2009b). Thus hematopoietic stem cell derived fibrocytes could 
contaminate MSC during isolations from bone marrow (Wilkins and Jones, 1996), and this 
impact upon downstream functions of cells used as a cellular therapy. Fibrocytes have been 
shown to promote fibrosis and inflammation (Keeley et al., 2010). This could explain why 
some data show that MSC promote fibrosis and inflammation (Ogawa et al., 2006), and some 
studies suggest no significant effect which contradicts most MSC research suggesting that 
MSC have anti-inflammatory and anti-fibrotic roles. Given the increased number of ongoing 
clinical trials with therapeutic MSC, and potential for fibrocyte contamination, we feel it is 
important to phenotype and characterise HSC derived fibrocytes, so measures can be taken to 
remove them from clinical MSC preparations. 
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5.3.1 SAP in fibrocyte differentiation 
 
Fibrocytes can be isolated in two ways, with and without culture in media containing serum 
(Curnow et al., 2010), but both methods yield different subsets of fibrocytes. Fibrocytes 
cultured in serum arise after 12-14 days of culture and fibrocytes without serum can appear 3 
days (Curnow et al., 2010). Curnow et al show that both types of fibrocytes appear 
morphologically similar and express similar stromal and hematopoietic markers. However, 
they are distinctly different in the way they differentiate from monocytes as part of a PBMC 
population and from purified CD14+ monocytes. PBMC give rise to higher numbers of 
fibrocytes in serum free conditions whereas greater numbers of fibrocytes appear from CD14+ 
monocytes in serum. Curnow et al go further to show that when serum is added to fibrocytes 
which arise in serum free conditions, the cells lose their characteristic spindle shaped 
morphology and become rounded but retain hematopoietic and stromal markers. If serum is 
removed from fibrocytes in serum, there is no change to their morphology or phenotype. 
Extensive microarray carried out by Curnow et al with the two fibrocyte types suggests that 
they differ in no less than 5144 genes. Microarray data also suggests that fibrocytes isolated in 
serum are closely related to macrophages, with upregulation of genes involved in immune and 
inflammatory response pathways, chemotaxis, RNA processing and lipid metabolism. 
Curnow et al suggest that serum free fibrocytes are a distinct population of cells likely to have 
a different function during fibrosis. Therefore in our choice of preparation procedure, we had 
to consider the type of fibrocyte that would likely contaminate bone marrow MSC isolations.  
 
Since most MSC isolation procedures require serum we concentrated on fibrocytes that may 
arise in media supplemented with serum. However there is evidence to suggest that fibrocytes 
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which arise in serum-free cultures do so due to a lack of SAP (Pilling et al., 2003). In support 
of this, SAP deficiencies have been observed in patients and mouse models with lung injury, 
particularly during resolution of inflammation and a corresponding increase in fibrocyte 
differentiation is seen from the blood of lung disease patients or models of lung injury. 
Reconstitution of SAP has alleviated levels of fibrosis in bleomycin induced lung injury 
(Pilling et al., 2003, 2007a, Pilling et al., 2007b). SAP has been shown to block 
differentiation through the FCγR receptor on fibrocytes and to inhibit fibrosis (Crawford et 
al., 2012). Evidence suggests that the anti-fibrotic effects of SAP in differentiation may relate 
to inhibition of macrophages rather than monocytes (Castano et al., 2009). Given the large 
numbers of liver-resident macrophages with the potential to differentiate into fibrocytes, we 
wanted to investigate whether human liver disease is associated with low levels of SAP as 
shown in lung disease. Thus as one of our specific aims for this chapter we measured SAP 
levels in normal and disease human serum and liver lysates and repeated this in a mouse 
model of carbon tetrachloride induced liver injury. Importantly we found there was either a 
significant increase or at times no significant difference in SAP levels after injury, and so 
fibrocytes in liver disease would arise in an environment with normal or higher SAP levels.  
 
We found that there was a significantly higher level of serum in mouse injured livers and 
more strikingly in injured mouse serum compared to uninjured livers. There are three reasons 
for such a substantial increase in SAP levels in the liver. Firstly, during injury and in the early 
stages of repair, there is a loss of tissue integrity and increased endothelial permeability 
(Curnow et al., 2010).  The second reason is more specific to the liver, in mice, SAP is an 
acute phase protein synthesised by hepatocytes (Hutchinson et al., 1994). Mouse hepatocytes 
have been shown to increase SAP secretion during an acute phase response, like CCl4 injury, 
278 
 
in vivo and in vitro, this increase is mediated by activated macrophages which may occur 
during inflammation and fibrosis or by IL1 and IL6, typically upregulated cytokines during 
liver injury (Le and Mortensen, 1984a, b, Lin et al., 1990). Lastly, mouse hepatocytes are 
responsible for the removal of SAP (Hutchinson et al., 1994), and CCl4 injury drastically 
reduces the number of functioning hepatocytes, thus impairing the ability of the liver to 
catabolise SAP. However data suggests processes involved in increased synthesis of SAP are 
bigger factors for increased levels of serum SAP than a reduced rate of SAP removal and 
processing (Baltz et al., 1985). SAP does not behave like an acute phase protein in humans as 
shown in SLE patients (Bijl et al., 2004, Levo et al., 1986) so this may be why there is not a 
similar effect to what we observe in mice. 
 
Although we saw a significant increase of SAP in human liver disease compared with normal 
livers, NASH and PBC livers had strikingly higher levels of SAP compared with AIH, which 
showed a small but significant increase in SAP, and we did not see any significant changes in 
serum SAP levels from ALD patients. This can be explained as ALD serum was taken from 
end stage cirrhotic patients, who were likely to be abstinent from alcohol. Stopping the 
disease causing stimuli could reduce the hepatocyte stress and cell death therefore returning 
SAP levels to normal. During resolution of injury, tissue integrity would eventually be 
restored and endothelial permeability reduced, coupled with reduced inflammatory stimuli 
responsible for macrophage activation, would result in reduced SAP levels, both in explanted 
livers and in serum. Similar to what we have observed in human serum and human livers, 
circulating levels of SAP would most likely reduce back to normal first, followed then by 
SAP levels at the source of SAP synthesis in the liver. Earlier experiments by Levo et al 
suggest SAP levels significantly decrease in patient serum with liver disease, this could be 
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true particularly as the cohort of donors for their study was larger and we have only measured 
serum in ALD patients whereas they considered a range of diseases (Levo et al., 1982). Thus 
our results may be limited by low donor numbers and potentially by the disease type we have 
tested. 
 
Curnow et al, suggest fibrocytes can arise in both serum and non serum conditions but both 
cells can be classed as fibrocytes due to the expression of hematopoietic and stromal markers, 
these fibrocytes are functionally distinct and serum may be what regulates this change 
(Curnow et al., 2010). Thus fibrocytes present during early and late stages of repair are 
different and may fulfill different functional roles. Curnow et al also suggest that although 
this change could be regulated by SAP they found no evidence to support this, but other 
studies have shown the influence of various other cytokines in fibrocyte differentiation 
suggesting the regulation of fibrocyte differentiation may not solely regulated by SAP 
(Maharjan et al., 2010, 2011, Niedermeier et al., 2009, Shao et al., 2008). Alternatively, 
fibrocytes differentiated by proteins other than SAP, could yield further, functionally distinct 
subsets which may come under the umbrella term of fibrocytes. Subsequent research by 
Tennent et al has been highly critical of the findings of Pilling et al regarding decreased levels 
of SAP and has shown that normal levels of SAP are sustained in patients with systemic 
sclerosis (Tennent et al., 2007). 
 
5.3.2 Isolation of fibrocytes from whole blood 
 
Although fibrocytes originate from cell populations in human bone marrow, most research is 
based upon fibrocytes isolated directly from blood. Thus we attempted to isolate fibrocytes 
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from blood and phenotype them to identify markers we could later use to identify 
contaminating fibrocytes in MSC isolations. Much of our research centres on using MSC as a 
cellular therapy in liver disease, so we also wanted to see if it is possible to identify fibrocytes 
in liver tissue as a step towards gauging their fibrotic and inflammatory potential. A common 
method of isolating fibrocytes from blood involves isolating PBMC and culturing them for 4 
days before washing and culturing for a further 10 days in serum+ media (Bucala et al., 1994, 
Phillips et al., 2004). We initially attempted this using a Lympholyte-H density gradient. 
However, we did not observe any spindle shaped cells in these isolations, and no cells 
expressed fibrocyte markers. Next, by necessity we isolated PBMC from blood rather than 
Leukophoresis packs (Phillips et al., 2004) using Ficoll-Paque and then depleted cells which 
did not express fibrocyte markers. The cells were then cytospun onto slides and labelled for 
fibrocyte markers. The cells were CD45+ as expected but at best only weakly positive for 
collagen-1. Of note, we saw no collagen-1 staining if we used Lympholyte-H gradients. 
 
The number of PBMC we isolated after 14 days of culture was small, leaving fewer fibrocytes 
available after the depletion of contaminating cells. This was disappointing and likely reflects 
the fact that the original protocol used Leukophoresis packs, which are a far more 
concentrated leukocyte cell suspension compared to blood. Due to a lack of available 
Leukophoresis packs for our study, we attempted to mimic this highly concentrated, leukocyte 
preparation using buffy coats. This strategy did not have the desired effect and due to the low 
number of fibrocyte precursors in circulation it seems that Leukophoresis packs are an 
essential part of this protocol and must be acquired for future studies. However we continued 
to use buffy coat rather than whole blood as this significantly reduced the time the leukocytes 
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were kept on the separation gradient, and sped up the process so PBMC could be isolated 
without them being too stressed. 
 
Since we found differences in final yield of fibrocytes dependent on gradient and material 
used for culture, we tested whether cell recovery differed with Lympholyte-H and Ficoll-
Paque.  However we found no significant difference in initial cell yield or morphology of 
fibrocytes at the end of the culture protocol. Ficoll-Paque seems to be the preferred gradient to 
isolate fibrocytes, and although it shares a similar density with Lympholyte-H, it seems there 
must be a toxic effect that Lympholyte-H may have on the mononuclear cells isolated, this 
may be why the percentage viability of mononuclear cells isolated from Lympholyte-H has 
not been specified but the mononuclear cell population isolated using Ficoll-Paque should 
yield 95+5% mononuclear cells. Although it is difficult to say what may cause this suspected 
high toxicity, the presence of Edetate Calcium Disodium in Ficoll-Paque could prevent the 
aggregation of PBMC during separation, but Lympholyte-H has no such chemical. 
Aggregated leukocytes can become activated, and via oxygen free radicals and proteolytic 
enzymes can lead to increased aggregation of red blood cells but decreased deformability and 
partitioning. Contaminating aggregated RBC can therefore create an environment where 
isolation of PBMC is distorted (Baskurt and Meiselman, 1998).        
 
The use of blood or buffy coat with Ficoll-Paque or Lympholyte-H did not cause a significant 
difference in the amount of spindle shaped cells that arose but the surface on which the cells 
were plated and cultured seemed to be the determining factor. Uncoated tissue culture plastic 
seemed to produce a significantly greater number of spindle shaped PBMC although the 
number varied between donors. This was an unexpected result as the literature suggests 
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fibronectin coating tissue culture plastic should yield more fibrocyte like cells. An explanation 
for this could be that papers citing this protocol often use a large number of cells in the form 
of Leukophoresis packs as their cell source (Phillips et al., 2004). Due to the comparatively 
low number of cells available to us, it can be suggested that fibronectin may have enhanced 
binding of contaminating cells, in support of this we saw that when we increased the density 
of PBMC, they gave rise to more spindle shaped cells when grown on fibronectin coated 
tissue culture plastic. The low number of fibrocyte precursors in such an active environment 
could have negatively affected fibrocyte differentiation.  
 
One possible factor which has been reported to influence the outcome of fibrocyte cultures 
grown in the absence of serum is the density at which the cells are cultured, specifically 2.5 to 
5x105 cells/ml (Pilling et al., 2009b), and as these were in 96 well plates the approximate 
density per well was 3.2x105/ml/cm2. Interestingly we observed an increased number of cells 
bound and in cells which morphologically resembled fibrocyte-like spindle shaped at higher 
cell densities, 8x105cells/ml/cm2. At such higher densities coating plates with fibronectin 
increased the appearance of fibrocyte-like spindle shaped cells. This may well be because 
there is increased cell contact between a higher number of fibrocyte precursors. Although 
increased binding to fibronectin via integrin or adhesion molecule ligation similar to binding 
shown to Hyaluronic acid via CD44 (Maharjan et al., 2011), would occur, a higher density of 
cells may promote an environment where fibrocytes would not only adhere but also survive 
for longer periods on fibronectin. We need to take into consideration that like, hyaluronic 
acid, fibronectin may also influence the differentiation of the fibrocyte (Maharjan et al., 
2011). 
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When we tried to phenotype these PBMC, only 1 out of 4 donors had cells that expressed 
collagen-1, interestingly this donor did not express αSMA but the other 3 donors expressed 
αSMA and not collagen-1. This inconsistency in fibrocyte isolation is well documented in the 
literature as some donors have been shown to yield little or no fibrocytes (Pilling et al., 
2009b). This may be due to the variability in proportions of fibrocyte differentiation factors 
found in different donors, but equally may be due to how these PBMC subsets fare in culture 
conditions. 
 
5.3.3 Fibrocytes in circulation and effects of cell culture conditions 
 
The definitive method for identifying fibrocytes is collagen-1 expression, the literature 
suggests fibrocytes express very low levels of collagen-1 (Kisseleva et al., 2006) so we used 
flow cytometry which is a more sensitive and quantitative assay than immunohistochemistry. 
Also we measured procollagen-1, a pre-cursor of PBMC rather than collagen-1 to try and 
identify any cells with the potential to express mature collagen-1 or those that expressed 
collagen-1 at very low levels. In 9 donors we did not see any procollagen-1 positivity in 
freshly isolated PBMC in the lymphocyte or monocyte fractions, which although expected 
had not previously been tested, and suggests the term “circulating” fibrocytes is inappropriate 
for these cells. Also we observed no expression of pro-collagen-1 in any of the isolated and 
cultured PBMC in both the lymphocyte or monocyte fractions from 9 donors. This was a 
highly unusual result as most papers show presence of dual positive cells using flow 
cytometry (Phillips et al., 2004), however this is a true result as we have tested procollagen-1 
staining and it has worked well in flow cytometry experiments using collagen-1 producing 
fibroblasts as a control. A key difference in our work compared with others is in the antibody 
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used. Commonly an anti-collagen-1 biotinylated antibody (Rockland) is used for these 
experiments. However if a cell expresses collagen-1 it is highly likely that it will express 
procollagen-1. The only instance where collagen-1 but not procollagen-1 can be observed is 
in macrophages which phagocytose collagen producing cells (Roderfeld et al., 2010). The 
cells identified as fibrocytes could be macrophages, which, based on how closely they are 
related, is a strong possibility, Western blot analysis for collagen-1 and procollagen-1 could 
be used to validate this date, but ideally mRNA levels of collagen-1 need to be identified in 
these cells, as was done in work by Chesney et al (Chesney et al., 1998) but with stronger 
negative controls. This suggests there is either inconsistency among antibodies used by 
different groups and/ or the cells that we and other groups have seen are not fibrocytes.  
 
A reason for such inconsistencies between our findings and those in the literature could be the 
affinity of the antibodies used. For this reason we tested the anti-collagen-1 antibody (Sigma) 
and anti-αSMA (Dako), which we used initially, against anti-collagen-1 (Rockland) and anti-
αSMA (R and D Systems). Notably anti-collagen-1 antibody (Rockland) is the antibody 
commonly used to identify fibrocytes (Curnow et al., 2010, Phillips et al., 2004). 
Comparisons using these antibodies were made using synovial and PBC liver myofibroblasts. 
Interestingly there was a clear difference between the anti-αSMA and anti-collagen-1 
expression with antibodies from different companies and this coupled with the inherent high 
variability between donors could be a reason why we did not identify fibrocytes to the same 
extent or reproducibility as other groups. Currently from this data, with no procollagen-1 
expression alongside morphology alone, one can only infer these are not fibrocytes. Further 
experiments identifying characteristic pro-inflammatory cytokine secretion, reduced 
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phagocytic ability, T cell priming, tri-lineage differentiation and differentiation into 
myofibroblasts will tell us if these cells are actually fibrocytes but do not express collagen-1. 
 
We wanted to assess what effect the fibrotic environment may have on the appearance of 
spindle shaped fibrocyte-like cells among PBMC in culture. The aim was to investigate the 
effect of the niche on the fibrocyte differentiation and also to harness this effect to try to 
enhance the number of fibrocyte–like cells we could isolate. Culturing PBMC on collagen 
coated tissue culture plastic increased the number of spindle shaped fibrocyte-like cells 
among PBMC in all donors. This is consistent with fibrocyte research in lung disease which 
suggests myofibroblasts or fibroblasts, which express high levels of collagen, from areas of 
fibrosis recruit fibrocytes (Andersson-Sjoland et al., 2011). A subset of PBMC may then 
come into contact with the high levels of collagen and differentiate into a fibrocyte like 
phenotype (Andersson-Sjoland et al., 2011). Similar to collagen, hyaluronic acid has also 
been implicated in serum- fibrocyte differentiation, regulated through CD44 (Maharjan et al., 
2011). There is evidence that PBMC differentiate into fibrocytes depending on their 
recruitment to a particular niche (Andersson-Sjoland et al., 2011) and this could account for 
the range of fibrocyte subsets as shown by the different roles when isolated from the spleen 
(Kisseleva et al., 2011) and skin during wound healing (Wang et al., 2008).  
 
It is well documented that fibrocytes differentiate from CD14+ monocytes (Curnow et al., 
2010), therefore CD14+ monocytes were isolated from PBMC before culture and selected 
using CD14 conjugated Dynabeads. CD14+ monocytes only differentiated into spindle shaped 
fibrocyte-like cells on normal tissue culture plastic. Surprisingly we noticed that culturing 
PBMC without CD14+ monocytes on tissue culture plastic had a similar effect but gave rise to 
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a higher number of spindle shaped cells. Unfortunately the purity of the CD14- PBMC 
fraction was not tested so there may have been a contamination of CD14+ monocytes. We 
proposed then than a higher proportion of CD14- PBMC (predominantly lymphocytes) is able 
to cause spindle shaped fibrocyte like cells to differentiate from CD14+ PBMC 
(predominantly monocytes).  
 
To investigate our hypothesis further, monocytes were depleted from PBMC by using plastic 
adherence for 2 hours and the non adherent fraction was collected and cultured separately.  
Interestingly over a longer period of time in culture we saw PBMC binding from the non 
adherent fraction. We found that the adhered PBMC fraction differentiated into the highest 
number of spindle shaped cells on collagen coated plastic however the non adherent fraction 
which would have far fewer monocytes in proportion to lymphocytes was able to give rise to 
larger numbers of spindle shaped cells regardless of the condition PBMC were cultured. This 
suggested that lymphocytes or their associated cytokines played a large part in causing 
monocytes to differentiate into spindle shaped fibrocyte like cells. It has been shown that 
cytokines, like TGFβ1, IL4 and IL13, produced by T cells are able to promote, while IFNγ 
and IL12 inhibit serum- fibrocyte differentiation, but the effect is not as dominant as SAP 
(Shao et al., 2008). However, serum+ fibrocytes from mice are inhibited by IL2, TNF, IFNγ 
and IL4 (Niedermeier et al., 2009). It seems that fibrocytes may differentiate as a result of 
their niche in fibrotic conditions; similarly this may be why fibrocytes arise in culture.  
 
Spindle shaped fibrocyte-like cells may arise due to disproportionately high lymphocyte 
numbers compared to monocytes and also, less significantly, due to high levels of collagen. A 
hierarchical effect of conditions can be deduced due to a lack of fibrocyte-like cells 
287 
 
developing from CD14 monocytes on collagen. This could be because the presence of the non 
CD14- PBMC fraction is essential for spindle shaped cells to develop from CD14+ monocytes 
on collagen in long term culture conditions. Collagen may adversely affect CD14+ monocytes 
in long term culture when they are isolated from other PBMC subsets, hence why we saw no 
cells on collagen coated plastic after 14 days. However the adherent PBMC on normal tissue 
culture plastic, and the non adherent PBMC fraction on all culture surface conditions, may 
give rise to different subsets of fibrocytes. Most inflammatory fibrotic disorders are usually 
composed of high lymphocyte levels and high levels of collagen in an environment shared by 
monocytes. Although we have not considered low SAP levels in this report, this may still be a 
factor in bringing about a different subset of fibrocytes; this report focuses on a fibrocyte 
subset which arises in areas of high collagen or disproportionately high lymphocytes and 
under high SAP levels. 
 
5.3.4 Fibrocytes presence in explanted cirrhotic livers  
 
To identify fibrocytes in human livers we tested the two collagen antibodies on sections from 
normal and disease livers. There was no CD45 and collagen-1 co-expression in any cells in 
normal or diseased livers using anti-collagen-1 (Sigma) but using anti-collagen-1 (Rockland) 
a higher number of CD45 and collagen-1 expressing fibrocytes were detected in injured liver 
sections, particularly in PSC, ALD and AIH livers. However, compared with anti-collagen-1 
(Sigma), anti-collagen-1 (Rockland) staining in normal livers was unusually high and there 
seemed to be higher staining of the parenchyma even in normal livers which is unusual and 
uncharacteristic collagen-1 expression. As there is high non-specific binding of the antibody 
which we do not see with the control, this could mean anti-collagen-1 (Rockland) is 
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specifically staining more than just collagen-1, perhaps cross reacting with a different type of 
collagen. If the anti-collagen-1 (Rockland) staining is accurate, it seems that ALD livers 
express fibrocytes in fibrotic scar regions. There is also an increase in ALD serum and 
diseased liver SAP levels, suggesting fibrocytes can arise in a high SAP environment contrary 
to existing research. However, fibrocytes have previously been identified in mouse liver 
fibrotic parenchyma and not in scar areas (Roderfeld et al., 2010). This could mean that 
mouse liver fibrocytes are found in a different area to human liver fibrocytes, alternatively, 
the fibrocytes in human livers may not be real and this may be an effect of the antibody. 
 
Although fibrocytes have been identified and isolated from fibrotic mouse livers (Kisseleva et 
al., 2006, Roderfeld et al., 2010, Scholten et al., 2011), this has yet not been done in human 
livers. A common method of isolating myofibroblasts from explanted human livers is to 
culture liver waste from HSEC and BEC isolations (Holt et al., 2009). Often a large number 
of macrophages are seen in these populations but they are lost with time in culture. We 
wanted to isolate CD45+ cells from this waste in the hope of isolating fibrocytes, or fibrocyte-
like cells among macrophages. We cultured the CD45- waste which would have been a purer 
myofibroblast population fraction alongside CD45+ cells. Interestingly, we identified some 
clear differences between the CD45+ population from the normal liver waste and from ALD 
liver waste. CD45+ selected cells from normal livers appeared uniformly circular and had the 
typical “fried egg” macrophage shape. However, CD45+ cells isolated from the ALD diseased 
liver were far more spindle shaped and irregular, and they appeared to be spindle shaped 
fibrocyte-like cells. The myofibroblasts from both populations were very similar and but ALD 
myofibroblasts grew to confluence much faster than their normal counterparts probably as a 
property of a more activated phenotype. 
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5.3.5 Similarities between macrophages and fibrocytes 
 
Macrophages, like fibrocytes, differentiate from monocytes, and studies have shown that 
splenic fibrocytes can differentiate into macrophages and dendritic cells (Kisseleva et al., 
2011). Fibrocytes may be a subtype of macrophages, perhaps even representing an activated 
form of macrophages (Reilkoff et al., 2011). The plasticity of macrophages has been 
investigated in detail and under certain conditions these cells can take on a fibrocyte-like 
morphology (Porcheray et al., 2005). Macrophage plasticity can be dictated by cytokines to 
take on a spindle shaped fibrocyte-like morphology, particularly TGFβRI, IFNγ, IL10, TNFα 
and M-CSF (Porcheray et al., 2005), and this may go some way to explain why certain donors 
may yield fibrocytes and certain donors do not. PBMC are cultured for 3-5 days, in a mixture 
of cells which can vary greatly in number and proportion between patients. Culturing PBMC 
for 3-5 days can also mean there are different levels and proportions of cytokines, which may 
have variable effects on the adherent monocytes.  
 
IL4, IL13 and TGFβ have been shown to alternatively activate macrophages (Gordon, 2003, 
Gordon and Martinez, 2010), causing them to adopt a spindle shaped fibrocyte-like 
morphology and also yield a subtype which has lower phagocytic properties, increased 
inflammatory cytokine secretion, but sustained antigen presenting capabilities (Varin et al., 
2010) similar to fibrocytes. More recently, macrophages have been shown to express 
collagen-1 (Pilling et al., 2009a). This suggests that the fibrocytes we observe could be 
alternatively activated macrophages. Spindle shaped fibrocyte-like cells can arise from 
macrophages, this suggests macrophages are a very plastic cell type (Porcheray et al., 2005). 
However this does not suggest that fibrocytes are the same cell as macrophages. In fact there 
is evidence to suggest plasticity between macrophages and dendritic cells, which are 
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considered a different but related cell type. It can be suggested that fibrocytes are a subtype of 
macrophages with a different functional role as these are far more closely related to 
macrophages than dendritic cells (Curnow et al., 2010).  
 
5.3.6 Conclusion 
 
In this project we set out to investigate the phenotype of fibrocytes which arise in high serum 
environments to permit future incorporation of a fibrocyte exclusion step in the MSC isolation 
procedure. We also wanted to identify fibrocytes and understand their pro-fibrotic potential in 
the liver. However it is clear that fibrocyte research is still in its early stages with many 
unanswered questions. The isolation of fibrocytes is highly variable and makers for fibrocyte 
expression are not as robust as they should be. We could not reproduce fibrocyte isolation 
between donors, although we found cell-cell contact is a major factor as higher densities from 
similar donors yield more spindle shaped fibrocyte-like cells. Higher numbers of fibrocytes 
are seen in diseased compared to normal livers but this varies between different antibodies 
used, bringing into question some of the methods and antibodies used to identify fibrocytes.  
 
We have found that altering conditions of PBMC culture can drastically alter the spindle 
shaped fibrocyte-like morphology of the cell populations we obtain, and that the niche can 
influence differentiation of spindle shaped fibrocyte-like cells, similar to what has been 
observed in vivo. In particular we have found that high proportions of lymphocytes at a high 
ratio to monocytes can influence fibrocyte differentiation which can be further supported by 
high levels of collagen in the matrix. This suggests that the high degree of variability of 
fibrocyte differentiation observed is because isolation of fibrocytes comes from a very crude 
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method of fibrocyte isolation involving a 5 day culture of PBMC, thus fibrocyte 
differentiation is dependent on the mixture of cytokines and cell proportions exists at highly 
variable proportions in different donors, that we do not control.  
 
We have also found that we can identify a population of cells from diseased liver which 
resembles fibrocytes in morphology but the same population from normal livers resembles a 
macrophage-like morphology bringing into question whether fibrocytes are alternatively 
activated macrophages. However with reference to the high degree of plasticity of 
macrophages and the overlap which is inherent between cell types such as macrophages and 
dendritic cells, it is clear that fibrocytes may be a subtype of macrophages with a different 
phenotype and potentially a different role to macrophages. Of particular importance is that 
fibrocytes are able to phenotypically resemble MSC at some stage, but at the same time 
possess the opposite functional effect. This is a cause for concern in MSC research, 
particularly as we move towards using MSC as a therapy in a clinical setting. To properly 
address this question, efforts must be focussed on identifying and isolating fibrocytes from 
bone marrow, but clearly more pertinent questions need to be answered regarding fibrocyte 
existence and function before this can happen. 
 
Further work is required to identify optimum cell culture methods for fibrocyte isolation, 
particularly using negative depletion to remove lymphocytes and then gradually re-
introducing lymphocytes to elucidate the effects of lymphocytes and the cytokines they 
release. Fibrocytes then need to be identified and isolated from bone marrow and compared to 
myofibroblasts to identify markers that are common and differ aside from hematopoietic cells. 
Furthermore antibodies need to be tested extensively to use the most accurate antibodies to 
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identify fibrocytes. To confirm whether fibrocytes do actually exist in diseased human livers, 
it would be ideal to investigate fibrocyte presence in explanted livers from liver transplant 
patients with gender mismatched bone marrow transplant using fluorescence in situ 
hybridisation and co staining with collagen-1. To further investigate the fibrotic effect of 
fibrocytes, their presence and comparison of markers in lung and liver biopsies from patients 
with diseases in both organs can be assessed.  
 
Finally, robust experiments have been carried out in this chapter to identify and phenotype 
fibrocytes particularly with commonly used antibodies, specifically anti-collagen-1 
(Rockland). These antibodies have been used extensively in fibrocyte research. We have 
identified major flaws with this antibody, in regard to non specific staining and differences in 
staining compared with other anti-collagen-1 antibodies. We have on a rare occasion 
identified CD45+ and collagen-1 cells indicating these cells are real and present, but this 
brings into question much of the existing fibrocyte research.  
 
We have only been able to identify such cells as an artefact of culture from peripheral blood 
and although they may exist in the lungs it is unlikely these cells exist in human liver or bone 
marrow. The data that exists on fibrocytes in mouse liver injury is limited to the findings of 
one group who have reported limited influence of fibrocytes on fibrosis. Our experiments 
have identified some serious flaws in existing fibrocyte research. The future of research into 
fibrocytes in liver injury is limited and this is demonstrated by the drastic fall in new research 
from the field in the last few years. Fibrocyte research will continue to be hazy unless 
appropriate experiments are done to answer some very important questions regarding 
fibrocyte phenotype, in vitro and in vivo using robust, proven and tested reagents. We have 
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come to the conclusion that there is such a lack of robust fibrocyte data, that in MSC research, 
it would be of greater value to try and identify markers which could be used to sort MSC 
directly from bone marrow rather than using techniques such as plastic adherence to isolate 
MSC which could harbour fibrocyte contaminants in culture. 
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CHAPTER 6: FINAL REMARKS 
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6.1 Cell dissociation buffer (CDB) mediated preservation of surface CCR 
expression after MSC detachment 
 
CCR were preserved on MSC after non-enzymatic detachment from tissue culture plastic. 
Although highest levels of viability were maintained by enzymatic detachment, as previously 
reported, we saw almost complete loss of surface CCR expression using these methods and so 
CDB was the best alternative. In chapter 4 we also tested the effects of methods of 
detachment on integrin expression and saw no difference (Figure 4.18). This suggests that 
integrins have a different response to enzyme detachment compared to CCR, making integrins 
less resistant to enzymatic cleavage (Taubenberger et al., 2007). After re-plating cells which 
had been detached by non-enzymatic methods we observed the greatest recovery in cell 
viability with MSC detached by CDB. The method of cell survival appears to rely on MSC 
entering autophagy (Levine and Yuan, 2005) which could lead to more MSC recovered 
compared to other non-enzymatic detachment methods (Figure 3.7-3.9). 
 
In chapter 3 we confirmed that preserved expression of MSC surface CCR is functionally 
relevant and showed increased migration towards corresponding ligands (Figure 3.6). We 
were also able to show consistent surface CCR expression on MSC among multiple donors 
(Chapter 4, Figure 4.1). We demonstrated that addition of serum improved viability of non-
enzymatically dissociated cells, in agreement with studies of  increased survival when bound 
to ECM or serum proteins (Yang et al., 2012, Yu et al., 2012).  However levels were not 
restored to those observed with enzymatic detachment methods (Figure 3.10). Importantly we 
also tested effects of dissociation strategies upon downstream functions of MSC in the form 
of tri-lineage differentiation and suppression of T cell proliferation. Interestingly CDB 
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seemed to reduce but not prevent adipogenic differentiation (Figure 3.12). This may be due to 
a loss of receptors like PDGRα, important for promoting adipogenic differentiation. However 
it is more likely that those cells with adipogenic potential are reduced by cell death upon 
detachment. Certainly it has previously been reported that there are fewer cells with 
adipogenic potential in an MSC population which might suggest a loss in viability will effect 
this population more than cells with osteogenic potential (Russell et al., 2010). Differences in 
chondrogenic differentiation were difficult to assess as it was not possible to quantify levels 
reliably but chondrogenic differentiation was preserved with CDB detachment (Figure 3.12). 
 
CDB detached MSC were able to suppress T cell proliferation but with significantly less 
potency compared with TrypLE detached MSC (Figure 3.14). Although cell numbers were 
similar in both conditions, higher numbers of autophagic cells were present after CDB 
detachment suggesting they were not functioning at their optimum (Figure 3.9). This may also 
suggest that soluble mediators are not as influential in immunomodulation as CDB 
detachment would preserve any surface receptor but could reduce the secretion of soluble 
mediators. Also an important fact is that although we have used equal numbers of viable cells 
in these assays from TrypLE or CDB detached MSC, CDB detached MSC contain a higher 
proportion of dead cells and factors produced by these dead cells. This may have an effect on 
the immunomodulatory properties of the existing cells. A soluble factor implicated in 
suppression of T cells is PGE2 (Vercammen and Ceuppens, 1987). In chapter 4 MSC were 
shown to mediate their suppressive actions through PGE2 which has previously been reported 
(Bouffi et al., 2010), and a reduction in PGE2 may result from CDB mediated detachment 
(Figure 4.21). PGE2 receptors are trypsin sensitive (Lord and Ziboh, 1979) and as PGE2 has 
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been linked with cell apoptosis (Prijatelj et al., 2011), this seems to be avoided by cleavage of 
receptors in MSC detached by TrypLE, promoting the survival of MSC. 
 
We have shown that surface CCR which can play a major role in engraftment are cleaved 
with an associated loss of function with commonly used enzymatic detachment protocols. Use 
of MSC with preserved chemokine expression could enhance the efficiency and efficacy of 
engraftment in clinical trials whilst retaining significant immunosuppressive properties. 
However although we could promote engraftment, the issue of reduced levels of viability 
which could lead to reduced immunosuppressive properties needs to be addressed. We have 
shown there are methods to increase viability of MSC and have shown significant 
improvement of viability by using serum in the cell washing process post detachment. This 
raises the need to use autologous serum from patients as this increases the potential of 
infusing serum into the patient along with MSC. Serum can be collected and stored and we 
show significant improvements with low levels of 1% serum, this would still place increased 
demands on the patient and could potentially lead to more discomfort. It is important to 
elucidate what mechanism may be responsible for maintaining viability so that alternative 
methods may be determined. 
 
Direct infusion of MSC to diseased livers in a clinical setting may cause more damage than 
any therapeutic benefit the cells may have. Non-invasive methods would be the method of 
choice in such a scenario. The prospect of maintaining high levels of surface receptor 
expression on MSC would serve to increase the migration along a chemokine gradient which 
is often present in patients with liver injury. Preserving surface receptor expression makes 
recruitment of cells after non-invasive methods a more likely prospect. We go further in this 
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project to use an intraportal vein infusion method to investigate engraftment. Further work 
would investigate migration of MSC along a chemokine gradient set up in circulation of liver 
injury models and would employ less invasive methods such as intravenous infusions which 
would more likely be attributable to a clinical setting.  
 
We also observe reduced adipogenic differentiation after detachment with CDB. At first this 
may appear to alter the MSC tri-lineage potential by either pushing the cells to a progenitor 
cell type or eliminating adipogenic progenitors from the MSC population, as detailed earlier 
in this chapter. However immunosuppressive properties are still retained by the MSC and 
adipogenic differentiation is less likely to be important in the context of repairing fibrotic 
liver injury. However, such a reduction in adipogenic differentiation properties coupled with 
immunosuppression could encourage the prospect of introducing a cell into diseases such as 
NASH where there is already a heavy load of fatty tissue. Adipogenic differentiation may add 
to this load and cause a net increase on inflammation negating any anti-inflammatory 
properties the cell might initially have had. To further this work it would be important to test 
whether the effects of serum can restore tri-lineage differentiation and immunosuppressive 
properties of the MSC can be restored with viability.   
 
In summary we have identified that methods of MSC detachment from tissue culture plastic 
need to be carefully considered depending on what downstream function of an MSC is being 
studied or utilised. It is important to note that our strategies which preserve receptor 
expression and therefore may increase the delivery of cells, which is the main focus of this 
project, do not completely eliminate the beneficial properties of the cell. Although at reduced 
levels, the MSC detached by CDB maintain tri-lineage potential and immunosuppressive 
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properties compared with TrypLE detached MSC. In essence we have identified a method to 
preserve the migratory capabilities of MSC once detached and in suspension, the challenge 
now is to reverse or minimise some of the associated effects of this method. In this study we 
have proved that viability even after CDB can be maintained by modifying the preparation 
procedure to include serum. We would suggest that to maintain high viability, tri-lineage 
differentiation, and immunosuppressive abilities, MSC need to be detached with TrypLE. 
Importantly, if CCR expression, with associated migration, is the main focus then detachment 
with CDB needs to be adopted. Further work needs to investigate temperature sensitive 
methods of detachment on CCR expression, as this method has been reported to preserve 
viability at higher levels than enzyme detachment methods (Yang et al., 2012).  
 
6.2 Increased engraftment in injured liver via TGFβ1 up-regulated MSC 
surface CXCR3 expression  
 
Once we had demonstrated successful detachment of functionally competent MSC we next 
investigated their ability to adhere to and engraft within the liver environment. Here we found 
that TGFβ1 significantly increased levels of CXCR3 surface expression on MSC and 
engraftment of MSC in injured liver (Figure 4.15). Engraftment was found to be dependent on 
TGFβ1 regulated CXCR3 expression since functional blockade of CXCR3 reduced MSC 
engraftment to baseline levels after TGFβ1 stimulation but had no effect on binding of 
unstimulated MSC (Figure 4.15). We have yet to define the mechanisms which underlie this 
observation but it agrees with the TGFβ1 stimulated increase in CXCR3 surface expression 
previously reported on NK cells (Inngjerdingen et al., 2001).  
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There is evidence for the interaction of TGFβ1 with cytokine receptor expression on human 
airway fibroblast cell surfaces. TGFβ1 appears to be able to regulate cytokine receptor 
expression. TGFβ1 has been linked to the regulation of IL13 signalling by reducing IL13Rα 
expression via the MEK/ERK pathway (Zhou et al., 2012). However TGFβ1 does not alter 
CXCR3 mRNA levels (Figure 4.8), and coupled with high intracellular stores of CXCR3 
(Figure 4.1) in MSC it seems likely that CXCR3 recycling to the cell surface is enhanced after 
TGFβ1 stimulation. Recycling of CCR has previously been reported, in particular for CCR5, 
due to its relevance in HIV research (Mueller et al., 2002). Although recycling of CCR occurs 
at a baseline level for some CCR, CXCR3 has been reported to be degraded after 
internalisation (Meiser et al., 2008). The mechanism of CXCR3 upregulation on MSC cell 
surface is unlikely to be dependent on SMAD signalling as we see no increase of cell surface 
CXCR3 after MSC stimulation with TGFβ1. TGFβ1 seems to be able to activate the Rab4 
pathway. TGFβR also recycles via a Rab11 dependent pathway and this could affect the other 
ligands passing through a similar pathway after TGFβ1 ligand binding (Miaczynska et al., 
2004). It is possible that this mechanism exists in MSC in order to mobilise them during 
fibrosis. TGFβ1 allows cells to remain responsive to migratory stimuli. Allowing the CCR to 
be degraded will stop the migration of the cells. Recycling CCR continually to the surface 
induces migration across a chemokine gradient. During fibrosis there is an increase in TGFβ1 
inducing mesenchymal cell mobilisation, proliferation and migration, in order to provide a 
stromal platform for recruited inflammatory or immune cells (Kershenobich Stalnikowitz and 
Weissbrod, 2003). To understand the mechanism involved in the observed MSC recruitment 
to the injured liver via CXCR3 we could consider the findings of Sahin et al. They show a 
fibrogenic dependent increase in CXCL9 expression in the livers of CCL4 injured Wild Type 
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C57BL/6 mice. They observed that recruitment of CXCR3+ cells to the liver played a 
significant role in preventing fibrosis progression using CXCR3-/- mice (Sahin et al., 2012).  
 
We have previously shown that low levels of engraftment of unstimulated MSC into injured 
tissue occurs independently of a role for CCR (Aldridge et al., 2012). Indeed we observed a 
similar effect in the current study but also observed that stimulation with TGFβ1 caused 
CXCR3 to become functional and involved in the engraftment process. TGFβ1 stimulation 
significantly increases the number of MSC that bind to injured liver (Figure 4.15). Due to the 
heterogeneous sizes of MSC, 5µm to 50µm in culture, physical entrapment can cause cells to 
arrest in the vasculature rather than physical engagement of receptors. However our previous 
study suggests that MSC actively engraft in injured liver as there was no significant increase 
in number of larger cells which engrafted. The focus of this study is on the effect of 
chemokines in MSC engraftment and effects of chemokines are observed after arrest or 
adhesion to endothelium. Although it would be interesting to identify if engraftment via CCR 
is linked with size, and if TGFβ1 can increase the size of MSC, it was not pertinent for this 
study. Although we cannot identify whether binding is due to active or passive methods in 
this study we can assume that regardless of method of initial binding in the vasculature, the 
method of extravasation which would involve CCR is enhanced with TGFβ1 stimulation as 
blocking the function of CXCR3 significantly reduced engraftment of MSC. When we 
observe sections from transplanted livers the engrafted cells were located within the 
parenchyma, suggesting MSC had migrated into the tissue. 
 
Although it cannot be overlooked that higher levels of surface expression could increase 
baseline engraftment, enzymatic cleavage of receptors after TGFβ1 stimulation suggests that 
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CCR function is dependent on its internalisation and subsequent recycling (Figure 4.16) 
which enables the cell to move across a particular gradient (Neel et al., 2005). Such a 
mechanism suggests that we could maintain high levels of viability and immunosuppressive 
potential while still maintaining an increased migratory potential, allowing the use of non 
invasive methods of infusion. 
 
Based on our findings we propose that internalised stores of CXCR3 not only avoid 
degradation after TGFβ1 stimulation and upon recognition of ligand also enter a rapid 
recycling pathway rather than the slow recycling pathway, which is otherwise utilised by 
receptors at base line levels (Neel et al., 2005). This would in effect increase engraftment and 
migration towards a CXCR3 ligand. Indeed we observed increased migration of TGFβ1 
stimulated MSC to the CXCR3 ligand IP-10/ CXCL10 (Figure 4.11) and furthermore 
observed significantly higher levels of binding to HSEC which have previously been reported 
to express high levels of IP-10/ CXCL10 (Curbishley et al., 2005) (Figure 4.12). CXCR3 has 
been reported to mediate T cell recruitment to the liver during injury through interaction with 
CXCR3 ligands on HSEC (Curbishley et al., 2005, Oo et al., 2012, Oo et al., 2010). Thus it 
may be postulated that TGFβ1 increases MSC engraftment into injured liver through binding 
to HSEC via its association with IP-10/ CXCL10, with a potential role for CD44. CD44 
expression was also increased on TGFβ1 stimulated MSC but was not investigated further in 
this project. We have previously shown that β1 integrin and CD44 are used by MSC to roll 
and firmly adhere, respectively, to injured HSEC (Aldridge et al., 2012). CD44 has also been 
implicated in playing an integral role in recruitment of HSC to injured liver with an associated 
role of CCR (Crosby et al., 2009). We observed increased CD44 expression on MSC after 
TGFβ1 stimulation and this may also enhance MSC engraftment in a chemokine mediated 
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way (Aldridge et al., 2012). Cellular transplantation has been reported to cause local 
ischemia, and could influence adhesion of MSC but this can take 1-4 hours to develop. Our 
experiments were shorter than this (15 minutes) but our previous work has reported no 
increase in hepatic MSC adhesion in a murine model of hepatic reperfusion injury (Aldridge 
et al., 2012).   
 
Cytokine stimulation of MSC has been reported to affect tri-lineage potential and 
immunosuppressive capabilities (Lacey et al., 2009, Liu et al., 2011b). However we report no 
effect on MSC tri-lineage differentiation after TGFβ1 stimulation but we see increased 
potency of T cell suppression by stimulated MSC (Figure 4.21). As reported in the literature, 
PGE2 was identified as the mediator of this suppression (Aggarwal and Pittenger, 2005) and 
TGFβ1 may enhance PGE2 expression or add to the suppression via other factors. Although 
we cannot rule out other factors may also suppress T cell proliferation after TGFβ1 
stimulation, including IDO, we can rule out direct effects of  IL10 and TGFβ1 on immune 
cells since these were undetected or detected at negligible levels, respectively, in our MSC 
supernatants. In clinical therapy, infusion of MSC into an injured liver environment with high 
levels of T cell infiltration will serve to reduce the impact of inflammation on liver and 
resultant fibrosis. We have shown increased binding of TGFβ1 stimulated MSC to livers from 
patients with NASH and PSC (Figure 4.12). In these diseases chronic inflammation is a 
common feature. Thus enhanced binding in these livers and increased suppression of 
inflammation could act to halt the progression of injury and encourage resolution. Similarly 
this type of therapy can also be utilised post-transplant to protect from rejection or diseases 
such as graft-versus host (Hong et al., 2009). The use of a cellular therapy that not only 
engrafts to the area of injury but promotes stronger local immunosuppressive effects can 
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potentially stop the use of immunosuppressive or anti-inflammatory drugs which deliver a 
systemic loss of immunity, potentially paving the way for higher incidence of infections or in 
worst cases, the development of tumours. 
 
A major concern for TGFβ1 stimulation of MSC before exogenous administration for liver 
therapy is that such treatment may promote a myofibroblastic phenotype of MSC (Li et al., 
2009). However our findings suggest that there is no significant difference in production of 
pro-fibrotic factors such as collagen-1 and αSMA after TGFβ1 stimulation (Figure 4.17). 
Future long-term experiments would need to determine whether infusion of TGFβ1 stimulated 
MSC into injured environments where there are already high levels of TGFβ1 would 
differentiate into a pro-fibrotic phenotype with detrimental results. Alternatively, MSC could 
take on a myofibroblastic phenotype and push the liver further towards cirrhosis cancelling 
out any beneficial effects the MSC might have. Alternately infusion of such cells could reduce 
inflammation thereby reducing fibrosis and have a negligible contribution to fibrosis by 
adopting a myofibroblastic phenotype. These outcomes can only be determined by long term 
engraftment experiments in liver injury models, perhaps with repeat infusions of MSC, which 
would likely be the case in clinical treatments, and assessing how MSC may progress or 
reduce fibrosis. The advantage of such animal models makes it possible to infuse MSC at 
different stages in disease development and resolution. Furthermore cell tracking experiments 
could also be used to track the fate of such cells in the liver, identifying whether or not these 
cells have taken on a myofibroblastic phenotype.    
 
MSC can engraft into injured liver when infused via the portal vein and this engraftment in 
enhanced with TGFβ1 pre-stimulation of MSC by increased surface recycling of CXCR3. 
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This implies that the migratory capacity of MSC can be enhanced with TGFβ1 stimulation as 
can the immunosuppressive potential serving as a potential strategy in MSC therapy in liver 
disease. Cytokine treatment of MSC is a relatively low cost way of enhancing MSC 
engraftment and could easily be incorporated into protocols to enhance the efficacy of this 
treatment. Increased engraftment of infused cells with increased immunomodulatory capacity 
could lead to the use of fewer cells requiring less expansion and passaging in culture, 
therefore altering the intrinsic therapeutic capabilities of MSC. This also implies a faster 
application of these cells in therapy. Using fewer cells to maximum effect could mean a 
shorter time frame in which cells can be prepared for therapy. T cell infiltration is responsible 
for a large proportion of the damage done during chronic inflammation and resultant fibrosis 
(Fernandez-Cruz et al., 1978). By increasing the potency of the MSC immunomodulatory 
effect, TGFβ1 stimulation could also increase suppression of T cell proliferation during 
hepatic inflammation.  The crucial next step is to investigate the effect of these cells in pre-
clinical models of disease after increased engraftment. Future research needs to focus on the 
therapeutic effect of TGFβ1 stimulated MSC in long term engraftment in models of liver 
injury, the fate of the cells, the method, time and number of infusions need to all be 
considered and investigated in detail. 
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6.3 Unsuccessful isolation and identification of fibrocytes with current 
protocols, markers and antibodies 
 
In the final section of the thesis I attempted to phenotype fibrocytes from peripheral blood. 
The central focus of this project was to increase the therapeutic potential of MSC. Previous 
sections explored increasing engraftment but in this section we tried to identify markers which 
could be used to select and deplete pro-inflammatory and pro-fibrotic fibrocytes from cultured 
bone marrow MSC isolates. This approach was taken with a view to enhancing therapeutic 
potential of the typically heterogeneous population of MSC by concentrating MSC into a 
purer MSC population.  
 
Fibrocytes could go undetected due to similar marker expression and reported tri-lineage 
differentiation potential to MSC (H. Peng and Herzog, 2012). Fibrocytes could thus 
contaminate MSC isolations competing with them for space and oxygen in bioreactors 
making conditions highly unfavourable for MSC. Furthermore in clinical applications any 
beneficial anti-fibrotic and immunosuppressive properties of MSC could be reduced or even 
reversed by contaminating fibrocytes. Although fibrocytes have been reported in the bone 
marrow (Ogawa et al., 2006), recent literature has identified them in peripheral blood with 
comprehensive isolation methods (Phillips et al., 2004).  
 
The isolation of fibrocytes from blood proved to be challenging in our hands since fibrocytes 
expressing procollagen-1 were not identified in blood before or after culture (Figure 5.14). 
Attempts to isolate fibrocytes from peripheral blood mononuclear cells (PBMC) yielded 
fibrocyte-like, spindle shaped cells which were not consistently positive for stromal and 
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hematopoietic markers, collagen-1 and CD45 respectively (Figure 5.15). We then attempted 
to increase numbers of spindle shaped cells in an effort to increase numbers of fibrocytes, 
assuming that the low cell number was making it difficult to identify them. Increasing cell 
density was successful in increasing spindle shaped cells (Figure 5.8). We also observed that 
growing both PBMC and isolated monocytes on collagen increased the presence of spindle 
shaped cells (Figure 5.10). Surprisingly we discovered that if we depleted monocytes from 
PBMC, conditions most favoured the development of spindle shaped fibrocyte like cells 
(Figure 5.13). T cell cytokines have been proven to increase fibrocyte differentiation from 
monocytes and a high proportion of contaminating lymphocytes in our cultures could have 
caused this result (Shao et al., 2008). In support of this, monocytes with depleted lymphocyte 
populations can only differentiate to fibrocyte-like cells on collagen. 
 
However we were not able to consistently identify the existence of fibrocytes among these 
spindle shaped cells from peripheral blood with collagen-1 expression (Figure 5.15). On 
further investigation we found inconsistent staining between multiple, commonly used 
antibodies for collagen-1 and αSMA using control cells (Figure) and fibrocytes with high 
levels of non specific labelling (Figure 5.17).  We next moved to staining tissue since 
fibrocytes have been reported in CCl4 injured livers in mice (Scholten et al., 2011). In our 
efforts to identify human fibrocytes we labelled sections from multiple diseased livers but 
only observed collagen-1 and CD45 dual staining using a collagen-1 antibody we considered 
unreliable (Figure 5.18). Finally we digested tissue samples in an attempt to collect fibrocytes, 
and whilst fibrocyte-like spindle shaped cells were identified in the adherent CD45+ fraction 
from diseased liver (Figure 5.18), normal livers processed the same way yielded cells 
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resembling macrophages. This is not surprising and could lend support to the hypothesis that 
fibrocytes are alternatively activated macrophages (Reilkoff et al., 2011).   
 
Other groups have used what we believe to be an unreliable anti-collagen-1 antibody 
specifically in phenotyping isolated fibrocytes and have not phenotyped these cells in tissue 
(Curnow et al., 2010, Phillips et al., 2004). We have shown through staining for fibrocytes in 
liver tissue that this antibody may non-specifically detect other types of collagen which are 
not type 1 collagen. Using this antibody to phenotype cells, the presence of collagen-1 could 
be falsely detected as a range of cells can commonly express other forms of collagen. Cells 
co-expressing collagen-1 and CD45 were observed in areas of scarring where there are a large 
number of CD45+ cells and collagen-1+ myofibroblastic cells (Figure 5.18). The localisation 
of fibrocytes in these areas where other collagen-1 cells are present increases the likelihood of 
misidentification of cells. Furthermore we have shown there are apparent inconsistencies 
between staining with different antibodies for αSMA. Use of diffusely expressed cytoskeletal 
and ECM proteins for cell identification increases the possibility of erroneous or non specific 
identification in contrast to more robust discrete membrane markers. There is a necessity for 
identification a more robust specific cell membrane marker to identify these cells. 
 
SAP, a major contributor to the suppression of fibrocyte differentiation (Pilling et al., 2003), 
was significantly increased or showed no change in injured or diseased serum or livers in 
mice and humans (Figure 5.2). This may be because the SAP has different roles in mice and 
humans. SAP is an acute phase protein in mice and reacts to inflammatory and fibrotic stimuli 
(Baltz et al., 1985), whereas this is commonly the role for another protein, CRP in humans 
(Steel and Whitehead, 1994).  Therefore, contrary to existing reports of decreased SAP levels 
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in mice with lung injury, fibrocytes reported to exist in mice with liver injury must not be 
mediated by low levels of SAP (Pilling et al., 2003). This could mean that the reported cells 
are different and perhaps different from the fibrocytes observed from blood. These cells may 
come about from a similar precursor but the conditions they encounter in different organs 
could influence their differentiation into very different cell subtypes with different functions. 
We therefore propose that to term these cells fibrocytes is misleading when in essence these 
could all be different subtypes of monocytes, shaped by disease or culture conditions.  
 
To conclude, our data suggest it is of little value to phenotype fibrocytes in order to deplete 
them from MSC isolates. The phenotyping strategy to identify fibrocytes is unreliable and 
irreproducible. Although it has been reported that this is due to an inherent variability among 
donors, it seems the use of unreliable antibodies for non specific markers of fibrocytes could 
be a more obvious reason. Development of these cells seem to be influenced by culture 
conditions which can vary between experiments particularly as we have shown, if these cells 
are dependent on the mixture of cells in culture which can depend on donor variability and 
researcher error. Rather, we feel it will be more sensible to identify markers on MSC which 
could help isolate purer populations of MSC with high immunosuppressive and therapeutic 
properties. Importantly fibrocytes from humans are not as robust a cell type as the literature 
may suggest, and the drastically reduced research into fibrocytes in recent years appropriately 
reflects the unreliable and inconsistent identification and culture procedures for this unlikely 
subtype of cells.   
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6.4 Future perspectives 
 
We have found that MSC can be manipulated with TGFβ1 stimulation to increase therapeutic 
properties and engraftment in models of liver injury. We can learn from these experiments 
and take our findings closer to preclinical development in a translational setting by pursuing 
this investigation in the immediate future and developing our findings in the long term in the 
following ways: 
  
6.4.1 Immediate experiments. 
 
Based on the findings of this report, the experiments I feel would be important to address in 
the immediate future would include a closer investigation of the migratory properties to 
chemokine ligands utilized by receptors these MSC express. Although we potentially saw the 
migration of MSC to a range of chemokines the high degree of variability which exists within 
Boyden chamber experiments meant certain effects of cytokine stimulated increases in MSC 
migration could potentially be masked and overlooked. We have also not addressed the 
effects of multiple chemokines in combination which would recreate likely patterns of 
expression in vivo and may demonstrate hierarchical functionality. For example we report for 
the first time, the presence of high levels of CXCR7 expression and negligible CXCR4 levels, 
with high levels of migration of MSC towards SDF1α/ CXCL12. Due to recent reports 
focusing on CXCR7 and CXCR4 co-operation being involved in migration towards SDF1α/ 
CXCL12, we feel this could prove the existence of a mechanism of migration of MSC 
expressing apparently negligible levels of CXCR4 to the CXCR4/ CXCR7 ligand which has 
not previously been reported. It would also be important to consider measurement of 
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migration responses under conditions of shear stress in vitro as blood flow is known to be 
important as a stimulator of leukocyte migration and similar mechanisms may operate for 
MSC. 
  
6.4.2 Longterm experiments 
 
A key experiment to validate our findings would be to investigate the effects of increased 
MSC engraftment and immunosuppressive properties on liver injury. The therapeutic effect of 
TGFβ1 stimulated MSC can be measured in short term in vivo experiments investigating 
effects on immune cell infiltration and by measuring early markers of fibrosis. It would be 
interesting to investigate the effect MSC can have on infiltrating cell types in once engrafted 
in the liver. Here we could phenotype the immune component of the engrafted livers or 
consider utilizing flow based assays to observe the effect of MSC on recruitment of immune 
cell subtypes across endothelial monolayers. In particular we would investigate the well 
characterized immunomodulatory properties of MSC via the recruitment of 
immunosuppressive T regulatory cells. 
 
Long term engraftment studies with MSC infusions in mouse liver injury models can provide 
us with information regarding the long term efficacy of TGFβ1 stimulated MSC, and allow 
assessment of effects across the time-course of disease progression and resolution. The effect 
of MSC infusions on inflammation could be investigated after initial insult and subsequent 
fibrosis in the liver. Intravenous delivery needs to be investigated as a method of MSC 
infusion in this setting with regard to migration to the liver, with repeat infusions of MSC and 
investigation of effects at multiple time points. Such studies could also focus on retention in 
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the injured liver and infusion of MSC at a specific stage of injury, particularly with easily 
controlled and characterized models of liver injury and resolution induced by CCl4. Long term 
experiments should also address important safety issues raised with regard to reported cancer 
promoting properties and pro-fibrotic potential of MSC in models of liver injury. Such issues 
need to be carefully addressed before MSC can be utilized to their full potential as a means of 
clinical therapy for liver disease. 
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